Pleine conscience, régulation émotionnelle et psychose : états des connaissances et applications cliniques by EL-Khoury, Bassam
  
Université de Montréal 
 
 
Pleine conscience, régulation émotionnelle et psychose : 
états des connaissances et applications cliniques 
 
 
par 
Bassam EL-Khoury 
 
Département de psychologie 
Faculté des arts et des sciences 
 
Thèse présentée à la Faculté des études supérieures 
en vue de l’obtention du grade de Philosophiae Doctor (Ph. D.) 
en psychologie 
option psychologie clinique  
 
 
8 Novembre, 2013 
 
© Bassam Khoury, 2013 
Université de Montréal 
i 
 
Résumé 
Cette thèse est divisée en trois parties principales, ayant toutes trait à la régulation des 
émotions ou à l'efficacité des interventions issues de la troisième vague des thérapies cognitives 
comportementales, en particulier chez les personnes ayant des symptômes psychotiques. La thèse 
est composée d'un chapitre de livre rédigé en francais, de quatre articles rédigés en anglais 
(introduction, deux méta-analyses et une étude pilote) et d’une discussion générale rédigée en 
anglais. L'introduction, déjà publiée sous le format d’un chapitre de livre (et d’un article) 
constitue un examen exhaustif de la littérature portant sur la régulation des émotions dans la 
schizophrénie et dans les autres troubles psychotiques. Les individus présentant une 
schizophrénie présentent des dérégulations, indépendantes l’une de l’autre, dans les trois 
domaines distincts suivants: l’expression des émotions, le traitement des emotions, et 
l’expérience émotionnelle. Cette première partie de la thèse recommande fortement l'intégration 
des stratégies de régulation des émotions, notamment celles de la troisième vague des thérapies 
cognitives comportementales telles que la pleine conscience, l'acceptation et la compassion, dans 
le traitement des personnes souffrant de psychose.  
Dans la deuxième partie de la thèse, deux méta-analyses examinant l'efficacité des 
stratégies de la troisième vague des traitements cognitifs comportementaux dans la régulation des 
émotions sont présentées. La première méta-analyse vise à examiner l'efficacité de la thérapie 
basée sur la pleine conscience pour tous les troubles psychologiques ainsi que pour les conditions 
médicales. La deuxième méta-analyse porte plus spécifiquement sur l'efficacité des stratégies de 
la troisième vague pour la psychose. Les résultats des deux méta-analyses démontrent des tailles 
d'effet entre modérées et larges, avec un effet plus marqué sur les symptômes affectifs, 
notamment l'anxiété, la dépression et la détresse. En outre, les stratégies étudiées (la pleine 
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conscience, l'acceptation et la compassion) sont des fortes modératrices positives de l'efficacité 
des traitements. Ces résultats suggèrent que ces stratégies sont efficaces dans la régulation des 
émotions, du moins lorsqu'elles sont mesurées au sein de grands bassins de participants, y 
compris les personnes souffrant de psychose.  
La troisième partie de la thèse implique le développement et la validation préliminaire 
d'une nouvelle intervention de groupe pour des individus en début de psychose à l'aide d'une 
combinaison de stratégies d'acceptation, de compassion et de la pleine conscience. Douze 
individus ont participé à cette étude pilote. Les résultats démontrent la faisabilité et l'acceptabilité 
du traitement. Des améliorations significatives dans la régulation des émotions et dans les 
symptômes affectifs sont observées, et sont potentiellement liées à l'intervention.  
Globalement, la thèse offre un soutien empirique du rôle de la régulation émotionnelle 
dans le traitement des personnes atteintes de troubles psychotiques. Plus de recherches sont 
nécessaires pour valider l'efficacité du nouveau traitement.  
 
Mots-clés: pleine conscience, méditation, acceptation, compassion, troisième vague, régulation 
des émotions, psychose, schizophrénie, méta-analyse, efficacité des traitements  
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Abstract 
This thesis is divided into three main parts, all pertaining to emotional regulation or to the 
efficacy of third wave cognitive behavioral treatments particularly in individuals having 
experienced psychotic symptoms. The thesis consists of one book chapter published in French, 
four articles published in English (i.e., introduction, deux meta-analyses and a clinical pilot 
study), and a general discussion. The introduction already published as an article (and as book 
chapter) involves a comprehensive review of the literature on emotion regulation in 
schizophrenia and other psychotic disorders. Individuals with schizophrenia and other psychotic 
disorders tend to show emotional dysregulations at the experiential, expressive, and processing 
levels. This first part strongly recommends integrating emotion regulation strategies, namely 
third wave cognitive behavioral strategies such as mindfulness, acceptance and compassion in 
the treatment of individuals with psychosis. 
In the second part of the thesis, two meta-analyses reviewing the effectiveness of these 
third wave cognitive behavioral strategies in regulating emotions are presented. The first 
investigates the effectiveness of mindfulness-based therapy across all psychological disorders 
and medical conditions. The second meta-analysis focuses more specifically on the effectiveness 
of mindfulness interventions for psychosis. The results from both meta-analyses show moderate 
to large effect sizes, with higher ones for affective symptoms, especially anxiety, depression and 
distress. Furthermore, the investigated strategies (i.e., mindfulness, acceptance and compassion) 
are strong positive moderators of the treatments’ effectiveness. These results suggest that these 
strategies are effective in regulating emotions, at least when measured in large pools of 
participants, including individuals with psychosis. 
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The third part of the thesis involves the development and preliminary validation of a new 
group intervention for early psychosis using a combination of acceptance, compassion and 
mindfulness. Twelve individuals participated in this pilot study. Results indicated the feasibility 
and acceptability of the treatment, with improvements in emotion regulation and affective 
symptoms observed, and potentially linked to the intervention.  
The thesis overall empirically supports the important role of emotional regulation in 
treating individuals with psychosis. More research is warranted pertaining to the effectiveness of 
the new developed treatment. 
 
Keywords: mindfulness, meditation, acceptance, compassion, third wave, emotion regulation, 
early psychosis, schizophrenia, meta-analysis, treatment outcome 
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Preface 
This thesis is divided in three main parts, consisting of a total of four articles and a book 
chapter along with a general discussion: 
 
The introduction involves a comprehensive review of the literature on emotion regulation 
in schizophrenia and other psychotic disorders. It argues for the integration of emotion regulation 
strategies in the treatments of psychosis and schizophrenia. This part consists of an article 
entitled “Emotion Regulation and Schizophrenia” that was published in 2012 in the International 
Journal of Cognitive Therapy (volume 5, issue 1, pages 67-76). This article was also translated in 
French and rewritten as a book chapter entitled “Régulation des emotions et schizophrénie” that 
was published in 2012 in “Traité de regulation émotionnelle” by the Groupe de Boeck, Brussels, 
Belgium (pages 387-400) . We only included the original article written in English in the main 
text of the thesis for language compatibility. 
 
The second part consisting of two articles, each is portraying a meta-analysis reviewing 
the effectiveness of these third wave cognitive behavioral strategies in regulating emotions. The 
first meta-analysis investigated the efficacy of mindfulness-based therapy across all 
psychological disorders and medical conditions. The article entitled “Mindfulness-Based 
Therapy: A Comprehensive Meta-Analysis” was published in 2013 in Clinical Psychology 
Review (volume 33, issue 6, pages 763-771). The second one focused specifically on the 
effectiveness of third-wave strategies for psychosis. The article entitled “Mindfulness 
Interventions for Psychosis: A Meta-analysis” was accepted for publication in Schizophrenia 
Research in July, 2013, an electronic copy was published online in August, 2013). 
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The last part consists of a single article portraying the development and validation of a 
new group intervention for early psychosis using a combination of acceptance, compassion and 
mindfulness. The article describing this pilot study entitled “Third wave strategies for emotion 
regulation in early psychosis: A pilot study” was accepted for publication in Early Intervention 
in Psychiatry in August, 2013. 
 
The objectives of this thesis are three-folds: (1) to present a clear rationale, via a review 
of the  literature, of the role of emotion regulation in the etiology and development of psychosis 
and schizophrenia; (2) to investigate the effectiveness of third wave cognitive behavioral 
therapy’s strategies for emotion regulation; (3) to determine the feasibility and acceptability of a 
new third wave cognitive behavioral group therapy, combining effective strategies, for 
individuals with early psychosis. Therefore the thesis includes three parts each aiming at 
fulfilling one objective. The first objective is addressed in the first part of the thesis (i.e., the 
introduction) via the first article and book chapter; the second objective is fulfilled via the two 
meta-analyses comprised in the second part; and the third objective is achieved in the last article 
of the third part. These three parts are presented sequentially along with a general discussion at 
the end.
  
Part –I: Introduction 
Emotion Regulation and Schizophrenia 
Bassam Khoury1, Ph.D. Candidate 
Tania Lecomte2, Ph.D. 
Pierre Lalonde3, M.D., FRCPC 
 
1Ph.D. Candidate, teacher assistant, department of psychology, Université de Montréal 
2Associate professor, department of psychology, Université de Montréal, Researcher at the 
Fernand Séguin research center 
3Psychiatrist, program of psychotic disorders, Louis-H. Lafontaine Hospital, Montréal 
professor, Université de Montréal.  
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Gross (2007) defined emotion regulation as the process by which an individual influences 
which emotion will be experienced, when it will be experienced and how it will be experienced 
and expressed. Thus, emotion regulation processes involve both positive and negative emotions 
and include the coherence between different components of emotions, such as emotional 
experience, physiological responding, and facial expression. According to this definition, 
emotion regulation is distinct from emotion control, which is less flexible and adaptive, and 
involves restraint in the expression of emotions, rather than affecting the complete emotional 
process, including the experience and interpretation of emotions. Thompson (1991, 1994) 
considered that emotion regulation involved changes in “emotion dynamics” rather than changes 
in quality. In other words, emotion regulation does not change the emotion but alters its 
properties, such as latency, rise time, magnitude, duration, and speed of recovery. It also reduces 
or enhances the range of an emotional response in a particular situation, depending upon the 
individual’s goals in that situation (Gross, 2007; Koole, 2009).  
Many studies have suggested that emotion regulation plays an important role in both 
physical and mental health, and that failure to regulate emotions contributes to many forms of 
psychopathology (Koole, 2009). Recently, emotion regulation has received increased attention 
and many books and articles have been written about the link between emotional regulation and 
psychological disorders, including depression, anxiety, bipolar disorder, substance abuse, 
psychosis, schizophrenia, and personality disorders (e.g., Bradley, 2000; Flack & Laird, 1998; 
Rottenberg & Johnson, 2007). This part will concentrate on the role of emotion regulation in 
schizophrenia and strategies used in regulating emotions. 
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1. Emotional regulation in schizophrenia 
Schizophrenia has most often been considered a “non-affective” thought disorder, in 
contrast to affective disorders such as bipolar disorder (Phillips, 2008, chap 2). However, some 
authors, namely Watson et al. (2006) suggest that emotive and cognitive processes interact in the 
development and maintenance of psychotic symptoms. A review of 69 studies found that 
individuals with schizophrenia reported higher anhedonia and demonstrated more negative 
emotions in studies using real-life events (Trémeau, 2006). Furthermore, results suggest a 
dysregulation in the domains of: expression, processing, and experience of emotions, and that 
these dysregulations are independent of each other.  
1.1. Emotional expression in schizophrenia 
Multiple studies have consistently shown that individuals with schizophrenia are less 
emotionally expressive than individuals without schizophrenia in a variety of contexts and in 
response to evocative stimuli such as film clips, still pictures, cartoons, music, foods, and social 
interactions such as role play (Kring & Moran, 2008). Differences in emotional expressivity 
were observed through facial expressions and vocal responses, for positive and negative 
emotions, in both men and women, on and off medication. Clinical and non-clinical populations 
were compared, including individuals with major depression (Kring & Moran, 2008). The 
etiology behind the diminished emotional expressivity in schizophrenia is not yet completely 
understood (Kohler & Martin, 2006). For example, Phillips & Seidman (2008) showed that some 
of these deficits exist prior to development of the illness. Some researchers suggest that the 
deficits are linked to connectivity problems in areas of the brain important for social and 
emotional expression, such as the anterior cingulate area (Trémeau, 2006). Other researchers 
suggest that a link exists between limited emotional expression and heightened emotional 
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experience (e.g., Flack, Laird, & Cavallaro, 1999). For example, Mino et al. (1998) observed that 
individuals from families with highly expressed emotions demonstrate a higher level of negative 
symptoms, namely a flat effect. In a recent book, Beck, Rector, Stolar, & Grant (2009) suggested 
that limited emotional expression among individuals with schizophrenia may result from biased 
and negative expectations about social involvement. The authors argued that individuals with 
schizophrenia expect less pleasure and little success in social activities and perceive themselves 
as inadequate. These beliefs lead them to distance themselves from others and may result in 
social isolation. These arguments suggest that emotional expression is strongly related to other 
components of the illness (biased beliefs, inadequate self-perception, and negative symptoms) 
and that treatments for schizophrenia should address the expression of emotions. 
1.2. Emotional processing in schizophrenia 
Some definitions of emotional processing include the perception, recognition, expression 
and experience of emotions (e.g., Phillips & Seidman, 2008). In this section, we restrict the 
definition of emotional processing to the perception/recognition of an emotion and to the 
cognitive interpretation of the emotion within a social context (i.e., using the perceived emotion 
to understand the mental state of someone else). Similar to emotional expression, individuals 
with schizophrenia may be impaired in emotional processing prior to development of the illness 
(Phillips & Seidman, 2008), and this impairment may be present in multiple channels (i.e., 
verbal, facial, and acoustic) (Trémeau, 2006). Impairment in facial emotion recognition is a 
prominent deficit in individuals with schizophrenia (Couture et al., 2006; Hooker & Park, 2002; 
Wallace, 1984). Morris, Weickert, & Loughland (2009) found that individuals with 
schizophrenia avoid gazing at important facial regions (especially the eyes) and have greater 
difficulty to recognize fear. A study by Green, Waldron, & Coltheart (2007) found that 
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individuals with schizophrenia failed to use contextual information in judging facial emotions. 
Individuals with schizophrenia were also observed to be impaired in their ability to understand 
another person’s emotional state and intentions, or Theory of Mind (ToM). The effect size was 
large when compared to a control population (Bora, Yucel, & Pantelis, 2009; Sprong, Schothorst, 
Vos, Hox, & van Engeland, 2007).  
Treatments integrating facial emotional recognition and ToM include: Social Cognitive 
and Interaction Training (SCIT; Penn, Roberts, Combs, & Sterne, 2007), and Social Cognitive 
Skills Training (SCST; Horan et al., 2009). Both programs train participants in various aspects of 
emotional recognition and ToM. Other treatments that explicitly focus on facial emotional 
recognition are computerized emotion training programs such as the Micro-Expression Training 
Tool (METT; Ekman, 2003) and Training in Affect Regulation program (TAR; Wölwer et al., 
2005). Both training tools aim to enhance the user’s ability to recognize facial emotion cues and 
features, however, these treatments are new and more evaluation of their effectiveness is needed. 
Studies suggest also a relationship between impaired emotional processing and functional 
outcomes (i.e., social behavior, community functioning, social skills, and social problem solving) 
in individuals with schizophrenia (Addington & Haarmans, 2006; Couture, Penn, & Roberts, 
2006; Kee, Green, Mintz, & Brekke, 2003). These results emphasize the need for treatments 
addressing emotional processing deficits in schizophrenia. 
1.3. Emotional experiences in Schizophrenia 
A strong relationship has been observed between childhood trauma and psychotic 
symptoms. For example, Janssen et al. (2004), reported that child abuse before the age of 16 was 
a significant risk factor for developing psychotic symptoms later in life. Furthermore, Read, van 
Os, Morrison, & Ross (2005) argued that child abuse is a causal factor for psychosis and 
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schizophrenia. More specifically, childhood traumatic experiences can be represented in 
hallucinations exacerbating feelings of anxiety and depression (Beck et al., 2009, p. 339). 
Similarly, Myin-Germeys & van Os (2007) suggested the existence of an affective pathway to 
psychosis, with roots in childhood trauma, which could increase vulnerability to stressors and 
affect the ability to adapt to stressful situations. Mueser et al. (2004) found high rates of trauma 
and Post-Traumatic Stress Disorder (PTSD) among individuals with schizophrenia.  
In addition to childhood trauma, Mueser, Lu, Rosenberg, & Wolfe (2009) argued that the 
experience of psychosis is traumatizing and may lead to the development of PTSD symptoms. 
Social stigma as a traumatic factor may play an important role. For example, Lolich & 
Leiderman (2008) found that individuals with a diagnosis of schizophrenia were the group most 
affected by stigmatization among clinical populations. Negative social stigma can impact life 
opportunities, quality of life and self-esteem, leading to social anxiety, social isolation and severe 
distress among individuals experiencing their first psychotic episode or among individuals with a 
diagnosis of schizophrenia (Birchwood et al., 2007; Crisp, Gelder, Rix, Meltzer, & Rowlands, 
2000; Reed, 2008). 
Stress is another environmental factor affecting schizophrenia. Research shows that 
individuals with schizophrenia do not experience more stressful life events than the normal 
population but they report greater subjective distress (Norman & Malla, 1993; Walker & Diforio, 
1997). This high sensitivity to stress is considered one of the main reasons for symptomatic 
relapse despite the use of antipsychotic medication (Corcoran et al., 2003). Myin-Germeys & van 
Os (2007) suggested that failure to regulate emotions during a stressful situation could increase 
emotional reactivity and vulnerability to stress. Livingstone, Harper, & Gillanders (2009) 
examined emotional experience and regulation in individuals who had experienced psychosis, 
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individuals with mood and anxiety disorders and non-clinical individuals. They found that both 
clinical groups had similar emotional experiences and both relied on less effective emotion 
regulation strategies such as worry and rumination.  
Individuals with schizophrenia have better outcomes related to the experience of positive 
emotions such as: warmth, contentment, love, kindness, and compassion. In a pilot study, 
Mayhew & Gilbert (2008) taught six individuals hearing malevolent voices to develop feelings 
of warmth, contentment and compassion. The participants’ auditory hallucinations became less 
malevolent, less persecuting and more reassuring. Johnson et al. (2009) targeted negative 
symptoms by teaching study participants to develop feelings of love and kindness and to direct 
these feelings towards themselves and others. Negative symptoms improved. In a forensic 
setting, Laithwaite et al. (2009) showed that developing positive emotions such as warmth and 
compassion facilitates recovery among individuals suffering from psychosis. Other studies also 
suggest that feelings of hope, optimism, and empowerment are related to better outcomes in 
schizophrenia (Ho, Chiu, Lo, & Yiu, 2010; Lecomte et al., 1999; Warner, 2009). 
2. Emotion regulation strategies in schizophrenia 
Koole’s literature review (2009) suggested that people can manage every aspect of 
emotion processing including how emotion directs attention, the cognitive appraisals that shape 
emotional experience and the physiological consequences of emotions, including body 
sensations. Henry, Rendell, Green, McDonald, & O'Donnell (2008) suggested two different ways 
to regulate emotions: suppression and re-appraisal. Suppression involves modifying or 
redirecting the focus of conscious attention to modify an emotion (e.g., distraction, avoidance of 
people, places, or objects that trigger the emotion); it also occurs after the emotional response 
has been triggered and requires managing the emotional expression and physiological response. 
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In contrast, re-appraisal is a cognitive process that is applied earlier. Re-appraisal alters a 
situation’s meaning, influencing the expression and experience of the emotion (Gross, 2007). 
According to Henry et al. (2008) re-appraisal involves higher order cognitive functions and is 
associated with increased positive affects and improved interpersonal functioning. A recent study 
conducted by van der Meer, Van't Wout, & Aleman (2009) showed that individuals with 
schizophrenia used suppression strategies more frequently than reappraisal strategies. The same 
was shown among recovered depressed patients and these strategies were demonstrated 
ineffective in down-regulating negative emotions (Ehring, Tuschen-Caffier, Schnlle, Fischer, & 
Gross, 2010). Among suppression strategies is expression suppression (e.g. facial or vocal 
expressions), Badcock, Paulik, & Maybery (2011) showed that greater use of expressive 
suppression among individuals with schizophrenia was associated with an increase in severity of 
auditory hallucinations and greater disruption in daily life. The authors suggested targeting 
expressive suppression in cognitive and behavioral treatments for schizophrenia.  
The individual’s belief system plays also an important role in the outcomes of emotion 
regulation strategies (Tamir, John, Srivastava, & Gross, 2007). Watson et al. (2006) suggested 
that enhancing perceptions of controllability and working with beliefs regarding the emotional 
states following an episode of psychosis can be useful intervention targets. According to 
Freeman & Garety (2003), both negative emotions (e.g., unhappiness, fear, guilt, anger, disgust, 
and horror) and positive emotions (e.g., happiness, excitement, and over-confidence) influence 
the content, form and maintenance of delusions and hallucinations. They argued that the content 
of delusions is likely to be a direct reflection of the emotional state of the individual (e.g., 
anxiety/depression and persecutory delusions, over-confidence and grandiosity) and that emotion 
directly triggers auditory hallucinations in individuals with a hallucinatory predisposition. The 
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authors suggested that by conceptualizing delusions as emotional beliefs and by treating the 
emotion, the clinician could reduce positive symptoms. These strategies resemble those used in 
traditional cognitive-behaviour therapy for psychosis (CBTp) and have been demonstrated to be 
effective (Beck et al., 2009; Wykes, Steel, Everitt, & Tarrier, 2008).  
2.1. Emotion regulation in CBT for psychosis  
Beck et al. (2009) emphasized the importance of exploring emotionally relevant matters 
for individuals presenting psychotic symptoms such as concern, worry, and distress early in 
therapy in order to validate their emotional experience and to enhance the therapeutic alliance. 
Similarly, Chadwick (2006) presented a person-based approach to psychosis and stressed the 
importance of addressing distress in psychosis rather than focusing on symptoms. Birchwood & 
Trower (2006) criticized some studies on CBTp for focusing on reductions in psychotic 
symptoms rather than presenting outcomes in distress reduction. The authors noted the critical 
role of emotional disorders, such as depression, social anxiety and post-traumatic stress disorder, 
in psychosis. Tai & Turkington (2009) considered the importance of factors other than the 
content and style of thought in the development and maintenance of psychotic symptoms and 
schizophrenia. Those factors include: arousal, emotion, attachment and interpersonal issues, loss 
and trauma, self-esteem, accepting, and self-to-self relating. Pankey & Hayes (2003) suggested 
that the relationship between emotions and psychotic symptoms is not direct but is mediated by 
the relationship an individual builds with his symptoms and the emotional regulation strategies 
the individual uses. Chadwick (2006) argued for the integration of emotion regulation strategies 
in CBTp. Among these strategies are: positive emotions, acceptance, detachment, meta-
cognition, imagery, and mindfulness. Positive emotions include hope, optimism, warmth, 
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compassion, contentment, empowerment, love, and kindness were discussed in a previous 
section. We will turn our attention to the remaining strategies: 
According to Hayes, Strosahl et al. (1999) acceptance requires embracing thoughts and 
emotions evoked in the moment, actively and with awareness, without unnecessary attempts to 
change their frequency or form. For example, someone with psychosis could be taught to accept 
experiencing fearful thoughts and emotions in times of stress, and to notice the signs and 
impulses. Acceptance plays a crucial role in the cognitive aspect of emotional regulation, i.e., the 
conscious and cognitive way of handling the intake of emotionally arousing information 
(Garnefski & Kraaij, 2007; Garnefski, Kraaij, & Spinhoven, 2001; Thompson, 1991).  
The distancing or detachment strategy teaches individuals to “distance themselves” from 
stimuli, thus becoming a “detached observer” (Beauregard, Lévesque, & Bourgouin, 2001). 
Detachment is a central component of Segal’s Mindfulness-Based Cognitive Therapy (MBCT; 
Segal, Williams, & Teasdale, 2002), which has shown to be somewhat effective in treating 
affective disorders (Baer, 2003; Hofmann, Sawyer, Witt, & Oh, 2010). Hayes, Strosahl et al. 
(1999) used a similar strategy called “cognitive defusion” to teach individuals to separate 
thoughts from actions. Cognitive defusion is based on the premise that if thoughts and feelings 
are not directly linked to actions, they are less threatening. Hoppes (2006) suggested that the 
ability to de-center from mental events provides opportunities to practice gaining distance from 
more intense and painful thoughts or emotions when they occur in real-life situations. The 
concept of detachment is closely related to the concept of meta-cognitive awareness, defined as 
“the process of experiencing negative thoughts and feelings within a decentered perspective” 
(Chadwick, 2006, p. 17). The integration of meta-cognition in CBTp was extensively addressed 
in a review by Tai & Turkington (2009). 
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Mindfulness has been defined as the act of “inward contemplation and the intermediate 
state between attention to a stimulus and complete absorption into it” (cited in Johnson et al., 
2009). Mindfulness can be practiced through meditation, an ancient Buddhist practice, or 
through cognitive and behavioral techniques. Among the cognitive techniques is to observe an 
emotion without judgment and without changing its content or intensity; to describe the observed 
emotion and body sensations using words; and to participate in the activity of the moment in a 
state of flow and spontaneity without being self-conscious (observe-describe-participate) 
(Linehan, 1993a, 1993b). An extended review on the role of mindfulness in emotion regulation 
was conducted by Chambers, Gullone, & Allen (2009).  
Morrison (2004) suggested the use of imagery in treating persecutory delusions. He 
argued that psychosis-related images are associated with memory of past events, including 
trauma, and may identify unhelpful beliefs about self, world, and others. Furthermore, Morrison 
suggested integrating imagery in CBTp to reduce the frequency of distressing images or to alter 
the content or interpretation of such images.  
Many recent CBTp studies are investigating functional and social outcomes beside 
symptoms reduction and some of them are integrating and testing several of the emotion 
regulation strategies. For example, Lecomte et al.’s single-blind randomized controlled trial 
(2008) showed effects on self-esteem, active coping and social support in addition to the 
reduction of positive and negative symptoms among CBTp participants. Many studies are using 
mindfulness as an adjunct to CBTp (e.g., Chadwick, Hughes, Russell, Russell, & Dagnan, 2009; 
Chadwick, Taylor, & Abba, 2005; Lavey, 2005). The results are encouraging, reporting 
significant improvement in negative emotions, and improvement in general clinical functioning. 
These studies demonstrate the potential usefulness and feasibility of teaching mindfulness to 
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individuals with a history of psychosis. Trappler & Newville (2007) used a group modality of 
CBTp called Skill Training in Affect Regulation (STAIR) to treat 24 inpatients with 
schizophrenia and histories of significant trauma and Complex PTSD. The treatment included 
emotional regulation strategies such as controlled breathing, grounding, and mindfulness. 
Patients were asked to use the skills they learned to carry out an extended recall of their 
traumatic experiences. The treatment was compared to supportive psychotherapy. After 12 
weeks, only patients undergoing STAIR demonstrated significant improvement in measures of 
tension, excitement, hostility, suspiciousness, and anger-control. Multiple studies (Bach, Hayes, 
& Gallop, 2012; Bach & Hayes, 2002; Garcia Montes & Perez Alvarez, 2001; Gaudiano & 
Herbert, 2006; Gaudiano, Nowlan, Brown, Epstein Lubow, & Miller, 2012; Shawyer et al., 2012; 
White et al., 2011) were also conducted using elements of acceptance and detachment in treating 
individuals with psychosis. The results demonstrated a significant decrease in re-hospitalization 
rates, improvement in affective symptoms, such as a decrease in the level of distress associated 
with hallucinations, and an increase in social functioning compared to controls.  
The importance of emotional regulation skills in CBT was recently investigated (Berking 
et al., 2008). The researchers compared a traditional CBT with a CBT including specific training 
in emotion regulation skills (i.e., acceptance, distress tolerance, and non-judgmental awareness) 
using 204 inpatients with different psychiatric diagnoses. Participants using CBT with emotion 
regulation showed a greater reduction in depression and negative affects, and a greater increase 
in positive affects compared to participants in the traditional CBT group. These findings provide 
preliminary support for using emotion regulation strategies to enhance the effectiveness of CBT 
based treatments; however, further research is warranted. 
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3. Conclusion 
According to the reviewed literature, we suggest developing integrated emotion 
regulation interventions using the discussed strategies in targeting expression, processing, and 
experience of emotions in schizophrenia. These integrated interventions might have considerable 
clinical benefit, however, their feasibility and effectiveness must still be evaluated. 
Even though emotion regulation is getting increased attention in recent psychological 
interventions and is beginning to be integrated with new cognitive behavioral therapies, a paucity 
of research studies exist on emotion regulation compared to cognitive appraisal or cognitive 
restructuring. Very few studies discuss emotion regulation strategies and even fewer measure 
changes in emotion regulation following treatment for individuals with schizophrenia or other 
psychotic disorders. According to the arguments presented in this part, emotion regulation 
strategies may play an important role in the symptomatic and functional outcomes of 
schizophrenia and they deserve increased attention in future clinical research on schizophrenia.  
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Abstract 
Background: Mindfulness-Based Therapy (MBT) has become a popular form of 
intervention. However, the existing reviews report inconsistent findings. Objective: To clarify 
these inconsistencies in the literature, we conducted a comprehensive effect-size analysis to 
evaluate the efficacy of MBT. Data Sources: A systematic review of studies published in 
journals or in dissertations in PubMED or PsycINFO from the first available date until May 10, 
2013. Review Methods: A total of 209 studies (n = 12,145) were included. Results: Effect-size 
estimates suggested that MBT is moderately effective in pre-post comparisons (n = 72; Hedge’s 
g = .55), in comparisons with waitlist controls (n = 67; Hedge’s g = .53), and when compared 
with other active treatments (n = 68; Hedge’s g = .33), including other psychological treatments 
(n = 35; Hedge’s g = .22). MBT did not differ from traditional CBT or behavioral therapies (n = 
9; Hedge’s g = -.07) or pharmacological treatments (n = 3; Hedge’s g = .13). Conclusion: MBT 
is an effective treatment for a variety of psychological problems, and is especially effective for 
reducing anxiety, depression, and stress. 
 
Keywords: mindfulness, meditation, meta-analysis, treatment outcome 
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1. Introduction 
An increasing number of meta-analyses and systematic reviews have investigated the 
effectiveness of mindfulness-based therapy (MBT). These reviews (listed in Table 1) reported 
inconsistent findings about the size of the treatment effect of MBT for reducing stress, anxiety, 
and depression associated with physical illness or psychological disorders (Baer, 2003; 
Bohlmeijer, Prenger, Taal, & Cuijpers, 2010; A. Chiesa & Serretti, 2010, 2011; Cramer, Lauche, 
Paul, & Dobos, 2012; de Vibe, Bjørndal, Tipton, Hammerstrøm, & Kowalski, 2012; Eberth & 
Sedlmeier, 2012; Fjorback, Arendt, Ørnbøl, Fink, & Walach, 2011; Grossman, Niemann, 
Schmidt, & Walach, 2004; Hofmann, Sawyer, Witt, & Oh, 2010; Klainin-Yobas, Cho, & Creedy, 
2012; Ledesma & Kumano, 2009; Musial, Büssing, Heusser, Choi, & Ostermann, 2011; Piet & 
Hougaard, 2011; Sedlmeier et al., 2012; Zainal, Booth, & Huppert, 2012).  
These inconsistencies may be due to a number of factors, including the choice of the 
MBT protocols, the restriction to specific research designs, and the inclusion of a particular 
group of patients. Moreover, little is known about the stability of treatment gains (Baer, 2003; 
Hofmann et al., 2010), about the active ingredients that may account for the efficacy of MBT (A. 
Chiesa & Serretti, 2011; Fjorback et al., 2011), and about the relevant moderator variables. It is 
assumed that mindfulness is a central mechanism of MBT (e.g., Richard Bränström, Kvillemo, 
Brandberg, & Moskowitz, 2010; Greeson et al., 2011; Kuyken et al., 2010; Shahar, Britton, 
Sbarra, Figueredo, & Bootzin, 2010) that might enhance positive affect, decrease negative affect, 
and reduce maladaptive automatic emotional responses (Gross, 2007; Hofmann, Sawyer, Fang, 
& Asnaani, 2012; Koole, 2009; Thompson, 1991, 1994). Although this is consistent with the 
notion that mindfulness training is associated with changes in areas of the brain responsible for 
affect regulation, and stress impulse reaction (Davidson et al., 2003; Hölzel et al., 2011; Lazar et 
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al., 2005) the empirical evidence for explaining the mechanisms of MBT remains sparse. 
Similarly, little is known about the potential moderators, including treatment duration (de Vibe et 
al., 2012; Hofmann et al., 2010; Klainin-Yobas et al., 2012; Sedlmeier et al., 2012), homework 
practice (Carmody & Baer, 2009; Fjorback et al., 2011; Toneatto & Nguyen, 2007), course 
attendance (de Vibe et al., 2012), and the clinical and mindfulness training and practical 
experience of the therapists delivering MBT (Carmody & Baer, 2009; Crane, Barnhofer, Hargus, 
Amarasinghe, & Winder, 2010; Davidson, 2010; Fjorback et al., 2011; Piron, 2001; Pradhan et 
al., 2007; Segal, Teasdale, Williams, & Gemar, 2002).  
In order to address the weaknesses of the current literature, we conducted a 
comprehensive effect-size analysis with the following objectives: (1) to quantify the size of the 
treatment effect with the maximum available data; (2) to investigate and quantify the role of 
mindfulness in MBT; and (3) to explore moderator variables.  
2. Methods 
2.1. Eligibility criteria 
Any study examining the pre-post or controlled effects of MBT for a wide range of 
physical and medical conditions, psychological disorders, and in non-clinical populations was 
considered in our analysis. Studies were excluded if they (1) did not include a mindfulness 
meditation-based intervention; (2) did not aim to examine treatment effects; (3) consisted of 
comparisons among meditators or among meditation styles; (4) examined the non-direct effects 
of mindfulness (i.e., mindfulness treatment administered to therapists and not directly to their 
clients); (5) examined mindfulness as a component of another treatment; (6) reported no clinical 
outcomes; (7) reported insufficient information to compute an effect size (e.g., only correlational 
data); or (8) reported data that overlapped with the data from other included studies. 
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The meta-analysis excluded studies that examined mindfulness as part of another 
treatment, such as cognitive behavior protocol, because it was difficult to dissociate the effect of 
mindfulness from other components. This led to the exclusion of Acceptance and Commitment 
Therapy (ACT; Hayes, Strosahl, & Wilson, 1999) and Dialectical Behavior Therapy (DBT; 
Linehan, 1993a, 1993b). Also, the meta-analysis excluded protocols using other forms of 
meditation (e.g., guided or concentration, or a combination of many meditation styles), excluding 
as result Loving-Kindness Meditation (LKM; Salzberg, 1995). A review of this specific 
meditation strategy can be found elsewhere (Hofmann, Grossman, & Hinton, 2011). Finally, 
studies based on meditation instruction, induction, or retreats were also excluded from this meta-
analysis. 
2.2. Information sources 
Studies were identified by searching PubMed and PsycINFO from the first available date 
until May 10, 2013. No limits were applied for language and foreign papers were translated into 
English. 
2.3. Search 
We used the search term mindfulness alone or combined with the terms MBSR or MBCT. 
2.4. Study selection 
Eligibility assessment was performed in a non-blinded standardized manner by the first 
author and was revised by the second author. Disagreements between reviewers were resolved 
through discussions, and in a few instances the authors of the original studies were contacted for 
clarifications. 
2.5. Data collection process 
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We developed an electronic data extraction sheet, pilot-tested it on five randomly-
selected studies, and refined it accordingly. Data collection was conducted for the first time in 
April of 2010, was re-conducted and refined in April of 2011, and updated in May of 2013. 
When duplicate reports were identified for the same data, only the latest ones were included.  
2.6. Data items 
Information was extracted from each included trial based on (1) the characteristics of the 
trial (including the year of publication, design, randomization, blinding, therapist qualifications, 
number of participants, type of outcome measures, and follow-up time in weeks); (2) the 
characteristics of the intervention (including treatment protocol, target population, length of 
treatment in hours, attendance in number of sessions, length of assigned home practice in hours, 
quality of home practice as reported by participants, and treatment setting); (3) the characteristics 
of the control group, in controlled studies (including the number of participants, type of control, 
type of treatment, and length of treatment); and (4) the characteristics of participants (including 
mean age, percentage of males, attrition rate, and diagnosis). We made conservative assumptions 
for missing or unclear data. For example, if the report neglected to describe the qualifications of 
the therapists, we assumed that the therapists did not have appropriate clinical/mindfulness 
training. 
2.7. Risk of bias in individual studies 
To minimize the influence of data selection, we included data pertaining to all available 
outcomes, but we divided them into clinical and mindfulness, because effect sizes might vary 
between these two groups. The clinical outcomes included both physical measures (e.g., pain and 
blood pressure) and psychological measures (e.g., anxiety and depression). Mindfulness 
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outcomes consisted only of measures of mindfulness. We included data from follow-ups, when 
such data were available.  
We also included a study quality score, which was comprised of items based on Jadad’s 
criteria (Jadad et al., 1996) and others pertaining to mindfulness. The included items are 
adherence of the treatment to an established protocol (MBSR, MBCT, MBRP, or MMRP); 
administration of measures at follow-up; use of validated mindfulness measures (i.e., MAAS, 
KIMS, FMI, FFMQ, SMQ, TMS, or CAMS-R); clinical training of therapists (i.e., clinical 
psychologists, trainees in clinical psychology, or social workers); and the mindfulness training of 
therapists (i.e., formal training in validated protocols, or mindfulness meditation 
training/experience). For controlled studies, the items included whether participants were 
randomized between MBT and control groups, whether participants in both groups spent an 
equal amount of time in treatment, and whether evaluators or experimenters were blind regarding 
the MBT/control conditions and/or participants were blind regarding the study’s hypotheses. For 
all binary items (i.e., true or false), a value of 1 was assigned if the item was true and a value of 0 
if it was false. For the study design, pre-post studies were assigned a value of 0; studies with a 
waitlist, no-treatment, or drop-outs control group were assigned a value of 1; studies with a TAU 
control group were assigned a value of 2; studies with a treatment control group (other than 
TAU) were assigned a value of 3. For blinding, non-blinded studies were assigned a value of 0; 
single-blind studies were assigned a value of 1; and double-blind studies were assigned a value 
of 2. 
The inter-rater agreement was assessed by comparing the ratings of the first author (B.K.) 
to the ratings of each of the four co-authors (G.F., M.M., P.T. and V.B.). Each co-author 
received a set of articles to review, along with a written document including specific instructions 
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on rating the studies. A one-hour training and discussion about the rating procedure was also 
provided.  
2.8. Summary measures 
The meta-analyses were performed by computing standardized differences in means. We 
completed all analyses using Microsoft Excel or Comprehensive Meta-Analysis, Version 2.2.057 
(CMA; Borenstein, Hedges, Higgins, & Rothstein, 2005). 
2.9. Synthesis of results 
Effect sizes were computed using means and standard deviations (SD) when available. In 
the remaining studies, the effect sizes were computed using other statistics such as F, p, t, and χ2. 
In within-group designs, when the correlations between the pre- and post-treatment measures 
were not available, we used a conservative estimate (r = .7) according to the recommendation by 
Rosenthal (1993). For all studies, Hedge’s g, its 95% confidence interval (95% CI), and the 
associated z and p values were computed. To calculate the mean effect size for a group of 
studies, individual effect sizes were pooled using a random effect model rather than a fixed effect 
model, given that the selected studies were not identical (i.e., did not have either an identical 
design or target the same population).  
For all study groups, the mean Hedge’s g, the 95% confidence interval (95% CI), and the 
95% prediction interval (95% PI) were computed. The prediction interval describes the 
distribution of true effects around the mean, whereas the confidence interval reflects the 
precision of the mean effect size. We systematically assessed the heterogeneity among studies in 
each group using I2 and the chi-squared statistic (Q). I2 measures the proportion of heterogeneity 
to the total observed dispersion, and is not affected by low statistical power. Higgins, Thompson, 
Deeks, and Altman (2003) suggested that an I2 of 25% might be considered low, 50% considered 
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moderate, and 75% considered high. We used these values when dividing studies into groups and 
when interpreting the results.  
2.10. Risk of bias across studies 
To assess publication bias, we computed the fail-safe N (Rosenthal, 1993) and 
constructed a funnel plot.  
2.11. Additional analyses 
According to the objectives of this meta-analysis, we conducted meta-regression and 
clinical significance analyses. The aim of meta-regression analysis is to assess the relationship 
between one or more variables (moderators) and the pooled effect size. Borenstein et al. (2009) 
suggested a ratio involving at least ten studies for each moderator. In this meta-analysis, we 
investigated eight moderators: the mean effect size of mindfulness outcomes (measuring the 
improvement in mindfulness among participants), treatment length, duration of home practice (as 
indicated in the mindfulness protocol), therapist clinical training, therapist mindfulness training, 
study quality score, the mean age of participants, and the year of publication. The study-to-
moderator ratio was very high (26).  
The aim of the clinical significance analysis is to assess the clinical implications of our 
findings. As physical symptoms were rarely assessed using similar measures, we only assessed 
the clinical significance of MBT for psychological measures, specifically measures regarding 
anxiety and depression. Therefore, we selected the Beck Depression Inventory (BDI-I; Beck & 
Streer, 1987), (BDI-II; Beck, Steer, & Brown, 1996), the Beck Anxiety Inventory (BAI; Beck & 
Streer, 1993), the 20-items Center for Epidemiological Studies Depression Scale (CES-D), and 
the State-Trait Anxiety Inventory (STAI; Spielberger, 1983), because these were the most 
commonly used measures. Weighted average means were calculated at pre-treatment, post-
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treatment, and follow-up. The results were interpreted according to the corresponding 
instrument’s manual. For BDI-I, raw scores of 0-9 were considered asymptomatic (or “minimal 
level of depression”), whereas scores of 10-16 indicated mild depression, 17-29 indicated 
moderate depression, and scores above 30 indicated severe depression. For BDI-II, raw scores of 
0-13 indicated minimal depression, 14-19 indicated mild depression, 20-28 indicated moderate 
depression, and 29-63 indicated severe depression. For BAI, raw scores of 0-7 were considered 
asymptomatic (“minimal level of anxiety”), whereas scores of 8-15 indicated a mild level of 
anxiety, scores 16-25 indicated moderate anxiety, and scores above 26 indicated severe anxiety. 
For the CES-D, scores ranged from 0 to 60, with higher scores indicating increasing severity of 
depression. Scores of 16 or higher are considered indicative of depression. Finally, for the STAI, 
raw scores of 0-39 were considered non-clinically anxious, scores of 40-51 were considered 
moderately clinically anxious, and scores above 51 were considered highly clinically anxious.  
3. Results 
3.1. Study selection 
PubMed searches produced 902 publications and PsycInfo searches yielded 1974 
publications. We carefully assessed the identified publications and applied the exclusion criteria, 
resulting in 209 studies (177 from journal articles and 32 from dissertations). Of the 209 studies, 
207 reported post-treatment assessments, and two of them reported only follow-up data. The 
study selection process is illustrated in detail in Figure 1. 
3.2. Study Characteristics 
The effect size (Hedge’s g) and other characteristics for each study are shown in Table 2. 
Studies were divided according to the methodological design. Then, within each of these groups, 
studies were sorted in an ascending manner: first, according to the target population (i.e., type of 
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participants); second, according to the implemented intervention; third, according to the 
comparison group; fourth, according to the study’s first author name; and finally, according to 
the year of publication. Seventy one studies were included in the 16 previously published meta-
analyses (listed in Table 1), while 138 studies were not included in any of the previous meta-
analyses. The total number of participants included in our meta-analysis was 12,145.  
Pre-Post design studies accounted for 72 studies, whereas the number of waitlist-
controlled studies was 67. Treatment controlled studies accounted for 68 studies. The most 
common disorders were mood and cancer (n = 25), followed by anxiety (n = 23), pain (n = 17), 
alcohol/substance use (n = 8), and fibromyalgia (n = 6). Overweight/obesity and social 
anxiety/social phobia had a similar frequency (n = 5), followed by HIV and post-traumatic stress 
disorder (n = 4), and Headache (n = 3). Attention deficit hyperactivity disorder, 
psychosis/schizophrenia, personality disorders, child sexual abuse, irritable bowel syndrome, 
brain injury, heart disease, tinnitus, multiple sclerosis, and rheumatoid arthritis were all with a 
similar frequency (n = 2). The rest of the disorders or conditions accounted for a single study 
each. Many studies targeted more than one disorder.  
3.3. Risk of bias within studies 
Table 2 presents the included studies and their quality scores. One hundred and nine 
studies were randomized, 93 used at least one validated mindfulness measure, 35 assured an 
equal time between treatment and control groups, and 28 used blind evaluators, including four 
that were double-blinded. For controlled studies, the total score varied from a minimum of 1 
(lowest quality) to a maximum of 11 (highest quality) with a mean of 4.84 (SD = 2.19) and a 
median of 5. For pre-post studies, the total score varied from a minimum of 0 to a maximum of 
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5, with a mean of 2.93 (SD = 1.19) and a median of 3. Inter-rater agreement was high (kappa = 
.94).  
3.4. Results of individual studies 
Hedge’s g values for both clinical and mindfulness outcome measures, and at both post 
treatment and last follow-up, are presented in Table 2. 
3.5. Synthesis of results 
3.5.1. Effect on clinical outcomes at the end of the treatment. The results of the main 
groups are represented in Figure 2. Thirty-five studies compared MBT with other psychological 
treatments. MBT was more effective than psychoeducational interventions (n = 9; Hedge’s g = 
.61; 95% CI [.27, .96], p < .001), supportive therapies (n = 7; Hedge’s g = .37; 95% CI [.17, .57], 
p < .001), relaxation procedures (n = 8; Hedge’s g = .19; 95% CI [.03, .35], p < .05), and 
imagery/suppression techniques (n = 2; Hedge’s g = .26; 95% CI [.10, .53], p < .005). However, 
the heterogeneity of effect sizes was high among studies comparing MBT with psychoeducation 
(I2 = 82.72%, Q = 46.29), moderate to high among studies comparing MBT to supportive 
therapies (I2 = 64.30%, Q = 16.81), moderate among those comparing MBT to relaxation 
procedures (I2 = 59.11%, Q = 17.12), but low among those comparing MBT to 
imagery/suppression techniques (I2 = 0.00 %, Q = 0.12). MBT did not differ from traditional 
CBT or behavioral therapies (n = 9; Hedge’s g = -.07; 95% CI [-.26, .16], p = .60, ns) or 
pharmacological treatments (n = 3; Hedge’s g = .13; 95% CI [-.11, .37], p = .27, ns). 
As Figure 2 shows, when investigating pre-post and waitlist controlled studies separately, 
effect sizes associated with MBT were larger when treating psychological disorders, and smaller 
when treating physical or medical conditions. Among psychological disorders, anxiety disorders 
showed the largest effect sizes, followed by depression. These effects were even larger when 
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only measures corresponding to the target disorder were included (e.g., only anxiety measures 
when the treatment targeted an anxiety disorder). The mean effect size on anxiety was large for 
ten pre-post studies, Hedge’s g = .89 (95% CI [.71, 1.08], p < .001) with low heterogeneity (I2 = 
13.90%, Q = 10.45), and in four waitlist controlled studies, Hedge’s g = .96 (95% CI [.67, 1.24], 
p < .001). The mean effect size on depression was moderately strong for five pre-post studies, 
Hedge’s g = .69 (95% CI [.52, .86], p < .001) and moderate for eight waitlist controlled studies, 
Hedge’s g = .53 (95% CI [.32, .73], p < .001). Studies targeting non-clinical populations showed 
a moderate to high mean effect size in 18 pre-post studies, Hedge’s g = .65 (95% CI [.51, .80], p 
< .001) and in 16 waitlist controlled studies, Hedge’s g = .62 (95% CI [.42, .82], p < .001). 
However, heterogeneity was high in both groups. No differences in the mean of clinical 
outcomes were found among groups based upon gender. 
3.5.2. Effect on clinical outcomes at the last follow-up. Follow-up periods varied across 
studies from three weeks to three years with a weighted mean of 28.92 weeks. Results at follow-
up were largely similar to those at the end of treatment. The follow-up effect sizes of pre-post 
studies (n = 24) showed an average effect size (Hedge’s g) of .57 (95% CI [.44, .69], < .001), 
waitlist controlled studies (n = 17) showed a Hedge’s g = .43 (95% CI [.31, .55], p < .001), and 
treatment controlled studies (n = 30) showed a Hedge’s g = .24 (95% CI [.12, .35], p < .001), 
heterogeneity was high among the three groups. 
Seventeen studies compared MBT with other psychological treatments at follow-up. 
MBT was more effective than supportive therapies (n = 3; Hedge’s g = .34; 95% CI [.11, .56], p 
< .005). The heterogeneity of effect sizes was moderately high (I2 = 48.78%, Q = 3.90). The 
effect size was small and not significant of studies comparing MBT with relaxation (n = 5), 
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psychoeducation (n = 3), and traditional CBT or behavioral therapy (n = 6; Hedge’s g = .04; 95% 
CI [-.22, .29], p = .78, ns). 
Treatments targeting psychological disorders showed larger effect sizes compared with 
physical/medical conditions in both pre-post and waitlist controlled studies. In addition, MBT 
was associated with the largest mean effect sizes for anxiety and depression and the smallest 
effect sizes for cancer and pain. Six pre-post studies targeting anxiety showed a mean effect size 
of Hedge’s g = .91 (95% CI [.69, 1.14], p < .001) at follow-up when only including anxiety 
measures; two pre-post studies targeting depression showed a mean effect size of Hedge’s g = 
.75 (95% CI [.38, 1.12], p < .001) when only including mood measures.  
3.5.3. Effect on mindfulness at the end of the treatment. A total of 93 studies included 
measures of mindfulness. Mean effect sizes of MBT on mindfulness at the end of the treatment 
were lower for treatment controlled-studies (n = 23; Hedge’s g = .42; 95% CI [.27, .57], p < 
.001) than for waitlist controlled-studies (n = 28; Hedge’s g = .53; 95% CI [.42, .65], p < .001), 
and pre-post studies (n = 42; Hedge’s g = .69; 95% CI [.59, .80], p < .001), heterogeneity was 
moderate in the three groups. Mean effect size of mindfulness outcomes was also higher in 
studies targeting psychological disorders compared to studies targeting physical or medical 
conditions. Five studies comparing MBT with relaxation showed the superiority of MBT on 
mindfulness (n = 5; Hedge’s g = .37; 95% CI [.04, .69], p < .05), heterogeneity was moderate (I2 
= 49.35%, Q = 7.90). Studies comparing MBT with other treatments (e.g., support, CBT, and 
imagery) did not reach statistical significance. 
3.5.4. Effect of mindfulness at the last follow-up. Only 31 studies reported measures of 
mindfulness at follow-up. Results indicated that mindfulness was maintained with similar effect 
sizes. Treatment-controlled studies showed the smallest effect size (n = 9), Hedge’s g = .30 (95% 
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CI [.13, .47], p < .005), heterogeneity was low (I2 = 22.71%, Q = 10.35), followed by waitlist-
controlled studies (n = 8), Hedge’s g = .56 (95% CI [.34, .78], p < .001), heterogeneity was 
moderate (I2 = 47.71%, Q = 13.39), and pre-post studies (n = 14), Hedge’s g = .66 (95% CI [.41, 
.92], p < .001), however, heterogeneity was high (I2 = 79.58%, Q = 63.67). 
3.5.5. Prediction intervals. We computed the prediction intervals (95% PI) for different 
groups of studies; results are presented in Figure 2 along with the 95% CI. In all groups, the 
prediction interval was wider than the confidence interval, a predictable result.  
3.6. Risk of bias across studies 
The effect size of all pre-post studies corresponded to a z value of 37.35 (p < .00001) 
indicating that 26,078 studies with a null effect size would be needed to nullify our results (i.e., 
for the two-tailed p value to exceed .05). Using the Trim and Fill method, 19 studies would need 
to fall on the left of the mean effect size to make the plot symmetric (Figure 3). Assuming a 
random effects model, the new imputed mean effect size was Hedge’s g = .44 (95% CI [.42, 
.46]). Similar results were obtained for waitlist controlled studies, with a z value of 21.06 (p < 
.00001) and a corresponding fail-safe N of 7,675. No studies were trimmed. For treatment-
controlled studies, z value was 15.95 (p < .00001) and fail-safe N = 4,434. When 12 studies were 
trimmed, the new imputed mean effect size was Hedge’s g = .26 (95% CI [.23, .30]). These 
analyses suggest that the effect-size estimates were unbiased and robust. 
3.7. Additional analyses 
3.7.1. Meta-regression results. The effect size of MBT on clinical outcomes was positively 
moderated by the effect size on mindfulness outcomes (n = 91; β = .41, SE = .04, p < .00001) 
(Figure 4), the duration of treatment (n = 182; β = .01, SE = .0015, p < .00001), the mindfulness 
training of the therapist(s) (n = 154; β = .13, SE = .04, p < .0005), negatively moderated by the 
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study quality score (n = 207; β = -.05, SE = .004, p < .00001), and the year of publication (n = 
207; β = -.01, SE = .003, p < .0005). The effect of MBT on clinical outcomes was not moderated 
by the duration of home practice (p = .09, ns), the clinical training of therapists (p = .07, ns), or 
by the age of participants (p = .78, ns).  
At follow-up, the effect size of MBT on clinical outcomes was positively moderated by 
the effect size on mindfulness outcomes (n = 28; β = .58, SE = .08, p < .00001), and negatively 
moderated by the study quality score (n = 65; β = -.029, SE = .006, p < .00005). The remaining 
moderators did not reach significance level.  
3.7.2. Clinical significance. Pre-treatment, post-treatment, and follow-up outcomes using BAI 
showed that a mild level of anxiety (n = 9) at pre-treatment (M = 12.17) was further reduced at 
both post-treatment (M = 7.51) and follow-up (M = 8.14). A moderate level of anxiety (n = 12) at 
pre-treatment (M = 19.34) was decreased to a mild level at both post-treatment (M = 11.79) and 
follow-up (M = 11.38). A severe level of anxiety (n = 1) at pre-treatment (M = 31.32) was 
decreased to a mild level at post-treatment (M = 12.93), no data were available at follow-up. On 
both BDI-I and BDI-II, a mild level of depression (n = 24 for BDI-I and n = 16 for BDI-II) at 
pre-treatment (M = 14.08 for BDI-I and 16.19 for BDI-II) was decreased to a mild level of 
depression at post-treatment (M = 8.77 for BDI-I and 8.64 for BDI-II), and to a mild or minimal 
level at follow-up (M = 10.48 for BDI-I and 9.70 for BDI-II). A moderate level of depression (n 
= 6 for BDI-I and n = 5 for BDI-II) at pre-treatment (M = 22.13 for BDI-I and 23.27 for BDI-II) 
was reduced to a mild level at both post-treatment (M = 13.43 for BDI-I and 14.12 for BDI-II) 
and follow-up (M = 13.93 for BDI-I and 14.97 for BDI-II). A severe level of depression (n = 1 
for BDI-I and n = 4 for BDI-II) at pre-treatment (M = 30.33 for BDI-I and 32.29 for BDI-II) was 
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reduced to a moderate to mild level at post-treatment (M = 12.33 for BDI-I and 21.13 for BDI-II) 
and to a mild level at follow-up (M = 18.56 for BDI-II).  
On the CES-D, results showed that non-clinical depression in five studies at pre-
treatment (M = 11.03) was further reduced at both post-treatment (M = 6.76) and follow-up (M = 
8.44). Clinical depression (n = 9) at pre-treatment (M = 18.31) became non-clinical at both post-
treatment (M = 13.48) and follow-up (M = 15.49). Finally, on the STAI, non-clinical anxiety in 
13 studies at pre-treatment (M = 35.91) was further reduced at both post-treatment (M = 31.25) 
and follow-up (M = 29.35). A moderate clinical anxiety (n = 22) at pre-treatment (M = 42.94) 
was reduced to non-clinical level of anxiety at post-treatment (M = 39.73) and to a mild level at 
follow-up (M = 40.33). A high clinical anxiety (n = 8) at pre-treatment (M = 52.87) was reduced 
to moderate levels at both post-treatment (M = 47.20) and follow-up (M = 46.54).  
4. Discussion 
This meta-analysis examined 209 studies with a combined total of 12,145 participants of 
diverse ages, genders, and clinical profiles. The wide variety of studies, the variety of 
participants, and the use of meta-analytic validity measures allowed us to clarify some 
inconsistencies concerning the therapeutic value of MBT. The results showed that MBT is 
moderately effective in pre-post studies. When compared to some other active treatments 
(including psychoeducation, supportive therapy, relaxation, imagery, and art-therapy), the effect 
sizes were small to moderate, suggesting the superiority of MBT. However, MBT was not more 
effective than traditional CBT.  
MBT was more effective in treating psychological disorders than it was in treating 
physical or medical conditions. More specifically, MBT showed large and clinically significant 
effects in treating anxiety and depression, and the gains were maintained at follow-up. These 
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findings were similar to those obtained in previous meta-analyses (e.g., Hofmann et al., 2010). In 
addition, the average attrition among participants in the selected studies (16.25%) was smaller 
than the attrition rate usually obtained in cognitive and behavioral studies (e.g., 22.5% of 1,646 
patients offered CBT in an National Health Service clinic in the UK; Westbrook & Kirk, 2005). 
These results suggest a high commitment among participants to MBT. 
One obvious question is whether MBT also changes measures of mindfulness. 
Surprisingly, mindfulness was measured in only 45% of all studies. The results showed that 
participants in MBT were more mindful at the end of the treatment, and that gains were 
maintained at the last follow-up. In addition, there was a strong positive correlation between the 
mindfulness levels of the participants and the clinical outcomes. These results provide 
preliminary support for the role of mindfulness in the effectiveness of MBT. Future studies will 
need to explore the mechanism of action for MBT. Similarly, little is known about treatment 
moderators, such as therapists’ training. We observed that therapists’ experience with 
mindfulness, but not their general clinical training, moderated clinical outcomes at the end of the 
treatment, which was consistent with earlier reports (Pradhan et al., 2007), suggesting that 
therapists’ experience with mindfulness might have a direct or an indirect effect on the clinical 
outcomes of the participants (Grepmair et al., 2007). Unfortunately, however, very few studies 
have quantified the therapists’ training experience. Future studies should explicitly report this 
information. 
In contrast with previous meta-analyses of MBT (Hofmann et al., 2010; Klainin-Yobas et 
al., 2012; Piet & Hougaard, 2011), our results showed that the study quality score negatively 
moderated the efficacy of MBT, pointing to expectancy and other biases. Similar results were 
obtained in other meta-analyses (e.g., Wykes, Steel, Everitt, & Tarrier, 2008). However, the 
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duration of treatment and the assigned homework practice time did not consistently moderate the 
efficacy of MBT. These results are consistent with the contradictory outcomes found in the 
published literature. Better efficacy predictors could be attendance and the actual duration of 
home meditation practice, because they measure motivation and might indicate whether 
participants find the intervention useful (Carmody & Baer, 2008; Toneatto & Nguyen, 2007; de 
Vibe et al., 2012). Other possible moderators include meditation depth (Piron, 2001) and group 
cohesion (Imel, Baldwin, Bonus, & Maccoon, 2008). 
In order to conduct a comprehensive review of the literature, we inevitably included 
studies with different levels of quality, which we quantified and included in the analyses. Our 
meta-analysis only included mindfulness meditation protocols, limiting the scope of the results to 
this particular practice. To address our own expectancy bias, we implemented liberal selection 
criteria and included a large variety of studies. Despite these limitations, our results showed that 
MBT is moderately to largely effective. Furthermore, the findings suggest that mindfulness is a 
central component of the treatment effectiveness, and that the mindfulness of participants and of 
therapists is a strong predictor of effective MBT. We recommend conducting more 
methodologically rigorous studies to establish the efficacy of MBT in comparison with, or in 
addition to, other standard treatments (especially to CBT) and in order to thoroughly examine 
and quantify moderators and mediators of effective MBT. 
5. Funding 
No official funding was provided to conduct the current meta-analysis. Materials (e.g., 
software) were provided by the Laboratory for Education on Schizophrenia and Psychoses 
Oriented to Intervention and Recovery of Dr. Tania Lecomte.  
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Table 1. 
Results from previous empirical reviews and meta-analyses 
________________________________________________________________________________________________________________________ 
Review/Meta-analysis Description   Ns Np  g, d, r, rr, or 95%CI  p  FS N ES FU  I2 
________________________________________________________________________________________________________________________ 
Baer (2003)   General review  15 998 .59 (d)  -  -  - .59  - 
   Axis-I disordersa  4  .96 (d)  -  -  - -  - 
   Chronic pain   4  .37 (d)  -  -  - -  - 
Grossman et al. (2004) MBSR only  
   Mental health    18 894 .50 (d)  [.43, .57] <.0001  - -  - 
                                    Physical health   9 566 .42 (d)  [.34, .50] <.0001  - -  -
Ledesma & Kumano (2009) MBSR for cancerb            
   Mental health   7 416 .48 (d)  [.38, .59] <.0001  10 -  - 
   Physical health  8 516 .18 (d)  [.08, .28] <.0001  136 -  - 
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Table 1. (continued). 
________________________________________________________________________________________________________________________ 
Review/Meta-analysis Description   Ns Np  g, d, r, rr, or 95%CI  p  FS N ES FU  I2 
________________________________________________________________________________________________________________________ 
Bohlmeijer et al. (2010) MBSR for mental healthb 8 667 
    Depression outcomes  6  .26 (g)  [.18, .34] <.001  31 -  0.00 
    Anxiety outcomes  4  .47 (g)  [.11, .83] <.05  - -  53.95 
Hofmann et al. (2010)   MBT (MBSR + MBCT) 39 1,140    
    Anxiety outcomes    .63 (g)  [.53, .73] <.01  4,150 .60  - 
    Depression outcomes    .59 (g)  [.51, .66] <.01  4,302 .60  - 
                Anxiety disorders only  7  .97 (g)  [.72, 1.22] <.01  - -  - 
                         Mood disorders only  4  .95 (g)  [.71, 1.18] <.01  - -  - 
Chiesa & Serretti (2009) MBSR for healthy people 10 671  
               Stress outcomes    .74 (d)  [-.03, 1.51]   
                  Spirituality     .82 (d)  [-.01, 1.65] 
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Table 1 (continued). 
________________________________________________________________________________________________________________________ 
Review/Meta-analysis Description   Ns Np  g, d, r, rr, or 95%CI  p  FS N ES FU  I2 
________________________________________________________________________________________________________________________ 
Chiesa & Serretti (2011) MBCT for mental disorders 14 866 
    MBCT + TAU vs. TAU 4 384 .36 (or) [.24, .86] <.005  - -  29.00 
Fjorback et al. (2011)c MBT (17 MBSR, 4 MBCT) 21 1,827 
Piet & Hougaard (2011) MBCT vs. control  5 408 .66 (rr) [.53, .82] <.005  14 -  0.00 
    MBCT vs. m-ADM  2 179 .80 (rr) [.60, 1.08] .15, ns  - -  0.00 
Musial et al. (2011)  MBSR for Cancer  19 1,118 
    Mood states   10 411 .42 (d)  [.26, .58] <.0001  - -  73.50 
    Reduction in distress  15 587 .58 (d)  [.45, .72] <.0001  - -  67.20 
    Quality of life   6 248 .29 (d)  [.17, 0.40] ≤.00005 - -  23.40  
Klainin-Yobas et al. (2012) MBT for mental disorders 39 1,847 
               MBT vs. TAU   11 438 .53 (d)  [.39, 67] <.001  6 -  44.47 
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Table 1 (continued). 
________________________________________________________________________________________________________________________ 
Review/Meta-analysis Description   Ns Np  g, d, r, rr, or 95%CI  p  FS N ES FU  I2 
________________________________________________________________________________________________________________________ 
Sedlmeier et al. (2012) MdBT in non-clinical  163  .26 (r) d 
    MdBT versus relaxation 10  .21 (r)  
    MdBT versus no-treatment 125  .27 (r)  
de Vibe et al. (2012)  MBSR    31 1,942   
    Mental health outcomes 26  .53 (g)  [.46, 61] -  - -  0.00 
    Somatic outcomes  10  .31 (g)  [.10, .52] -  - -  11.00 
Eberth & Sedlmeier (2012)    MM in non-clinical                39                     .56 (d)              -                      -                       -           -                       - 
Zainal et al. (2012)                 MBSR for breast cancer         9          470 
                                     Stress                                       8          307       .71 (d)   [.51, .91]         -                       -           -                      37.99 
                                    Depression                              7           392       .58 (d)             [.43, .72]        -                       -           -                       .00 
                                    Anxiety                                   4           166       .73 (d)             [.45, 1.1]        -                       -           -                       40.23 
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Table 1 (continued). 
________________________________________________________________________________________________________________________ 
Review/Meta-analysis Description   Ns Np  g, d, r, rr, or 95%CI  p  FS N ES FU  I2 
________________________________________________________________________________________________________________________ 
Cramer et al. (2012)              MBSR or MBCT for BCb       3          327       
                                               Depression                              2           147       .37 (d)             [.08, .65]        < .05                -           -                       .00 
                                               Anxiety                                   2           147       .51 (d)             [.21, .80]        < .001              -           -                       .00 
                                   Spirituality                              2           147       .27 (d)             [-.37, .91]       .41, ns             -           -                       79.00 
 
Note. Ns = Number of reviewed studies; Np = Overall number of participants; g = Hedge’s g; d = Cohen’s d; r =  Standardized  effect size; rr = risk 
ratio; or = odds ratio; FS = Fail-Safe; ES FU = Effect Size at Follow-Up; aIncluded anxiety, depression, and binge eating; MBSR = Mindfulness-
Based Stress Reduction; bIncluded only randomized controlled studies; MBT = Mindfulness-Based Treatments;  MBCT = Mindfulness-Based 
Cognitive Therapy; TAU = Treatment As Usual; cEffect sizes were not pooled; Mm-ADM = maintenance Antidepressant Medication; MdBT = 
Meditation-Based Treatment; dr = .26 is equivalent to a Cohen’s d of .58 (assuming equal sample sizes for meditation and control groups); MM = 
Mindfulness Meditation; BC = Breast Cancer. 
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Table 2.  
Description and Effect Size Analyses of the Efficacy of the selected Mindfulness-Based Studies 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Pre-Post Studies 
Zylowska et al.,      ADHD-           -           38      MAPs(23)    -                 -          0      20      9.3    ADHD Sx;BAI;BDI             .59         -               2 
2008 (m5,11)          Dep-Anx(32) 
van de Weijer-        ADHD           13.4      50      MM              -                  -         0     12       -        CBCL;YSR;BRIEF;              -.01      16             4 
Bergsma et al.,        (10)                                       (8)                                                                         FFS;SHS (MAAS)                 (.08)     .29(.34) 
2012 
Zgierska et al.,        Alcohol        38.4      47      MMRP         -           -          -      16      24     PDA;HHD;TD                    .57         -                4 
2008                        depend(19)                            (15)                                                                       SCL-90R;OCDS (MAAS)   (.89) 
Miller et al.             Anxiety(22)    38         -         MBSR(17)   -                 -          -       -        -        MIA;BAI;BDI;FSSa;           .50         156(.57)   2 
1995 (m1,2,11)                                                                                                                                   HAM-A;HAM___________ 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Manzaneque           Anxiety-          -            43.8    MM(16)      -                 -           -       8       16     MH-5;                                  1.11            -          1 
et al., 2011             Depression (16)                
Joo et al., 2010       ASH(11)        52.6      45.5   MBSR(11)   -           -          -      20      -        BDI;STAI                      .70         26             1  
Deckersbach          Bipolar             38.7      25      MBCT         -                  -           25    24     45    HAM-D;YMRS;PSWQ;      .43        13              4  
et al., 2012             (12)                                         (12)                                                                       RSQ;ERS;ASRS;CPAS      (.64)      .31(.44) 
                                                                                                                                                            PWBS; LIFE-RIFT; 
Azulay et al.,         Brain injury      48.9     50       MBSR       -                  -          0       20     -         PQOL;PSES;SPSI-RSF       .34          -              4 
2012                       (22)                                         (22)                                                                       (MAAS) 
Smith et al., 2006   BED(25)        47.8      20      MBSR(25)   -                  -          -       -        -        STAI(MAAS)                      .67(.85)   -              3 
Sachse et al.,           BPD               39         13.6    MBCT         -                  -          27.3  16    -        STAI;BDI-II;DES-II           .20          -               2 
2011                        (22)                                        (22)                                                                       SDQ;BIS-11(FFMQ)          (.18)
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Lengacher et al.      Breast Canc.   56.8      0        MBSR(19)   -           -          -      16   36      PSS;STAI;CES-D;MSAS    .32          -               3 
2011 (m10, 15,16)  (19)                                                                                                                     LOT-R;QoL;Social Support  
Matousek and         Breast Canc.   56.4      0       MBSR    -           -          9      26    49 MSCL;Coping; CES-D;      .49        -           3 
Dobkin, 2010          (59)         (57)       PSS;SoC;(MAAS)          (.33) 
(m10,15)  
Chambers et al.,      Cancer-            67        100     MBCT        -                 -           21      20     28    HADS;IES-R;EPIC;          .00        13                5 
2012                        Prostate (19)                           (15)                                                                      MAX-PC;FACT-P             (.16)     .11(.53) 
                                                                                                                                                            (FFMQ) 
Ando et al., 2009    Cancer(28)      60         14.3   MBSR(28)   -           -          -       29.5   36 HADS;FACIT-Sp          .25        -                 3  
Birnie et al., 2010   Cancer(42)      62.9     50      MBSR(42)   -           -          50    15    - POMS;C-SOSI(MAAS)      .32(.42) -                2 
(m10) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Carlson and         Cancer(63)      54        22.2    MBSR(63)  -            -          -       15     36 POMS;SQ;SOSI          .63        -                  3 
Garland, 2005 (m3,5,10) 
Carlson et al.,          Cancer(59)      54.5     17       MBSR(42)   -           -          32.2 15    -        SOSI;Phy. measures;QoL    .38       -                  1 
2003 (m3,5,10) 
Garland et al.,         Cancer             53.5     15.7    MBSR          -                 -          -       26     36      C-SOSI;POMS                     .51       -                  3 
2013                        (268)                                       (268)                                                                     (MAAS;FFMQ)                   (.58) 
Kieviet-Stijnen        Cancer(47)      48.4     27.7   MBSR(46)  -           -          17    27.5  42 POMS;QoL;                         .33       52(.49)        3 
et al., 2008 (m5,10)           Phy. Sx(RSC);HDI  
Knauss , 2008         Cancer(20)       -          5        MBSR(20)  -           -           -      -    - QoL(MAAS;KIMS)          .68        -                  3   
                                    (1.00) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Epstein-Lubow       Caregivers       56.2     0         MBSR          -                 -          0     9.5    24      CESD;STAI;ZBI                 .49         4                2 
et al., 2011              (9)                                           (9)                                                                        SF-36(KIMS)                      (-.13)     .39(-.28) 
Minor et al.,          Caregivers      38        13.6     MBSR(44)   -           -          -      16    36 POMS;SOSI           .76        -         2 
2006          (44) 
Lengacher et al.,     Cancer            53.5      30.8    MBSR          -                 -          8.3   6      36      CESD;PSS;STAI;SF-36;     .34        -                 3 
2012                        patients (26) +                        (24)                                                                      MSAS;  
                                Caregivers     51.5      38.5     (23)              -                  -         11.5  6      36     CESD; PSS; STAI; SF-36;   .10        -                3 
                                (26)                                                                                                                     MSAS; 
Kimbrough et al.,    Child sexual   45        11       MBSR(23)   -           -         14.8  27    17.5 BDI-II;BSI;PCL                  .64        24       4 
2010 (m11)         abuse(27)         (MAAS)           (.57)     .43(.47) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Baer et al.,              Chronic            49       33      MBSR           -                -         17      -        -        PSS                                       .92        -                2 
2012                        illness (87)                            (87)                                                                       (FFMQ)                                (.80) 
Simpson &              Chronic          51        21      MBSR          -                    -      10     27      42       SF-36;DASS;VAS;PCS;     .63        26              5 
Mapel, 2011            illness (29)                           (29)                                                                        PGIC(KIMS)                        (.56)     .06(.09) 
Eisendrath et al.,     Depression      -          25.5    MBCT(51)   -           -         7       16     0 BAI;BDI;RRQ                  .58        -                 4 
2008 (m11)             (55)          (FMI)                                    (.58) 
Michalak et al.,       Depression     47.1     21.7     MBCT(20)  -           -         13     -     -       Phy. Measures                .54        -                 1 
2010          (20)                     (body movement & speed) 
Wood, N. A.,          Depression     46.3     92.6     MBCT(5)    -                 -          81.5  20      -       BAI;BDI;SF-36                    .68        8        5 
2010          in HIV/AIDS(27)        (MAAS)            1.13      .82(.74) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Kenny and         Depression/    43.3     26       MBCT(48)  -            -         2      17    56 BDI                   .85        -                2 
Williams, 2007       Bipolar(48) 
(m5,11) 
Mathew et al.,         Depression/    23.1     -       MBCT(14)   -           -         25.8  -      -          BDI-II                       .65        52     4 
2010 (m11)             Bipolar(39)                       .71 
Lush et al., 2009     Fibromyalgia  44       0       MBSR(24)  -                   -         20.9  20    36 BSI;BAI;BDI;                      .28        -          3 
(m5)         (24)          Physiological recording          
Craigie et al.,          GAD(23)        43.4    26       MBCT(20)   -           -         13.0  18    - BAI;BDI-II;PSWQ;           .64        13     4  
2008 (m5)             DASS(A,D&S);RRAQ;QoL            1.00 
Evans et al.,            GAD(11)        49       45.45   MBCT(11)  -           -          -       16    28 POMS;PSWQ;BAI;BDI      .83        -                 3 
2008 (m5,11)            (MAAS)           (.77) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Kabat-Zinn             GAD(20)        38        -       MBSR(10)   -                  -         8.3     -      - MIA;BAI;BDI;FSSa;          .5          13     2 
et al., 1992 (m1,2,5)           HAM-A;HAM-D                            .55  
Robinson, 2002       HIV(15)        41        94.1    MBSR(15)   -                  -         -        27.5  42 POMS;FAHI;           .22        13      4 
             Phy. Measures           .54 
Lovas and         Hypoch.        35.6     50       MBCT(10)   -           -         -        16    28 HCQ;Avoidance;BAI;         .82(.66) 13     5 
Barsky, 2010           (10)          BDI-II;HAI;PHQ;WI;             .97(.76) 
(m11)             QOLWHO(FFMQ) 
Carmody and         Mixed1(174)   47.1    37       MBSR    -           -         15      26    45 MSCL;BSI;PWBS          .65  -     2 
Baer, 2008           (174)      (FFMQ)            (.69) 
McKim, 2008         Mixed1(32)     50.4    34       MBSR(32)   -           -          -       16    - MSCL;BSI(MAAS)          .78(.55)   -      2 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Reibel et al.,         Mixed2        47.2     29       MBSR         -           -         11     -        - MSCL;SCL-90;SF-36         .56       52       2 
2001 (m1,2,5,11)    (121)         (103)                     .37 
Ree and Craigie,     Mood/        39.5     23       MBCT   -           -         11.6  20   36  SES;BDI;ISI                       .59        13      4 
2007 (m5,11)         Anx.(23)         (23)       DASS(A,D&S)(MAAS)     (.48)     .62 
Collard et al.,          Non-             -          16.7     MBCT       -           -         20     16    -  PANAS                     .40        -                  4 
2008           clinical(15)        (15)       (MAAS)                     (.48) 
Lee et al.,                Non                10.5     40       MBCT       -                    -         32     18   18  CBCL;MASC;STAIC;       .37        -       1 
2008           clinical(25)        (17)       RCDS 
Schroevers and       Non-               42.2      28      MBCT    -                  -          25    26    42  PANAS;                      .57        -                  4 
Brandsma, 2010     clinical(64)                            (64)       (KIMS;SCS)            (.53) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Chang et al.,         Non-              46.5      42.9    MBSR    -           -          35    26    36  PSOM;PSS           1.50      -      2 
2004 (m14)        clinical(43)                   (43)       (MSE)           (2.14) 
Deyo,                    Non-               28.6     28.6     MBSR    -                 -           56.3 -    -  RRQ;BDI;SOSI          .26        -            3 
2008         clinical(7)                                (7)         (KIMS)           (.64) 
Evans et al.,        Non-               48        35.7    MBSR          -                 -           -       28    35  POMS                      .77        -       4 
2010         clinical(14)                   (14)       (MAAS)           (1.21) 
Fang et al.,        Non-               50.8      33.3    MBSR    -                 -           21     20    20  BSI-18;SF-36           .53        -                 1 
2010         clinical(24)                   (17)       
Flugel Colle           Non-               46.7      12.5    MBSR         -                  -          6.3    27.5  -   LASA                                  .55        -                 2 
et al., 2010        clinical(16)                   (16) 
  
98 
 
 
Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Greeson et al.,         Non-               45        24.7    MBSR          -           -         0      27    23 SF-12;DSES                      .40        -                 3 
2011          clinical(180)                   (180)      (CAMS-R)           (1.09) 
Imel et al.,         Non-               46.3     28       MBSR          -                 -          -       29    36 MSCL;SCL-90          .78        -                 3 
2008          clinical(606)                         (606) 
Michaels,         Non-               45.6     33.3    MBSR    -           -          -       24     -        DASa                                  .80        -                 3 
2009          clinical(24)                   (24)      (KIMS)           (.89) 
Newsome,         Non-               29.3     12.9    MBSR    -           -         -        12    24 PSS                                      .99        4                5 
2010          clinical(31)                   (31)      (MAAS;SCS)                    (.95)     1.14(1.18) 
Frewen et al.,          Non-               -           30       MBSR +    -           -         33      20    - DASS(A,D&S);                   .89        -                 3 
2008          clinical(43)                   MBCT (24)     UBC-CI-LGR;Indiv-NGLG 
             (KIMS;MAAS)          (.92) 
  
99 
 
 
Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Galantino et al.,      Non-               43         4       MBSR +      -                 -          -       16   28 POMS;IRI;cortisol          .21        -                 0 
2005          clinical(84)                   MBCT (69) 
Duncan &               Non-               34.6      25      MBCP         -                  -          -       33   27 PANAS;DES;CES-D;         .57        -                 3 
Bardacke, 2010      clinical(27)                   (27)      PSS;Pregnancy anxiety       (.80) 
                                                                                                                                                 (FFMQ)            
Kearney et al.,       Obesity in        49         87.5   MBSR        -                    -        10.4   27    36      TFEQ;FFQ;PHQ;                .81         17              4 
2012                       veterans (48)                          (48)                                                                       PCL-C(FFMQ)                    (.79)      .46(.81) 
Dalen et al.,           Overweight     44         30      MEAL  -           -          0      16   21 TFEQ;BES;BAI;BDI;         .59        6                 2  
2010         (10)         (10)      PSS;PANAS(KIMS)           .60        .68(.79) 
Kim et al., 2010     Panic(23)        41.2      57      MBCT(23)   -           -         -       12    - HAM-A; PDSS          .68       52     2 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Zoysa et al.,            MH Pro.          35         22.2   MBCT         -                  -         -       20      36     GHQ-12;SWLS;PSWQ;       .78       78              5 
2012                        (18)                                        (18)                                                                       STAI;LES(MAAS)              (1.16)   1.31(1.14) 
Brady et al.,            MH Pro.         -            19      MBSR          -                  -         21.7   4       12     MBI;SOSS;MHPSS;           .46        -                2 
2012                        in an APU(16)                       (16)                                                                       (TMS)                                   (.63) 
Beddoe et al.,         Pregnancy       -         0       MBY(16)    -                 -          10.5  9   0 PSS;STAI            .50       -                 1 
2009          (16) 
Newsome et al.,      Professionals   29.3     12.9   MBSR (31)   -                 -        0       12     24      PSS;                                       .99       4               5 
2012                        in training (31)                                                                                                    (MAAS; SCS)                       (.95)    1.14(1.06) 
Smith, 2010         PSTD(29)       46.7     0       MBSR(15)   -           -         -      21    30 PSTD Sx;            1.29      -      4 
             (MAAS;SCS)            (1.08) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Green & Bieling,   Psychiatric        53.65   21.7  MBCT          -                 -        34     16     36       BDI-II;PLS-SDHS;              .47        -                4 
2012                       Patients (23)                          (23)                                                                        (TMS)                                  (.38) 
Goldin and Gross,   SAD        35.2     -         MBSR    -           -         12.5   27.5 18.1   SES; BDI-II; LSAS; STAI   .98        -                2 
2010 (m11)             (16)         (16) 
Bogels et al.,           SP(9)        32.4      33      MBCT(9)    -                  -         11    8    - FNE;SPB;SFA;           .74       8     3 
2006 (m5)            SCL-90;Self-Other-Ideal           .94 
Marcus et al.,          SU(21)        33.4      85.7   MBSR(16)   -                  -         23.8 20   42 PSS                                   .12       -                 3 
2003 
Maddox,                 SU                  44         -         MBRP         -                   -        0       12     10      UPPS+P;                               .07        -                3 
2012                       (14)                                        (14)                                                                       (FFMQ)                                 (2.24) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Gans et al.,              Tinnitus          58         75     MBSR         -                   -         20    27      24      THI;HRQoL;PAS;VAS;       .48       -                4 
2013                         (10)                                       (8)                                                                          HADS;SF-36;SCL-90-R       (.31) 
                                                                                                                                                            (FFMQ) 
Rimes &                 Trainee           -             0       MBCT        -                   -         0       -        -         PSS;HADS;RI;RRQ             .55       -                2 
Wingrove, 2011      Clinical Psychologists(20)    (20)                                                                       (FFMQ;SCS)                         (.52)   
Baker et al.,             Urinary          54.9      0        MBSR        -                   -         0      14.3    -        OABq-SF;HRQOL;PGI-I     .75       52              4 
2012          Incontinence (7)        (7) 
Waitlist/No-Treatment Controlled Studies 
Vøllestad et al.,       Anxiety        42.5      32.9   MBSR         Waitlist       yes     10.5  26   28 BAI;BDI-II;BIS;STAI          .70       26     6 
2011          (76)         (31)              (34)     PSWQ;SCL-90-R;(FFMQ)   (.83)    .78(.59) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Spek et al.,              Autism           42.3      65.9   MBCT          Waitlist      yes      2.4   22.5   45     SCL-90-R;RRQ;GMS;         .76        -                6 
2013                        (42)                                        (21)              (21)                                                  WAIS-III; 
Bédard et al.,          Brain Injury    42.1      23.08 MBSR   drop-outs    no       23.1 15   20 SF-36             1.56     -      2 
2003 (m5)         (13)         (10)    (3) 
Kang & Oh,            Breast Canc.    -          -       MBSR    No-Tx        no       -       24      -        PSS                                       .92       -                 4 
2012                        (50)                                        (25)              (25) 
Witek-Janusek        Breast Canc.   53         0       MBSR    No-Tx        no       13.6 25    - Phy. measures;QoL           .64       4     5 
et al., 2008 (m10)   (68)          (38)    (28)     (MAAS)             (.49) 
Hoffman et al.,        Breast Canc.   49        0         MBSR         Waitlist      yes      7      22.5   36     POMS;FACT-B;                   .36       4               6         
2012                        (229)                                      (114)            (115)                                                FACT-ES;WHO-5                            (.36) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Lengacher et al.,     Breast Canc.   57.5     0       MBSR   Waitlist       yes      2.4  12   36 MSAS;CESD;LOT;          .20        -                5 
2009                        (82)         (40)              (42)     PSS;QoL 
(m5,10,13,14,15,16)  
Perez-Blasco           BFM              34.33    0        MBSR+        No-Tx        yes      19.2 16      -        PES;DASS(A,D&S);SHS   .80        -                4 
et al., 2013              (26)                                       MBCT(13)  (13)                                                    SWLS(FFMQ; SCS)           (1.09) 
Monti et al.,            Cancer        53.6     0       MBAT         Waitlist      yes      16    20      24 SCL-90                      .51        -                 4 
2006 (m3,4,8,10)    (111)         (56)              (55) 
Van der Lee and     Cancer        52        16.3    MBCT   Waitlist       yes      5      28.5  40.5 CIS;SIP;Well-Being          .49        26    6 
Garssen, 2010         (100)         (59)              (24)                     .75 
Matchim et al.,       Cancer        59.3     0       MBSR   No-Tx         no       11.1 26   42 POMS;SOSI           .51        4               6 
2011 (m10,15)        (32)         (15)              (17)     (FFMQ)           (.43)      .33(.72)
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Bränström et al.,     Cancer        51.8     1.4      MBSR   Waitlist       yes      16.5 16    -  PPS;IES-R;PSOM          .39        26             7 
2010; 2012         (71)         (32)              (39)     (FFMQ)           (.44)      .28 
(m10,13) 
Campbell et al.,      Cancer             53.21   0         MBSR         Waitlist       yes     22.2 18    36       RRQ                                     .40         -               6 
2012                       (35)                                         (19)              (16)                                                  (MAAS)                               (.61) 
Foley et al.             Cancer        55.2     22.6    MBSR   Waitlist       yes     10.4  21   37.3   DASS(A,D&S);HAM-A;    .51        13    7 
2010 (m8,10)        (115)         (55)              (60)     HAM-D (FMI)          (.63)     .72(.75) 
Speca et al., 2000   Cancer        51        18.9    MBSR   Waitlist       yes     17.4  10.5   - SOSI;POMS           .35        -                3 
(m1,2,3,4,              (90)         (53)              (37)  
5,8,10,13) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Mackenzie et al.,    Caregivers       46.8     3.3     MBSR   Waitlist       no       -       2   5 SRDI;MBI;JSS;OLQ           .64        -                 2 
2006 (m12,14)        (30)         (16)              (14) 
Rimes &                 Chronic           43.5     17.1   MBCT         Waitlist       yes     11.1   18     -        CFS;WSAS;PF-10;BAES;   .48       26               7    
Wingrove , 2013     Fatigue (35)                          (16)              (19)                                                   HADS;CBRSQ(FFMQ)       (.47)    .38(.56)  
Alberts et al.,          Disordered      48.5      0        MBCT   Waitlist       yes      0        20     36    Weight; DEB-Q; BSQ;         .48        -                4 
2012                        Eating (26)                            (12)              (14)                                                   DTS; G-FCQ-T(KIMS-E)    (.56) 
Britton et al.,         Depression     47.7     23.1   MBCT   Waitlist       yes     19.2  26      - BDI;Sleep Diaries          .16        -                 5 
2010 (m7)         (26)         (12)              (8) 
Godfrin and van     Depression     45.7    18.9    MBCT   Waitlist       yes     10.4  22   48 POMS;BDI-II;HADS;         .79        56              5 
Heeringen, 2010     (106)         (34)              (41)     QLDS                     .39 
(m7,9,11) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Williams et al.,       Depression/    44        26.7    MBCT   Waitlist       yes     18.1  22   36 BAI;BDI           .70        -                 6 
2008 (m7,11)         Bipolar (48)        (21)              (27) 
Teixeira, 2010         DPN(22)        74.6     25       MM(10)   No-Tx(10)  yes     10      -   - Pain;QoL           .60        -                 3 
O’Connor et al.,      Depression     77        32.5    MBCT        Waitlist       no      33.3   18     36      BDI-II;HTQ;ICG-R;            .09        22              4 
2013                        in elderly (48)                       (18)             (18)                                                    CES;LNSeq; 
Thompson et al.,     Epilesy        35.9     19       MBCTip    Waitlist       yes      24.5 8   - BDI;mBDI;PHQ-9;          .11        -                 4 
2010          (40)         (13)              (27)     DCSES;BRFSS;(SCS) 
Sephton et al.,         Fbmlgia        48        0       MBSR    Waitlist      yes      17.7 27.5  30 BDI            .57        8     8 
2007 (m4,5,8,13)    (91)         (51)              (39)                   .43 
Weissbecker et al.,  Fbmlgia        48        0       MBSR   Waitlist       yes      25    20    -  Sense of coherence          .51        -      3 
2002 (m13)             (91)         (51)              (40)  
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Sumter et al.,          Forensic        33        0       MM   No-Tx         yes      -       17.5  0 Ph. Sx, NE;NB          .44        -                 4 
2009          (33)         (17)              (16) 
Asmaee Majid        GAD              32.19    100     MBSR         No-Tx         yes      -      16     28       BAI; BDI-II; PSWQ;                        -               4 
et al., 2012              (33)                                        (16)             (15)  
Houghton,         GAD        43.4     0       MBSRi   Waitlist       yes      27.6 5   8.8 STAI;FWS           1.09      -                4 
2008          (100)         (50)              (50)     (KIMS)                    (.91) 
Day et al.,               Headache       41.7     11.1     MBCT         Waitlist       yes      25   16     36      Headache diary;VAS;BPI;   .89        -                6 
2013                        (36)                                        (19)             (17)                                                   PCS;HMSE;CPAQ(MAAS) (.77)  
Cathcart et al.,         Headache     45.78     43       MBSR         Waitlist      yes       27.6  12    10.5   DASS;Headache diary;       .02         -                7 
2013                        (58)                                       (29)              (29)                                                   (FFMQ)                               (-.09) 
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
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________________________________________________________________________________________________________________________ 
Geary &                  Health care  45.27     10        MBSR         No-Tx       no        -        34    -         PSS;SF-36;DSES;              .88         52              4 
Rosenthal (2011)    employees (108)                    (59)             (49)                                                   SCL-90R                                           (.77) 
Robert-McComb     Heart        60        0       MBSR   Waitlist       yes      0      16    -   SF-36            .35        -      3 
et al., 2004 (m13)    Disease (18)        (9)               (9) 
Tacón et al., 2003    Heart        60.5     0       MBSR   Waitlist       yes     10     24    - PF-SOC;CECS;STAI          1.02      -      3 
(m4,5,12,13,14)      Disease (18)        (9)               (9) 
Duncan et al.,          HIV+             48        84       MBSR         Waitlist       yes     14     30     45      ACTCS-CL;BDI;PSS          .15        13               6 
2012                        (76)                                       (40)             (36)                                                    ART side effects (FFMQ)   (-.04)     .29(.07) 
Carmody et al.,       Hot flashes     53        0       MBSR   Waitlist       yes     9.1    26   36 HADS;PSS;SQ;QOL          .52        13     6 
2011          (110)         (57)              (48) 
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
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________________________________________________________________________________________________________________________ 
Morone et al.,         Low Back       74.9     43.2    modified   Waitlist       yes     19     12   36 MPQ-SF;CPAQ;          .27        13     6 
2008                        Pain (37)         MBSR(19)   (18)     QoL(SF-36);Ph. Fn 
(m4,8,12,13,14) 
Roth and         Mixed3        47.9     14       MBSR   No-Tx         no       34    16   30 SF-36;FH;SQ           .42        -                 3 
Robbins , 2004        (86)         (68)              (18) 
Sampalli et al.,        MS                 45.8     0       MBSR   Waitlist       no      16     31    - SCL-90-R;BSI;MPQ;          .32        10     4 
2009          (76)         (50)              (26)     QolWHO             .58 
Skovbjerg et al.,      MCS              51.6     5.4      MBCT          No-Tx        yes     29.7  20     36      SCL-92;Brief IPQ               .04         12             6 
2012                        (37)                                       (17)               (20)                                                                                                            .06 
Heeren et al.,           Non-               55.5     16.7   MBCT   No-Tx         no      14.3  8    - AMT;Cognitive measures   2.20       -                2 
2009 (m12,14)        clinical(36)                   (18)              (18) 
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
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________________________________________________________________________________________________________________________ 
Raes et al.,              Non-               41.6      41      MBCT   Waitlist       yes     -      -    - BDI-II;LEIDS-R          .43        -                 4 
2009 (m11)         clinical(39)                   (18)              (21)     (KIMS)           (.62) 
Berghmans et al.,    Non-               28.4      21      MBSR   No-Tx         yes     26.9  20    -       HADS;PSS;           .37        -                 3 
2010          clinical(26)                   (10)         (9)     Social Dysfunction 
Kang et al.,             Non-        22.5      0       MBSR   No-Tx         yes     22     14    - BDI;STAI;PWI-SF          1.26      -                 4 
2009         clinical(32)                   (16)         (16) 
Potek, 2012            Non-clinical     15         51.6   MBSR         No-Tx        yes      -        4         1     PSS;MASC;DERS               .48       -                7   
                               Adolescents(31)                     (16)              (15)                                                  (FFMQ)                                (.34) 
Anderson et al.,      Non-                39.2      -       MBSR         Waitlist       no      15.2  16    - NAI;PANAS;ARS;ASI;      .42        -                 4 
2007 (m12,13,14)  clinical(72)                   (39)         (33)     BAI;BDI;PSWQ;RSQ;RUM 
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________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Dziok, 2011           Non-                 43.7     15.4   MBSR   Waitlist       yes       -       12    36      STAI;CESD;PHQ-9;           1.11      -                 4                  
                               Clinical(52)                           (39)              (13)                                                   MaQ 
Nyklicek and        Non-                43.6     33      MBSR   Waitlist       yes      24    26   37.3   GMS;PSS;QoLWHO;VE    .63        -                 4 
Kuijpers, 2008       clinical(57)                   (29)         (28)     (KIMS;MAAS)          (.59) 
(m8,12,13,14) 
Klatt et al., 2009     Non-                45       28.5    MBSRld   Waitlist       yes      8.3   6   7.7 PSS;PSQI           .20        -                 4 
(m6,12,13,14)        clinical(45)                   (22)         (20)     (MAAS)           (.39) 
Robins et al.,          Non-                46.2    16       MBSR         Waitlist       yes      21.4  27     36     CFQ;DERS;AFQ;RRS;        .59        8               7 
2012                       clinical(56)                            (28)              (28)                                                  PSWQ;SAES;MSCDS         (.88)      .57(.92) 
                                                                                                                                                           (FFMQ;SCS)             
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Hoffmann Gurka,   Non-        -           20       MM    Waitlist      no       -      18    -  PWS;SCL-90-R;MSCL;      .16        2     3 
2006         clinical(109)                   (77)               (32)     USQ              .16 
Hanstede et al. ,      OCD        25.7     29.4    MM    Waitlist      no       -      8   28 OCI-R                       1.38      -                 2 
2008          (17)         (8)       (9)     (MQ)            (1.61)  
Daubenmier           Overweight      40.9     0        MB-EAT+    Waitlist      yes    29.2  29.5   27     BRS;WCSI;PSS;                 .44        -                 5 
et al., 2011             (47)                                        MBSR(24)    (23)                                                 STAI;DEB-Q(KIMS)         (.60) 
Poelke,                    Overweight    40.9      0       CALMM    Waitlist      yes      0      29.5  31.5  RSES;PStS;SSS;          .23        -        2 
2009          (38)         (18)     (15)                BASS;CRS   
Sagula and Rice,     Pain                -           25.64  MBSR    Waitlist      no       20.4  12   18.7   BDI;STAI                      .28        -                 3 
2004 (m5)         (39)          (27)     (13) 
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Nyklíček et al.,       Personality      46.07   31       MBSR         Waitlist      yes      12.5  26     36      PANAS;                              .32        -                5 
2012                        Type D (147)                         (73)              (74)                                                  (MAAS;KIMS)  
Vieten and Astin     Pregnancy5     33.9     0       MMI   Waitlist       yes      -      16   18.7  CESD;PANAS;PSS;STAI  .87        -      7 
2008 (m6,13)         (31)         (13)    (18)       (MAAS)           (.51) 
Chadwick and         Psych./SZ       41.6     21.7    MM   Waitlist       yes      9.1   10   15.2  CORE;PSYRATS;              .38        -                5 
Hughes, 2009         (18)         (9)       (9)       BAVQ-r (SMQ, SMVQ)     (.64) 
Pradhan et al.,         RA        54.5     12.7    MBSR   Waitlist       yes      7.9    27.5  36  DAS-28;SCL-90-R;PWBS  .21       17     7 
2007 (m4,5,8,13)    (63)         (31)    (32)       (MAAS)             (.13) .43(.16) 
Semple,                   Reading        10        40       MBCT-C   Waitlist       yes      14    12    -   CBCL;STAIC;GMRT         .28       13     4 
2006                  difficulties (25)        (13)     (12)                    .07 
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
De Raedt et al.,       RDP               45.2      26.7   MBCT         No-Tx         no        -       27     -        HAM-D;MINI;BDI-II         .64        -               3 
2012                        (71)                                       (45)              (26)                                                   (MAAS)                               (.44) 
Crane et al.,          RDP               44.65   -       MBCT   Waitlist       yes      30    22    0 BDI             .67       -                5 
2008 (m7,11)         (42)                    (19)    (23) 
Ramel et al.,         RDP    50.9     65                  MBSR   Waitlist       no        -      20    35 SCID;BDI;STAI;           .48       -                 4 
2004 (m5,11)         (23)             (11)    (11)      DASb 
Geschwind et al.,    RDS               43.9      24.6   MBCT        Waitlist        yes     2.3    20     36      HAM-D;IDS;                       .52        52              5 
2012                        (130)                                     (64)             (66) 
Arana,          SAD        -        31.8    MBSRi   Waitlist       yes      -      18   16 CBSS;Shy Q;BAI;BDI;      .87        -                 5 
2006          (22)         (10)    (12)      LSAS;SWLS (MAAS)        (.89)  
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Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
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________________________________________________________________________________________________________________________ 
Murray,         Sex as        19.4     100     MBSR   No-Tx         yes     18.5   -       - CUSI;NMRS;PANAS         .78        -                 4 
2005 (m13)         coping (22)        (11)    (11)  
Langer et al.,          Schizophrenia  34.7   58.74   MBCT         Waitlist       yes    21.7   8      -         CGI-SCH                             .55         -                7 
2012                       spectrum (23)                          (7)               (11)                                                   (SMQ)                                  (1.00)  
Spragg,                   Trainees in       25.5   6.25      MBSR         Waitlist      yes     -       27.5   36     SCoS;IRI;MBI                     .11         4               6 
2011                        mental-health(16)                   (8)                (8)                                                  (KIMS)                                (.16)      .13(.30) 
Ramel et al.,         RDP    50.9     65                  MBSR   Waitlist       no        -      20    35 SCID;BDI;STAI;           .48        -               4 
2004 (m5,11)         (23)             (11)    (11)       DASb 
Geschwind et al.,    RDS               43.9      24.6    MBCT        Waitlist       yes     2.3    20     36       HAM-D;IDS;                       .52        52            5 
2012                        (130)                                      (64)             (66) 
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________________________________________________________________________________________________________________________ 
Arana,          SAD        -        31.8    MBSRi   Waitlist       yes      -      18   16  CBSS;Shy Q;BAI;BDI;      .87        -                 5 
2006          (22)         (10)    (12)       LSAS;SWLS (MAAS)        (.89) 
Murray,         Sex as        19.4     100     MBSR   No-Tx         yes     18.5   -       -  CUSI;NMRS;PANAS         .78       -                 4 
2005 (m13)         coping (22)        (11)    (11) 
Treatment Controlled Studies 
Murphy,          Aggression     32.7     100     modified     Relaxation  yes     16.1  12   26  STAXI-II            .06       -                 7 
1995 (m2,13)         (31)         MBSR(15)  (16) 
Garland et al.         Alcohol dep.   40.3     79.2    MORE   Support       yes     30.2  10   17.5  GPS;PSS;Craving           .45       -                 8 
2010          (53)         (18)    (19)       (FFMQ)            (-.05) 
Kim et al.,               Anxiety        39. 5     63      MBCT   PsyEd          no       0      12   0  BAI;BDI;HAM-A;           1.36     -                 7 
2009 (m5,7,11)       (46)         (24)   (22)                  HAM-D;SCL-90(A&D) 
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________________________________________________________________________________________________________________________ 
Pbert et al.,             Asthma           52.8      32.5   MBSR         Education   yes      10.8  26     24      PEF;PSS;AQOL                   .48       52              7 
2012                       (83)                                        (42)              Program (41)                                                                                              (.54)  
Koszycki et al.,       Anxiety        38.3     47       MBSR   CBGT         yes     23     27.5  28 MINI;LSAS;CGI-SoI;          -.66      -       6 
2007 (m5,8,11,13)  (GSAD) (53)        (26)   (27)     SIAS;SPS;IPSM;BDI-II;    
             LSRDS;QoL 
Arch et al.,              Anxiety            46      83        MBSR        CBT            yes     32.4   18    30      PSWQ;MINI;BDI-II            .08        13              11 
2013                        (105)                                     (45)             (60)                                                                                                              .08 
Perich et al.,            Bipolar         -        34.7     MBCT +      TAU           yes      29.5   18    30      MADRS;YRMS;DASS;      .12         52             8    
2012                        (95)                                       TAU (48)     (47)                                                   STAI;DASb;RSQ(MAAS)   (.32)       -.21(.17) 
Lengacher et al.,     Breast Cancer   57.2   0         MBSR   TAU           yes    2.4       12   18      STAI;CES-D;LOT-R;PSS;   .21         -               5  
2012                        (82)                                       (40)              (42)                                                   SF-36;SoSS  
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________________________________________________________________________________________________________________________ 
Würtzen et al.,       Breast Cancer   54.14  0        MBSR +      TAU            yes      18.5   21      -      SCL-90R;GSI;CES-D          .25        52             7 
2013                       (336)                                      TAU (168)  (168)                                                                                                            (.24) 
Garland et al.,        Cancer        52.5     8.7      MBSR   Art Th.        no      24     15   42 POMS;FACIT-Sp;SOSI      .28        -      6 
2007 (m3,5,10)      (104)         (60)   (44)  
Oken et al.,        Caregivers       64.9     23.8   MBCT   PsyEd          yes    10     9    - PSS;SF-36;CES-D;             .05        -                 9 
2010         (31)         (10)    (11)      GPSE;PSQI;ESS;  
                                                                                                                                                            (MAAS;FFNJ)         (-.18) 
Whitebird et al.,    Caregivers        56.8      11.5  MBSR   CCES         yes      10    25      -        PSS;CES-D;STAI;              .32         26              9 
2012                      (78)                                         (38)               (40)                                                  SF-12;MBCBS;MOSSSS                 (.32) 
Pipe et al.,       Caregivers     49.8       3.1     MBSR   Course/       yes     3       10   56 SCL-90           .59        -                 6 
2009        (32)        (15)               seminar (17)  
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________________________________________________________________________________________________________________________ 
Wong et al.,            Chronic pain    47.9      0      MBSR          MPI            yes      15      27     -       NRS;POMS;SF-12;STAI;    .00       26              10 
2011                        (99)                                       (51)              (48)                                                   CES-D;Sick leaves;                          (.00) 
Mularski et al.,       COLD           67.4     98.8   MBBT   Support       yes     43       -    - MSAS;PSS;SFS-36;           -.10       -                10 
2009 (m8)               (86)         (20)    (29)      Phy. measures (FFMQ)        (-.04) 
Bieling et al.,          Depression      44        42       MBCT         ADM          yes      22.2  22     -        HAM-D;EQ                         .43         26             8 
2012                        (84)                                        (26)             (28)                                                   (TMS)                                   (1.26)              
Manicavasgar         Depression      45.8     35.4    MBCT   CBT           yes     23     16   42 BAI;BDI-II            -.24       28      9 
et al., 2010 (m11)   (45)          (19)    (26)                   -.28 
Chiesa et al.,         Depression      51.93     25     MBCT        PsyEd         yes     16.7   16    30     HAM-D;BAI                         1.01       -                9 
2012          (16)                                         (9)              (7)                                                    PGWBI(MAAS)                   (-.78)  
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________________________________________________________________________________________________________________________ 
Kingston et al.,       Depression      41.8     10.5    MBCT   TAU           yes     21.4 17    - BDI;RUM           .88        4     5 
2007 (m5,7,11)       (17)         (6)    (11) 
Barnhofer et al.,      Depression     41.9     32.1    MBCT +   TAU           yes      9.7  17   48 BDI-II;BSS           .80        -                 7 
2009 (m5,7,11)       (28)         TAU (14)    (14)  
Ma and Teasdale,    Depression     44.5     64       MBCT +    TAU           yes     4      16    -  RR            .92        13     7 
2004 (m7,8,9,11)     (75)         TAU (37)    (38) 
Weiss et al.,             Depression/   42.8      38       MBSR   Support       no       0      8    36  GSI            .62        26     7 
2005          Anxiety (31)                   (15)     (16) 
Pinniger et al.,        Depression      44.39   9.1      MM            Tango          yes     10.3   9      -         DASS-21;SWLS;RSES       -.06       -               8 
2012                       (97)                                         (16)            (21)                                                    (MAAS)                               (-.14) 
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________________________________________________________________________________________________________________________ 
Parra-Delgado &    Fbmlgia          52.7     0         MBCT +     TAU            yes     11.8  20     -          MINI;BDI;VAS;FIQ;         .82          13            7  
Latorre-Postigo,     (33)                                        TAU (17)    (16)                                                                                                                (1.27) 
2013 
Grossman et al.,      Fbmlgia        52        0       MBSR   Support       no       10    27    42  HADS;PPS;IPR;          .68 156     6 
2007 (m5)         (52)         (29)     (13)       SSI;QoL 
Schmidt et al.,         Fbmlgia        52.5     0       MBSR   Relax.         yes      18    27    49  PPS;CES-D;PSQI;          .18 8     12 
2011          (177)         (53)    (56)       STAI;QoL (FMI)          (.26) .18(.30) 
Hoge et al.              GAD               39.16   49.44  MBSR          SME         yes       15    20      18      HAM-A;CGI-S;CGI-I;       .45          -               7 
2013                        (93)                                       (48)               (45)                                                   BAI;TSST 
Nash-Mc Feron,     Headache        49.5     17.5    MBSR +   TAU          yes     7.5     4    - SCI;Headache Log;          .58 -     5 
2006          (40)         TAU (19)     (18)      SF-36  
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________________________________________________________________________________________________________________________ 
SeyedAlinaghi        HIV+              35.9     69       MBSR         Support       yes     29.4  16    -         SCL-90-R;MSCL                 .33       52             9  
et al., 2012              (173)                                      (87)             (86)                                                                                                             (.13) 
Gayner et al.,          HIV+              44        100      MBSR         TAU          yes      26.9 30    48       IES;HADS;PANAS;           .26        26              6 
2012                        (117)                                      (78)               (39)                                                (TMS)                                 (.98)     .37(.60) 
McManus et al.,      Hypochon.     42.64   24.3    MBCT +      TAU           yes       4     16   48        SHAI;WI;BAI;BDI-II;        .33        52             8 
2012                        (74)                                       TAU (36)     (38)                                                  (FFMQ)                                             .47 
Zernicke et al.,        IBS                44.4     10       MBSR          TAU           yes       23    15     -       POMS;C-SOSI;IBS-QOL;  .33         26             4 
2012                        (90)                                       (43)              (47)                                                  IBS-SSS; FACIT-Sp                        .09 
Gaylord et al.,         IBS                42.73    0        MBSR         Support        yes      5.6    20     -       IBS-SSS;IBS-QOL;BSI      .41        13             11 
2011                        (75)                                       (36)             (39)                                                   VSI (FFMQ)                        (.51)      .53(.48)  
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________________________________________________________________________________________________________________________ 
Gross et al.,         Insomnia        49.2     26.7   MBSR  Pharm.         yes      10     26   36 ISI;SF-12;PSQI          .04 13     7 
2011          (30)         (20)   (10)           .11 
Kristeller et al.,       BED              46.6       12      MB-EAT    PECB          yes      24.5  16     -        TFEQ;PFS;ESES;               .05          17            8 
2013                        (150)                                     (53)             (50)                                                   BDI-II;RSES;BMI                             (.03)  
Biegel et al.,            4Mixed          15.3     26.5    MBSR +    TAU          yes     18.3  16   25.7  GAF(DSM);SCL-90;           .47          13     7 
2009          (85)         TAU (34)    (40)      PSS;STAI              .73 
Grossman et al.,      MS        47.3     21       MBSR +     TAU          yes     5       27   37.3 MFIS;CES-D;STAI;           .71          26    7 
2010 (m13)         (150)         TAU (76)    (74)      HAQUAMS               .41 
Rosenzweig et al.,   Non-               -           -         MBSR   course/        no       -     15   20 POMS            .52         -   4 
2010          clinical (277)        (125)    seminar (152)  
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Shapiro et al.,          Non-               29.2     11.1   MBSR   course/        no       23.8 16    - PANAS;PPS;RRQ;          .82        -                7 
2007 (m6,12,14)     clinical (54)        (22)    seminar (32)     STAI (MAAS;SCS)          (.85) 
Trotter,                    Non-               23        36.4    MBSR   PsyEd         no        -      30    - HSCL;RPWS;SF-13          .11        -                6 
2010 (m12)         clinical (55)        (26)    (29)       (SCS)                      (.33)  
Agee,                     Non-               41.6     9.3      MBSR   Relaxation  yes      16.3  22.5  36 HS;BSI;PSS;STAI          -.31      13    9 
2007          clinical (43)        (19)    (24)       (MAAS)                     (-.10)    -.39(.12) 
Jain et al.,         Non-        25        18.5    MBSR   Relaxation  yes      22.1  12    -  PSOM;BSI;QoL          .22        -                7 
2007 (m6,12,13,14) clinical (51)        (27)    (24) 
Smith et al.,         Non-               44.9     20       MBSR   Relaxation  no       21.9  30     - BES;PWBS;PSS;       .59       -                8 
2008 (m12)         clinical (50)        (36)    (14)       BDI-II (MAAS)          (1.04) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Kingston et al.,        Non-        23        21       modified   Imagery      yes      6.7   26   7 PT;PANAS           .21        -                 8 
2007 (m12)         clinical (42)        MBSR(21)  (21)       (KIMS)                      (.61) 
Liehr and Diaz,       Non-        9.5       71       MI      PsyEd         yes      -      3   - STAI;SMFQ           .72        -                 6 
2010          clinical (18)        (8)       (8) 
Langer et al.,         Non-               21.3     15.7    MTI   course/        yes      39.7 8    - RHS            .29        16     6 
2010          clinical (38)        (18)    seminar (20)                   .43 
Blevins,                   Overweight    20.7     0       MBT   Exposure     yes     14    16    - RSES;QEWP-R;BASS;       -.19      13     8 
2009          (23)               (12)    Therapy (11)    ASS;BMI;Weight;BDI;       -.31 
Plews-Ogan et al.,   Pain        46.5     23.3    MBSR   Massage      yes     23.3 30    - STAI;SF-12           1.16      4     6 
2005 (m13)         (30)               (6)       Therapy (8) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Cusens et al.,          Pain        47.3     21.3    MM             TAU           no       9.1   20   35 DAPOS;CPAQ;PSEQ;        .50        -                 4 
2010          (53)               (24)    (20)                 PCS;SF-36(MAAS)          (.61) 
Bratton,         Pregnancy      29        0       MM   Relaxation  no       20     6   6 STAI;W-DEQ                      -.10        40     7 
2008          (20)                               (10)   (10)                                                    (KIMS)                      (.05)     -.10(.04) 
King et al.,              PSTD in         59.27   -          MBCT         TAU          yes       0       16     24      CAPS;                                 .61         -               6 
2013                        Veterans (37)                        (20)               (17) 
Niles et al.,              PSTD in         52.0     100     MBSR          PsyEd        no       18.2  3.5    10.5  CAPS;PCL-M;                    1.08       6               8                    
2012                         Veterans (33)                       (17)               (16)                                                                                                             (.03) 
Kearney et al.,         PSTD in         52        78.7    MBSR +       TAU          yes     6.4    27     36      PCL-C;PHQ-9;SF-8;           .31         17             7 
2013                         veterans (47)                        TAU (25)      (22)                                                 HRQOL;BADS(FFMQ)     (.59)       .31(.58) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Teasdale et al.,        RDP        43.3     24.1    MBCT +   TAU           yes     9       26.5  16 Depression -                    .53        60     7 
2000                        (145)                               TAU (76)   (69)                                                   Relapse rate 
(m1,7,8,9,11) 
van Aalderen           RDP        47.5     29.3    MBCT +   TAU           yes     8.1    26     36     HAM-D;BDI;PSWQ;           .40        52             8   
et al., 2012              (205)                               TAU (102)  (103)                                                 RSS;QoLWHO(KIMS)        (.54) 
Williams et al.,        RDP        43.9     26.8    MBCT +    TAU           yes      -      16    - HAM-D           .35        17     5 
2000 (m1,7)         (41)                               TAU (21)   (20) 
Zautra et al.,         RA        54.3     31.9    MM&ER   Pharm.        yes      1.4   16    - Pain Diary;PANAS;Pain;    .04        -          10 
2008          (144)                               (41)   (35)                                                   Depressive Sx;Coping;Control 
Goldin et al.,           SAD                32.9     50      MBSR        Aerobic       yes       25   27       -        LSAS;SDS;MSCDS           .40         -                8 
2012                        (56)                                        (31)             (25)                                                   (FFMQ)                               (.64)                         
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Brotto et al.,        Sexual distress  35.9     0        MBT            CBT            yes      0      3        -      FSDS; FSFI                         .06         -                7                 
2013         in women (20)                        (12)               (8)                           
Brewer et al.,         Smokers         45.9     62.1    MBRP +        ALA-FFS  yes      12    12     14     TLFB                                  .45        -                  8 
2011                         (88)                                      MMRP (41)   (47) 
Piet et al.,                SP        21.8     30.8    MBCT   CBT           yes      22.7 16    32.7   SIAS;IIP;SDS;BAI;SPS;     .00        52     7 
2010 (m7)         (26)                               (14)   (12)                                                    BDI-II;FNE;LSAS;SCL-90-R         .06 
Bowen et al.,           SU        37.4     79.2    MBRP   TAU           no       49.7 60    0  DDQ;DDTQ;BSI          .57        26     4 
2006 (m12)         (87)                               (29)   (58) 
Bowen et al.         SU        40.5     63.7    MBRP   TAU          yes       45   16      42      TLFB; PACS; SIP-AD          .20       16     7 
2009                     (168)          (93)    (75)      (FFMQ)            (.29)     .08(-.16) 
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Table 2 (continued). 
________________________________________________________________________________________________________________________ 
Study          Type               Mean   %       Treatment    Comp.         Rand  %     Tx     Prac   Clinical Measures                Post      Foll wks    Qual 
                                Particip(N)     Age      Male  Group (n)     Group (n)   Assn   Att   hrs     hrs     (Mindfulness Measures)      g(gm)   g(gm)        Scor 
________________________________________________________________________________________________________________________ 
Lee et al.,                SU in              40.7    100      MBRP          TAU          yes       -      15      -       DUDIT-E;DASE;BDI-II;      1.60       -              6 
2011                        inmates (24)                          (10)              (14) 
Brewer et al.,         SU        38.2     72       MMRP    CBT          yes     44     9    - DES;Alcohol/Cocaïne         .29        -                 8 
2009          (25)                               (9)       (5)                    consumption (FFMQ)          (.33) 
Jimenez,         Sx of        19.8     39.2    MM   Relaxation  yes      2.5   -         - PANAS;PWBS;RRQ;         .23       20      7 
2009          Depression (120)                   (61)   (59)                   CESD (FMI)                        (.49)     .13(.35) 
Philippot et al.,        Tinnitus          60       50       MBCT         Relaxation  yes      16.7   13.5   -      QIPA;BDI;STAI                 .27       13                9 
2012                        (30)                                       (12)              (12)                                                                                                           .57 
Delgado et al.,         Worry        21        0       MM             Relaxation  yes      11.1 10    - PANAS;PSWQ;STAI;         .06       -                 5 
2010          (36)                               (15)   (17)                                                   SHC;TMMS-24;DSROW 
Note. m1 = meta-analysis/review from Baer (2003); m2 = meta-analysis/review from Grossman et al. (2004); m3 = meta-analysis/review from 
Ledesma & Kumano (2009); m4 = meta-analysis/review from Bohlmeijer et al. (2010); m5 = meta-analysis/review from Hofmann et al. (2010); m6 = 
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meta-analysis/review from Chiesa & Serretti (2009); m7 = meta-analysis/review from Chiesa & Serretti (2011); m8 = meta-analysis/review from 
Fjorback et al. (2011); m9 = meta-analysis/review from Piet & Hougaard (2011); m10 = meta-analysis/review from Musial et al. (2011); m11 = 
meta-analysis/review from Klainin-Yobas et al. (2012); m12 = meta-analysis/review from Sedlmeier et al. (2012); m13 = meta-analysis/review from 
de Vibe et al. (2012); m14 = meta-analysis/review from Eberth & Sedlmeier (2012); m15 = meta-analysis/review from Zainal et al. (2012); m16 = 
meta-analysis/review from Cramer et al. (2012); mi,j,k = study included in meta-analyses/review mi, mj and mk. Comp. = Comparaison; Tx = 
Treatment; Prac = Practice; Foll = Follow-up; wks = weeks;  Qual = Quality; Particip = Participant; Assn = Assignement; Att = Attrition; hrs = 
hours; gm = Hedge’s g of Mindfulness outcomes; Scor = Score; ADHD = Attention Deficit Hyperactivity; MAPS = Mindful Awareness Practices; 
Disorder; Sx = Symptoms; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; Dep-Anx = Depression-Anxiety; CBCL = Child 
Behavior Checklist; YSR = Youth Self Report; BRIEF = Behavior Rating Inventory of Executive Function; FFS = Flinders Fatigue Scale; SHS = 
Subjective Happiness Scale; MMRP = Mindfulness Meditation Relapse Prevention; PDA = Percent Days Abstinent; HHD = Heavy Drinking Days; 
TD = Total Drinking; depend = dependency; SCL-90R = Symptoms Checklist 90-Revised; OCDS = Obsessive Compulsive Drinking Scale; MAAS 
= Mindful Attention and Awareness Scale; ASH = Aneurysmal Subarachnoid Hemorrhage; MBSR = Mindfulness-Based Stress Reduction; STAI = 
Strait-Trait Anxiety Inventory; MIA = Mobility Inventory for Agoraphobia; FSSa = Fear Survey Schedule; HAM-A = Hamilton Anxiety Rating 
Scale; HAM-D = Hamilton Depression Rating Scale; MH-5 = 5-item Mental Health; YMRS = Young Mania Rating Scale; PSWQ = Penn State 
Worry Questionnaire; RSQ = Response Style Questionnaire; ERS = Emotion Reactivity Scale; ASRS = Adult ADHD Self-Report Scale; CPAS = 
Clinical Positive Affective Scale; PWBS = Psychological Well-Being Scales; LIFE-RIFT = Longitudinal Interval Follow-up Evaluation – Range of 
Impaired Functioning Tool; PQOL = Perceived Quality of Life Scale; PSES = Perceived Self Efficacy Scale; SPSI-RSF = Social Problem-Solving 
Inventory—Revised Short Form; BED = Binge-Eating Disorder; BPD = Borderline Personality Disorder; DES-II = Dissociative Experience Scale; 
SDQ = Somatoform Dissociation Questionnaire; BIS-11 = Barratt Impulsiveness Scale-11; Canc. = Cancer; PSS = Perceived Stress Scale; MSAS = 
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Memorial Symptom Assessment Scale; LOT-R = Life Orientation Test Revised; QoL = Quality of Life; MSCL = Medical Symptoms Check List; 
SoC = Sense of Coherence; HADS = Hospital Anxiety and Depression Scale; IES-R = Impact of Event Scale - Revised; EPIC = Expanded UCLA 
Prostate Cancer Index; MAX-PC = Memorial Anxiety Scale for Prostate Cancer; FACT-P = Functional Assessment of Cancer Therapy-Prostate; 
FFMQ = Five-Facet Mindfulness Questionnaire; FACIT-Sp = Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being; POMS = 
Profile of Mood States; C-SOSI = Calgary Symptoms of Stress Inventory; SQ = Sleep Quality; SOSI = Symptoms of Stress Inventory; Phy. = 
Physiological; RSC = Rotterdam Symptom Checklist; HDI = Health and Disease Inventory; KIMS = Kentucky Inventory of Mindfulness Skills; 
CESD = Center for Epidemiological Studies Depression Scale; ZBI = Zarit Burden Interview; SF-36 = Medical Outcomes Studies–Short-Form 
General Health Survey; BSI = Brief Symptom Inventory; PCL = Post-Traumatic Stress Disorder Checklist; DASS = Depression Anxiety Stress 
Scales; VAS = Visual Analog Scale; PCS = Pain Catastrophising Scale; PGIC = Patient Global Impression of Change; MBCT = Mindfulness-Based 
Cognitive Therapy; RRQ = Ruminative Response Scale; FMI = Frieburg Mindfulness Inventory; SF = Health Status Inventory; GAD = Generalized 
Anxiety Disorder; DASS(A,D&S) = Depression Anxiety Stress Scales(Anxiety, Depression and Stress scales); RRAQ = Reactions to Relaxation and 
Arousal Questionnaire; FAHI = Functional Assessment of HIV Infection; Hypoch. = Hypochondrias; HCQ = Hypochondriacal Cognitions 
Questionnaire; HAI = Health Anxiety Inventory; PHQ-9 = Patient Health Questionnaire; WI = Whiteley Index; QOLWHO = Quality Of Life World 
Health Organization; 1Mixed clinical population; 2Mixed physical and psychological disorders; SES = Rosenberg Self-Esteem Scale; ISI= Insomnia 
Severity Index; Anx. = Anxiety; PANAS = Positive Affect Negative Affect Scale; CBCL = Child Behavior Checklist; MASC = Multidimensional 
Anxiety Scale for Children; STAIC = State-Trait Anxiety Inventory for Children; RCDS = Reynolds Child Depression Scale; SCS = Self-
Compassion Scale; PSOM = Positive States of Mind; MSE = Mindfulness Self-Efficacy; LASA = Linear Analogue Self-Assessment Scale; DSES = 
Daily Spiritual Experiences Scale; CAMS-R = Cognitive And Affective Mindfulness Scale-Revised; DASa = Dyadic Adjustment Scale; UBC-CI-
LGR = University of British Columbia Cognition Inventory-Letting-go Revised; Indiv-NGLG = Individualized Negative Cognition & Letting-Go 
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Scale; IRI = Interpersonal Reactivity Index; MBCP = Mindfulness-Based Childbirth and Parenting; DES = Differential Emotions Scale; TFEQ = 
Three-Factor Eating Questionnaire; FFQ = Food Frequency Questionnaire; PCL-C = Post-Traumatic Stress Disorder Checklist-Civilian; MEAL = 
Mindful Eating And Living; BES = Binge-Eating Scale; PDSS = Panic Disorder Specific Scale; MH = Mental Health; Pro = Professionals; GHQ-12 
= General Health Questionnaire; SWLS = Satisfaction With Life Scale; LES = Life Events and Stress; APU = Acute Psychiatric Unit; MBI = 
Maslach Burnout Inventory; SOSS = Sense of Self Scale; MHPSS = Mental Health Professionals Stress Scale; MBY = Mindfulness-Based Yoga; 
PSTD = Post-Traumatic Stress Disorder; PLS-SDHS = Perceived Life Stress: Shortened Daily Hassles Scale; TMS = Toronto Mindfulness Scale; 
SAD = Social Anxiety Disorder; LSAS = Liebowitz Social Anxiety Scale; SP = Social Phobia; FNE = Fear of Negative Evaluation scale; SPB = 
Social Phobic Belief scale; SFA = Self-Focused Attention; SU = Substance Use/Abuse; UPPS+P = Urgency, Premeditation, Perseverance, Sensation 
Seeking, and Positive Urgency Impulse Behavior Scale; THI = Tinnitus Handicap Inventory; HRQoL = Health Related Quality of Life; PAS = 
Percent of Awareness Scale; OABq-SF = Overactive Bladder Symptom and Quality of Life-Short Form; HRQL = Health-Related Quality of Life; 
PGI-I = Patient Global Impression of Improvement; BIS = Bergen Insomnia Scale; GMS = Global Mood Scale; WAIS-III = Wechsler Adult 
Intelligence Scale; FACT-B = Functional Assessment of Cancer Therapy–Breast; FACT-ES Functional Assessment of Cancer Therapy–Endocrine 
Symptoms; WHO-5 = World Health Organization five-item well-being questionnaire; LOT = Life Orientation Test; BFM = Breast Feeding Mothers; 
PES = Parental Evaluation Scale; MBAT = Mindfulness-Based Art Therapy; CIS = Self-Report Checklist Individual Strength; SIP = Sickness Impact 
Profile; PPS = Pain Perception Scale; SRDI = Smith Relaxation Dispositions Inventory; JSS = Job Satisfaction Scale; OLQ = Orientation of Life 
Questionnaire; CFS = Chalder Fatigue Scale; WSAS = Work and Social Adjustment Scale; PF-10 = Physical Functioning; BAES = Beliefs about 
Emotions Scale; CBRSQ = Cognitive and Behavior Responses to Symptoms Questionnaire; DEB-Q = Dutch Eating Behavior Questionnaire; BSQ = 
Body Shape Questionnaire; DTS = Dichotomous Thinking Scale; G-FCQ-T = General Food Craving Questionnaire Trait; 
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QLDS = Quality of Life in Depression Scale; DPN = Diabetic Peripheral Neuropathy; MM = Mindfulness Meditation; HTQ = Harvard Trauma 
Questionnaire; ICG-R = Inventory of Complicated Grief-Revised; CES = Centrality of Event Scale; LNSeq = Letter-number sequencing; MBCTip = 
MBCT (internet + phone); mBDI = modified form of the BDI; DCSES = Depression Coping Self-Efficacy Scale; BRFSS = Behavioral Risk Factor 
Surveillance System; Fbmlgia = Fibromyalgia; FIQ = Fibromyalgia Impact Questionnaire; Ph. = Physical; NE = Negative Emotions; NB = Negative 
Behaviors; MBSRi = Mindfulness-Based Stress Reduction via internet; FWS = Friedman Well-Being Scale; BPI = Brief Pain Inventory; HMSE = 
Headache Management Self-Efficacy Scale; CPAQ = Chronic Pain Acceptance Questionnaire; PF-SOC = Problem-Focused Styles Of Coping; CECS 
= Courtauld Emotional Control Scale; ACTCS = AIDS Clinical Trials Group symptom checklist; ART = Advances in antiretroviral therapy; MPQ-
SF = McGill Pain Questionnaire Short Form; Fn = Functioning; 3Mixed psychiatric disorders in adolescents; FH = Family Harmony; MS = Multiple 
Sclerosis; MPQ = McGill Pain Questionnaire; QolWHO = Quality of Life World Health Organization; MCS = Multiple Chemical Sensitivity; IPQ = 
Illness Perception Questionnaire; AMT = Autobiographical Memory Test; LEIDS-R = Leiden Index of Depression Sensitivity Revised; PWI-SF = 
Psychosocial Well-being Index-Short Form; DERS = Difficulties in Emotion Regulation Scale; NAI = Novaco Anger Inventory; ARS = Anger 
Rumination Scale; ASI = Anger Sensitivity Index; RUM = Rumination; MaQ = Maastricht; Questionnaire; VE = Vital Exhaustion; MBSR-ld = 
Mindfulness-Based Stress Reduction (low dose); PSQI = Pittsburgh Sleep Quality Index; CFQ = Cognitive Failures Questionnaire; ACS = Affective 
Control Scale; RRS = Ruminative Response Scale; SAES = Spielberger Anger Expression Scale; MSCDS = Marlowe–Crowne Social Desirability 
Scale; PWS = Perceived Wellness Survey; USQ = Undergraduate Stress Questionnaire; OCD = Obsessive-Compulsive Disorder; OCI-R = 
Obsessive-Compulsive Inventory Revised; MQ = Mindfulness Questionnaire; MB-EAT = Mindfulness-Based Eating Awareness Training; BRS = 
Body Responsiveness Scale; WCSI = Wheaton Chronic Stress Inventory; CALMM = Craving and Lifestyle Management through Mindfulness; 
RSES =  Rosenberg Self-Esteem Scale; PStS = Perceived Stigma Scale; SSS = Stigmatizing Situations Scale; BASS = Body Areas Satisfaction 
Scale; CRS = Coping Responses Scale; 5Pregnancy with history of mood concerns; MMI = Mindful Motherhood Intervention; Psych. = Psychosis; 
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SZ = Schizophrenia; CORE = Clinical Outcomes in Routine Evaluation; PSYRATS = Psychiatric Symptom Rating Scale; BAVQ-r = Beliefs about 
Voices Questionnaire revised; SMQ = Southampton Mindfulness Questionnaire; SMVQ = Southampton Mindfulness Voices Questionnaire; MBCT-
C = Mindfulness-Based Cognitive Therapy for Children; GMRT = Gates-MacGinitie Reading Tests; RDP = Recovered Depressed Patients; SCID = 
Structured Clinical Interview for the DSM-IV; DASb = Dysfunctional Attitudes Scale; RDS = Residual Depressive Symptoms; IDS = Inventory of 
Depressive Symptoms; RA = Rheumatoid Arthritis Patients; DAS-28 = Disease Activity Score of 28 Joints; CBSS = Cheek and Buss Shyness Scale; 
Shy Q = Shyness Questionnaire; CUSI = Coping Using Sex Inventory; NMRS = Negative Mood Regulation Scale; CGI-SCH = Clinical Global 
Impression-Schizophrenia Scale; SCoS = Self-Consciousness Scale; IRS = Interpersonal Reactivity Index; STAXI = State and Trait Anger; MORE = 
Mindfulness Oriented Recovery Enhancement; GPS = Global Psychiatric Symptoms; PsyEd = Psychoeducation; A&D = Anxiety and Depression 
subscales; CBGT = Cognitive-Behavioral Group Therapy; PEF = Peak Expiratory Flow; AQOL = Asthma Quality of Life Questionnaire; MINI = 
Mini International Neuropsychiatric Interview; CGI-SoI =  Clinical Global Impression - Severity of Illness subscale; GSAD = Generalized Social 
Anxiety Disorder; SIAS = Social Interaction Scale; SPS = Social Phobia Scale; IPSM = Interpersonal Sensitivity Measure; LSRDS = Liebowitz Self-
Rated Disability Scale; MADRS = Montgomery-Åsberg Depression Rating Scale (MADRS); SoSS = Social Support Scale; GSI = Global Severity 
Index; Th. = Therapy; GPSE = General Perceived Self-Efficacy; ESS = Epworth Sleepiness Scale; FFNJ = measure of being NonJudgmental adapted 
from Factor Five; CCES = Community Caregiver Education and Support; MBCBS = Montgomery Borgatta Caregiver Burden Scale ; MOSSSS = 
Medical Outcomes Study Social Support Survey; COLD = Chronic Obstructive Lung Disease; MBBT = Mindfulness-Based Breathing Therapy; 
TAU = Treatment As Usual; MPI = Multidisciplinary Pain Intervention; NRS = Numerical Rating Scale; ADM = Antidepressant Medication; EQ = 
Experiences Questionnaire; CBT = Cognitive-Behavioral Therapy; PGWBI = Psychological General Well-being Index; BSS = Beck Scale for 
Suicide Ideation; RR = Relapse Rate; IPR = Inventory of Pain Regulation; SSI = Somatic Symptom Inventory; SME = Stress Management 
Education; TSST = Trier Social Stress Test; SCI = Shapiro Control Inventory; Hypochon. = Hypochondriasis ; SHAI = Short Health Anxiety 
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Inventory; IBS = Irritable Bowel Syndrome; IBS-QOL= Irritable Bowel Syndrome-Quality of Life; IBS-SSS = Irritable Bowel Syndrome-Severity 
Scoring System; Pharm. = Pharmacotherapy; PECB = PsychoEducational/Cognitive–Behavioral intervention; PFS = Power of Food Scale; ESES = 
Eating Self-Efficacy Scale; GAF = Global Assessment of Functioning in the DSM; MFIS = Modified Fatigue Impact Scale; HAQUAMS = Hamburg 
Quality of Life Questionnaire in Multiple Sclerosis; HSCL = Hopkins Symptom Checklist-21; RPWS = Ryff's Psychological Well-Being Scale; HS 
= Hassle Scale; PT = Pain Tolerance; MI = Mindfulness Intervention; SMFQ = Short Mood and Feelings Questionnaire; MTI = Mindfulness 
Training Intervention; RHS = Revised Hallucination Scale; MBT = Mindfulness-Based Therapy; QEWP-R = Questionnaire of Eating and Weight 
Patterns - Revised; ASS = Appearance Satisfaction Scale; BMI = Body Mass Index; DAPOS = Depression, Anxiety and Positive Outlook Scale; 
PSEQ = Pain Self-Efficacy Questionnaire; W-DEQ = Wijma Delivery Expectancy/Experience Questionnaire; CAPS = Clinician Administered PTSD 
Scale; PCL-M = Post-Traumatic Stress Disorder Checklist- Military Version; BADS = Behavioral Activation for Depression Scale; RSS = 
Rumination on Sadness Scale; MM&ER = Mindfulness Meditation and Emotional Regulation (MBSR + MBCT); SDS = Sheehan Disability Scale; 
FSDS = Female Sexual Distress Scale; FSFI = Female Sexual Function Index; MBRP = Mindfulness-Based Relapse Prevention; ALA-FFS = 
American Lung Association’s freedom from smoking; TLFB = Timeline Follow back; IIP = Inventory of Interpersonal Problems; DDQ = Daily 
Drinking Questionnaire; DDTQ = Daily Drug-Taking Questionnaire; TLFB = Timeline Followback; PACS = Penn Alcohol Craving Scale; SIP-AD 
= Short Inventory of Problems; DUDIT-E = Drug Use Identification Disorders Test- Extended; DASE = Drug Avoidance Self-Efficacy Scale; QIPA 
= Tinnitus Psychological Impact Questionnaire; SHC = Subjective Health Complaints; TMMS = Trait Meta-Mood Scale; DSROW = Daily Self-
Report Of Worry. 
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Figure 1. Flow diagram of the study selection process
Studies selected for further 
screening (n = 1121) 
Publications initially identified in PUBMED 
and PSYCINFO (n = 2876) 
Excluded (n = 1485): 
Conceptual/Empirical Reviews (n = 909) 
Qualitative (n = 118) 
Psychometric (n = 103) 
Case studies/single case design (n = 76) 
Cost-effectiveness studies (n = 5) 
Not accessible (n = 64)  
Duplicated (n = 210) 
Excluded (n = 496): 
No mindfulness-based intervention (n = 326) 
Study examining mindfulness trait (n = 99) 
Comparison among meditators or meditation 
styles/parameters (n = 32) 
Non-direct effect of mindfulness (n = 11)  
Description of future studies (n = 28) Studies selected for detailed 
evaluation (n = 625) 
Excluded (n = 326): 
Mindfulness is only a component in the 
treatment (n = 44) 
No clinical outcomes (n = 188) 
Mixed Protocols (n = 31) 
Guided meditation (n = 15) 
Other types of meditation: retreats, flow, 
web-based, induction/instruction (n = 48)
Studies to be considered for 
inclusion (n = 299) Excluded (n = 90): 
Sample overlapped with another study (n = 
31) 
Insufficient data to calculate effect sizes (n = 
59)Studies added to the meta-
analysis (n = 209) 
Journal articles (n = 2326) 
Dissertations (n = 280 studies in 278 publications) 
Books (excluded, n = 272)  
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Figure 2. Mean Hedge’s g, 95% confidence interval, and 95% prediction interval of main study groups. Note that the effect sizes were calculated at 
the end of the treatment and solely based on the clinical outcomes. Note also that MM = Mindfulness Meditation (meaning mindfulness protocols 
other than MBSR or MBCT). 
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Figure 3. Funnel plot of precision by Hedge’s g of pre-post studies including only clinical outcomes. 
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Figure 4. Relationship between mindfulness effect size and clinical effect size at the end of treatment for all studies. Each circle represents a specific 
study; its diameter is proportional to the study weight (i.e. to the ratio of the number of participants of the study to the total number of participants for 
the present meta-analysis). Note that Tx = Treatment. 
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Abstract  
Background: An increasing number of mindfulness interventions are being used with 
individuals with psychosis or schizophrenia, but no known meta-analysis has investigated their 
effectiveness. Objective: To evaluate the efficacy of mindfulness interventions for psychosis or 
schizophrenia, we conducted an effect-size analysis of initial studies. Data Sources: A 
systematic review of studies published in journals or in dissertations in PubMED, PsycINFO or 
MedLine from the first available date until July 25, 2013. Review Methods: A total of 13 studies 
(n = 468) were included. Results: Effect-size estimates suggested that mindfulness interventions 
are moderately effective in pre-post analyses (n = 12; Hedge’s g = .52). When compared with a 
control group, we found a smaller effect size (n = 7; Hedge’s g = .41). The obtained results were 
maintained at follow-up when data were available (n = 6; Hedge’s g = .62 for pre-post analyses; 
results only approached significance for controlled analyses, n = 3; Hedge’s g = .55, p = .08). 
Results suggested higher effects on negative symptoms compared with positive ones. When 
combined together, mindfulness, acceptance, and compassion strongly moderated the clinical 
effect size. However, heterogeneity was significant among the trials, probably due to the 
diversity of interventions included and outcomes assessed. Conclusion: Mindfulness 
interventions are moderately effective in treating negative symptoms and can be useful adjunct to 
pharmacotherapy; however, more research is warranted to identify the most effective elements of 
mindfulness interventions. 
 
Key words: mindfulness, acceptance, compassion, meta-analysis, psychosis, schizophrenia 
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1. Introduction 
Mindfulness has its roots in eastern contemplative traditions and is often associated with 
the formal practice of insight meditation known as Vipassana. However, operational definitions 
of mindfulness include multiple dimensions, both cognitive and affective ones, including self-
regulation of attention, decentering, awareness of sensations, thoughts, and emotions, openness 
and acceptance of all inner-experiences with calmness, non-reactivity and non-judgment, as well 
as other perceptual and cognitive aspects such as observing and describing (Baer, Smith, & 
Allen, 2004; Baer et al., 2008; Brown & Ryan, 2003; Cardaciotto, Herbert, Forman, Moitra, & 
Farrow, 2008; P. Chadwick et al., 2008; Feldman, Hayes, Kumar, Greeson, & Laurenceau, 2007; 
Lau et al., 2006; Walach, Buchheld, Buttenmuller, Kleinknecht, & Schmidt, 2006). Furthermore, 
Davidson (2010) suggested that mindfulness includes equanimity, kindness, and compassion. 
This diversity in defining, describing, and measuring the different aspects of mindfulness is also 
portrayed in mindfulness interventions. While some interventions concentrated on the awareness 
and attention aspects of mindfulness (e.g., meditation-based practices), others focused on 
acceptance and detachment (e.g., acceptance-based practices) or on kindness and compassion 
(e.g., compassion-focused therapy or loving-kindness meditation). This family of mindfulness 
interventions is often been referred as the “third wave” of cognitive behaviors interventions, in 
contrast to the first wave that concentrated on classical conditioning and operant learning and the 
second wave, which focused more on information processing and cognition (Hayes, 2004). Even 
though the third wave interventions can be perceived as different in terms of the techniques used, 
they all aim at regulating negative emotions by increasing the willingness of embracing present 
experiences in the moment, whether negative or positive, rather than automatically avoiding or 
suppressing them.  
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Developing mindfulness qualities (i.e., presence in the moment, acceptance, detachment, 
non-reactivity, non-judgment, and compassion) can be particularly helpful in alleviating the 
distress associated with psychosis rather than focusing solely on controlling psychotic symptoms 
such as voices, images, and paranoid intrusions (P. D. J. Chadwick, Birchwood, & Trower, 
1996). Naturalistic studies of individuals coping with psychosis suggest the benefits of taking an 
accepting and mindful stance toward psychotic symptoms (Romme & Escher, 1989; Vilardaga, 
Hayes, Atkins, Bresee, & Kambiz, 2013). In fact, mindfulness based interventions focus 
primarily on how people relate with and respond to their psychotic experiences rather than 
identifying and directly challenging thoughts and beliefs about these experiences (Dannahy et al., 
2011). According to Chadwick et al. (2005), a mindful response involves clear awareness and 
acceptance of psychotic sensations as transient experiences that are fundamentally “not me” (i.e. 
do not define the self), and not necessarily accurate reflections of reality. As a result, it involves 
observing unpleasant psychotic sensations as they pass, and allowing this movement in and out 
of awareness without getting caught in rumination or confrontation. Although psychotic 
sensations experienced mindfully likely remain unpleasant, or painful, the distress (or suffering) 
that comes from reacting against them is absent. A grounded theory analysis of 16 individuals 
with psychosis who had taken part in an outpatient mindfulness group suggested that 
mindfulness helps people relate differently to their psychotic experience, specifically by opening 
awareness to the experience, allowing the experience to be as it is (i.e., allowing thoughts and 
voices to come and go without reacting), and reclaiming power through accepting oneself and 
the experience (Abba, Chadwick, & Stevenson, 2008). 
From an empirical point, randomized clinical trials have found that traditional Cognitive 
Behavior Therapy for psychosis (CBTp), which emphasizes identifying dysfunctional beliefs and 
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directly testing them out in behavioral experiments, is efficacious for treating residual positive 
and negative symptoms (Wykes, Steel, Everitt, & Tarrier, 2008). However, the evidence for 
treating emotional dysfunction in psychosis (such as anxiety, depression, and hopelessness) is 
less clear (Birchwood, 2003). Although Wykes et al. (2008) found a moderately strong effect 
size of CBTp on mood, when studies with ‘poor’ methodological quality were controlled for, the 
weighted effect size on mood in the adequate quality studies was not significant. In a review of 
mindfulness treatments for severe mental illness (including psychosis), Davis and Kurzban 
(2012) concluded that “mindfulness-based interventions may be uniquely suited to impact 
distress related to symptoms and internalized stigma that are particularly salient for individuals 
living in the community with severe mental illness who are susceptible to experiences of social 
rejection and interpersonal stress” (p. 227-228).  
Mindfulness interventions for psychosis are fast growing and have been implemented for 
different patient groups. These interventions can be divided into three categories on the basis of 
the strategies they utilize. The first category comprises protocols that are mindfulness meditation 
based (i.e., using direct meditation practices), the second group is the acceptance based 
protocols, and the third can be called compassion based. By retraining attention, mindfulness 
meditation aims to regulate emotions by enhancing positive affect, decreasing negative affect, 
and reducing maladaptive automatic emotional responses (Gross, 2007; Hofmann, Sawyer, Fang, 
& Asnaani, 2012; Koole, 2009; Thompson, 1991, 1994). In addition, acceptance plays a crucial 
role in the cognitive aspect of emotional regulation, i.e., the conscious and cognitive way of 
handling the intake of emotionally arousing information (Garnefski & Kraaij, 2007; Garnefski, 
Kraaij, & Spinhoven, 2001; Thompson, 1991). For example, someone with psychosis could be 
taught to accept experiencing fearful thoughts and emotions in times of stress, and to notice the 
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signs and impulses. Furthermore, compassion activates the self-soothing system, increasing 
positive emotions such as hope, optimism, warmth, contentment, love, and kindness, and 
decreasing negative emotions such as shame, fear, and helplessness (Trémeau, 2006). As shown, 
all these interventions use somewhat different strategies for regulating emotions, and emotional 
regulation is suggested to be central in the treatment of psychotic disorders (e.g., Khoury & 
Lecomte, 2012).  
Acceptance and Commitment Therapy, one acceptance/mindfulness-based approach, is 
currently recognized as an empirically supported treatment for psychosis by the American 
Psychological Association (American Psychological Association, n.d). However, beside the 
growing popularity of mindfulness interventions, no meta-analysis has investigated their 
effectiveness for psychosis. Moreover, the role of mindfulness, compassion, and acceptance 
components in the effectiveness of these interventions remains unknown. Two recent systematic 
reviews found that meditation and mindfulness interventions are useful adjuncts to usual care for 
psychotic disorders in reducing distress and hospitalization rates and in increasing feelings of 
self-efficacy (Davis & Kurzban, 2012; Helgason & Sarris, 2013). Another more general meta-
analysis found that mindfulness meditation strongly moderated the effectiveness of mindfulness-
based treatments for multiple psychiatric disorders and medical conditions (Khoury et al., 2013). 
Therefore, the aim of the current study was to conduct a meta-analysis of the initial studies that 
form the emerging evidence-base for mindfulness treatments specifically for psychosis. 
In order to address the void of the current literature, we conducted an effect-size analysis 
with the following objectives: (1) to quantify the size of the effect of mindfulness interventions 
for psychotic disorders; and (2) to investigate and quantify the moderators of the effectiveness of 
mindfulness interventions for psychosis.  
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2. Method 
2.1. Power analysis 
 Assuming an average sample size of 25 individuals per group (on the basis of 
previous meta-analyses, e.g., Khoury et al., 2013), a small to moderate effect size of 0.3 and a 
large heterogeneity among the studies (as mindfulness interventions differ in strategies used), for 
a power of 80%, 15 studies will need to be included in the meta-analysis. For a power of 90%, 18 
or 19 studies will be needed (Borenstein, Hedges, Higgins, & Rothstein, 2009, p. 272). 
2.2. Eligibility criteria 
Given the early state of the literature, the limited number of available studies, and in 
order to have a sufficient power, any study examining the pre-post or controlled effects of a 
clinical intervention using any mindfulness protocol for any psychotic disorders was considered 
in our analysis. Studies were excluded if they: (1) did not aim to examine treatment effects; (2) 
reported no measures of symptoms or other psychosocial outcomes; (3) reported insufficient 
information to compute an effect size (e.g., only correlational data); or (4) reported data that 
overlapped with the data from other included studies. 
The protocols included: Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & 
Wilson, 1999); Acceptance-Based Cognitive Behavior Therapy (ABCBT; Shawyer et al., 2012); 
Acceptance-Based Depression and Psychosis Therapy (ADAPT; Gaudiano, Nowlan, Brown, 
Epstein Lubow, & Miller, 2013); Mindfulness-Based Cognitive Therapy (MBCT; e.g., Segal, 
Williams, & Teasdale, 2002); Mindfulness-Based Psychoeducation Program (MBPP; Chien & 
Lee, 2013); Person-Based Cognitive Therapy (PBCT; P. Chadwick, 2006; P. Chadwick, 
Sambrooke, Rasch, & Davies, 2000); Loving-Kindness Meditation  (LKM; Salzberg, 1995); and 
Compassionate Mind Training (CMT; Gilbert, 2001). Most of these protocols were tailored for 
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the people with psychotic disorders by: (1) decreasing the duration of sessions (most lasted less 
than 90 minutes); (2) including only one or two meditation practices, each lasting less than 15 
minutes in order to decrease the risk of experiencing intense psychotic symptoms while 
meditating; (3) focusing on concrete strategies, such as acceptance of thoughts and emotions, and 
building compassion towards self and others rather than abstract/theoretical material (e.g., 
mindfulness philosophy). Also, the protocols varied as to the extent that they include formal 
mindfulness meditation practice. 
2.3.  Information sources 
Studies were identified by searching PubMed, PsycINFO, and MedLine from the first 
available date until July 25, 2013. Additional searches included scanning reference lists of 
articles and inquiring about in press articles. No limits were applied for language and foreign 
papers were translated into English. 
2.4. Search 
We used the search term mindfulness alone or combined with the terms meditation or 
acceptance or detachment or compassion and combined with one of the terms psychosis or 
psychotic or schizophrenia. 
2.5. Study selection 
Eligibility assessment was performed in a non-blinded, standardized manner by the first 
author and was revised by the second author. Disagreements between reviewers were resolved 
through discussions, and in a few instances the authors of the original studies were contacted for 
clarifications. 
2.6. Data collection process 
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We developed an electronic data extraction sheet, pilot-tested it on three randomly-
selected studies, and refined it accordingly. Data collection was conducted for the first time in 
September of 2012, was re-conducted and refined in March of 2013, and was updated again in 
July of 2013. When duplicate reports were identified for the same data, only the latest ones were 
included.  
2.7. Data items 
Information was extracted from each included trial based on: (1) the characteristics of the 
trial (including the year of publication, design, randomization, blinding, therapist qualifications, 
number of participants, type of outcome measures, and follow-up time in weeks); (2) the 
characteristics of the intervention (including treatment protocol, target population, length of 
treatment in hours, attendance in number of sessions, length of assigned home practice in hours, 
quality of home practice as reported by participants, and treatment setting); (3) the characteristics 
of the comparison group, in controlled studies (including the number of participants, type of 
control, type of treatment, and length of treatment); and (4) the characteristics of participants 
(including mean age, percentage of males, attrition rate, and diagnosis).  
2.8. Risk of bias in individual studies 
To minimize the influence of data selection, we included data pertaining to all available 
outcomes. We identified different types of outcomes, namely positive symptoms, negative 
symptoms, affective symptoms, thought disorder, functioning, re-hospitalization, quality of life, 
and mindfulness/acceptance/compassion. We included data from follow-ups, when such data 
were available.  
We also included a study quality score, which was comprised of items based on Jadad’s 
criteria (Jadad et al., 1996) and others pertaining to mindfulness. The included items are 
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adherence of the treatment to an established protocol (ACT, MBCT, LKM, CMT, or CBT with 
mindfulness/acceptance); administration of measures at follow-up; use of validated 
mindfulness/acceptance/compassion measures (i.e., MAAS, KIMS, FMI, FFMQ, SMQ, MQ, 
SMVQ, AAQ-II, SeSC or CAMS-R); clinical training of therapists (i.e., clinical psychologists, 
trainees in clinical psychology, or social workers); and the mindfulness training of therapists 
(i.e., formal training in validated protocols). For controlled studies, the items included whether 
participants were randomized between the treatment and control groups, whether participants in 
both groups spent an equal amount of time in treatment, and whether evaluators or experimenters 
were blind regarding the treatment/control conditions and/or participants were blind regarding 
the study’s hypotheses. For all binary items (i.e., true or false), a value of 1 was assigned if the 
item was true and a value of 0 if it was false. For the study design, pre-post studies were assigned 
a value of 0; studies with a waitlist, no-treatment, or drop-outs control group were assigned a 
value of 1; studies with a TAU control group were assigned a value of 2; studies with a treatment 
control group (other than TAU) were assigned a value of 3. For blinding, non-blinded studies 
were assigned a value of 0; single-blind studies were assigned a value of 1; and double-blind 
studies were assigned a value of 2. 
The inter-rater agreement was assessed by comparing the ratings of the first author (B.K.) 
to the ratings of the fourth co-author (K.P.), who received a written document including specific 
instructions on rating the studies and a one-hour training discussion about the rating procedure.  
2.9. Summary measures 
The meta-analyses were performed by computing standardized differences in means. We 
completed all analyses using Microsoft Excel or Comprehensive Meta-Analysis, Version 2.2.057 
(CMA; Borenstein, Hedges, Higgins, & Rothstein, 2005). 
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2.10. Synthesis of results 
Effect sizes were computed using means and standard deviations (SD) when available. In 
the remaining studies, the effect sizes were computed using other statistics such as F, p, t, and χ2. 
In within-group analyses, when the correlations between the pre- and post-treatment measures 
were not available, we used a conservative estimate (r = .7) according to the recommendation by 
Rosenthal (1993). For all studies, Hedge’s g, its 95% confidence interval (95% CI), and the 
associated z and p values were computed. To calculate the mean effect size for a group of 
studies, individual effect sizes were pooled using a random effect model rather than a fixed effect 
model, given that the selected studies were not identical (i.e., did not have either an identical 
design or target the same population).  
For all studies groups, the mean Hedge’s g, the 95% confidence interval (95% CI), and 
the associated p-values were computed. We systematically assessed the heterogeneity among 
studies in each group using I2 and the chi-squared statistic (Q). I2 measures the proportion of 
heterogeneity to the total observed dispersion, and is not affected by low statistical power. 
Higgins, Thompson, Deeks, and Altman (2003) suggested that an I2 of 25% might be considered 
low, 50% considered moderate, and 75% considered high. Only two studies reported intent-to-
treat data; therefore we omitted intent-to-treat analyses. 
2.11. Risk of bias across studies 
To assess publication bias, we computed the fail-safe N (Rosenthal, 1993) and we 
constructed a funnel plot.  
2.12. Additional analyses 
According to the objectives of this meta-analysis, we conducted meta-regression meta- 
analyses. The aim of meta-regression analysis is to assess the relationship between one or more 
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variables (moderators) and the pooled effect size. In this meta-analysis, we included only pre-
post results and we investigated six moderators: (1) mean effect size of mindfulness outcomes, 
(2) mean effect size of acceptance outcomes, (3) mean effect size of compassion outcomes, (4) 
mean effect size of these three strategies combined, (5) study quality score, and (6) current 
treatment length (as defined in the protocol). We did not include the duration patients spent 
under treatment as only one study reported such information. Also, only three studies reported 
the duration of the illness. 
3. Results 
3.1. Study selection 
PubMed searches produced 378 articles, including 68 reviews. PsycInfo/Medline 
searches yielded 94 publications. We carefully assessed the identified publications and applied 
the exclusion criteria, resulting in 14 publications (13 different studies and a one-year follow-up 
study). The study selection process for PubMed is illustrated in detail in Figure 1. 
3.2. Study Characteristics 
The effect size (Hedge’s g) and other characteristics for each study are shown in Table 1. 
The total number of participants included in our meta-analysis was 468 individuals with different 
psychotic spectrum disorders.  
3.3. Risk of bias within studies 
Table 1 presents the included studies and their quality scores. Seven studies were 
randomized, five used at least one validated mindfulness measure, twelve included measures at 
the end of the treatment, nine included follow-up measures, two assured an equal time between 
treatment and control groups, and four used blind evaluators. The quality score varied from a 
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minimum of 3 (lowest quality) to a maximum of 10 (highest quality) with a mean of 5.69 (SD = 
2.39) and a median of 5. Inter-rater agreement was high (kappa = .94).  
3.4. Results of individual studies 
Hedge’s g values for both clinical and mindfulness outcome measures, and at both post 
treatment and last follow-up, are presented in Table 1. 
3.5. Synthesis of results 
The effect size (Hedge’s g) for both within-group and between group analyses at the end 
of treatment and at the last follow-up and other characteristics for each study are shown in Table 
1. Effect sizes, 95% confidence intervals, and heterogeneity (i.e., I2 and Q) for different 
outcomes (i.e., positive symptoms, negative symptoms, affective symptoms, thought disorder, 
functioning, re-hospitalization, quality of life, and mindfulness/acceptance/compassion) at both 
the end of treatment and at the last follow-up are available in Table 2. Results suggest higher 
effects in pre-post analyses (n = 12; Hedge’s g = .52; 95% CI [.40, .64], p < .0001) in 
comparison with controlled analyses (n = 7; Hedge’s g = .41; 95% CI [.23, .58], p < .0001); 
however heterogeneity was moderate to high, suggesting caution in drawing definite 
conclusions. Higher effects were also found for negative symptoms compared with positive ones 
in both the pre-post and controlled analyses with moderate heterogeneity. Acceptance-based 
treatments showed highest effects (n = 5; Hedge’s g = .63; 95% CI [.40, .86], p < .0001) in pre-
post analyses but not in controlled ones (n = 4; Hedge’s g = .35; 95% CI [.12, .58], p < .005). 
The type of the control treatment (waitlist, TAU, or active treatment) might have played a role in 
that difference as most of the acceptance-based interventions (i.e., four out of five) had an active 
control treatment, which can lead to a lower comparative effect size. No differences were found 
between treatment modalities (i.e., individual versus group). Pre-post analyses at follow-up 
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suggest maintenance of the effects; however heterogeneity was very high making it difficult to 
draw definite conclusions about the long-term effectiveness of the interventions. Only three 
controlled trials had follow-up data available so statistical power was even lower in this analysis. 
3.6. Risk of bias across studies 
The effect size for all pre-post analyses corresponded to a z value of 16.28 (p < .000001) 
indicating that 817 studies with a null effect size would be needed to nullify our results (i.e., for 
the two-tailed p value to exceed .05). Using the Trim and Fill method, three studies would need 
to fall on the right of the mean effect size to make the plot symmetric (Figure 2). Assuming a 
random effects model, the new imputed mean effect size was Hedge’s g = .48 (95% CI [.42, 
.53]). Similar results were obtained for controlled studies, with a z value of 6.23 (p < .00001) and 
a corresponding fail-safe N of 64. Using the Trim and Fill method, three studies would also need 
to fall on the right of the mean effect size to make the plot symmetric, the new imputed mean 
effect size was Hedge’s g = .27 (95% CI [.17, .37]). These analyses suggest that the effect-size 
estimates for pre-post analyses were unbiased and robust, whereas for controlled analyses, the 
effect-size estimates were less robust and might vary between small to moderate values based on 
the strength of the control group used. 
3.7. Additional analyses 
At the end of treatment, the average pre-post effect size of clinical outcomes was 
positively moderated (medium effect) by the effects on mindfulness outcomes (n = 5; β = .33, SE 
= .11, p < .005), and positively moderated (large effect) by the effects on the mindfulness, 
acceptance and compassion strategies combined together (n = 6; β = .52, SE = .13, p < .0005) 
(Figure 3). For acceptance measures solely, there was a trend without reaching significance, 
possible affected by the small number of studies (n = 3; β = .14, SE = .21, p = .52, ns). Only one 
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study used a measure of compassion, rendering it impossible to verify whether compassion 
separately was a moderator of the clinical effect size. Finally, the effect size on clinical outcomes 
was not moderated by the study quality score (p = .47, ns) or by the treatment duration (p = .16, 
ns). 
4. Discussion 
This meta-analysis examined 13 studies (based on 14 articles) with a combined total of 
468 inpatients or outpatients with different psychotic disorders. The results showed that 
mindfulness interventions are moderately effective in pre-post studies. When compared with a 
control group (waitlist, TAU, or other treatments), the effect sizes were small to moderate.  
Even though mindfulness interventions do not target symptoms reduction but distress 
resulting from these symptoms, results showed that they were moderately effective in reducing 
negative and affective symptoms and in increasing functioning and quality of life. For positive 
symptoms, results suggest smaller effects. Findings are comparable to those obtained for CBTp 
(Wykes et al., 2008) and for mindfulness-based treatments for other disorders (e.g., Khoury et 
al., 2013). In addition, the average attrition among participants in the selected studies (12.14%) 
was smaller than the attrition rate usually obtained in cognitive and behavioral studies (e.g., 
22.5% of 1,646 patients offered CBT in an National Health Service clinic in the UK; Westbrook 
& Kirk, 2005). These results suggest a higher commitment among participants to mindfulness 
interventions. Results are similar to previous ones obtained by Kahl et al. (2012) suggesting a 
trend for better acceptance of third wave treatments in particular patient groups (e.g., borderline 
personality disorder and psychosis) in comparison with traditional CBT. An explanation of these 
results was given by Gaudiano and Herbert (2006), who suggested that patients with psychosis 
would be more willing to engage in a treatment that focuses on modifying the person’s 
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relationship to his or her thinking through the cultivation of mindfulness and acceptance (i.e., 
separating self from thinking), rather than one that focuses on directly modifying dysfunctional 
thought content through rational deliberation, such as the case in traditional CBT, at least during 
early treatment. 
When interpreting findings, it is important to consider that the mindfulness interventions 
included in this meta-analysis varied on the basis of their content. Some protocols focused 
almost exclusively on mindfulness meditation (e.g., Johnson et al., 2011), whereas others 
included components from traditional CBTp (e.g. Shawyer et al., 2012) or instead focused more 
on building acceptance and personal values than meditation per se (e.g., Gaudiano & Herbert, 
2006). This diversity of treatment approaches and the corresponding outcomes assessed may 
have been a large factor in the heterogeneity in effect sizes found in the current study. However, 
despite this heterogeneity, all the included interventions focus on the similar processes: changing 
the relationship to psychotic symptoms rather than the symptoms directly through processes of 
mindfulness/acceptance/compassion to better regulate negative emotions, decrease distress, and 
improve functioning.  
One obvious question is whether the interventions also change measures of mindfulness, 
compassion, and acceptance. Surprisingly, only half of the studies included a validated measure 
of mindfulness, acceptance, and/or compassion. The results showed that participants in 
mindfulness interventions were more mindful and accepting at the end of the treatment, and that 
gains were maintained at the last follow-up. In addition, there was a strong positive correlation 
between the mindfulness levels of the participants and the clinical outcomes. Results are 
inconclusive for acceptance and compassion when each was analyzed solely; however when 
combined together with mindfulness, the correlation with the clinical outcomes was even higher 
 157 
than the one obtained with mindfulness alone. These results provide preliminary support for the 
role of mindfulness strategies in the effectiveness of the interventions and suggest that 
acceptance and compassion might be complementary strategies, optimizing the mindfulness 
moderation of the clinical effects. Future studies will need to explore the mechanisms of action 
for mindfulness interventions and specifically the comparative role of mindfulness, acceptance, 
and compassion based strategies. In contrast with previous meta-analyses (e.g., Wykes et al., 
2008), our results showed that the study quality score did not moderate the efficacy of 
mindfulness interventions. Insufficient power could explain the absence of significant 
moderation effects, as the meta-analysis did not include a sufficient number of studies according 
to the power analysis we conducted. The duration of the treatment was also not a moderator for 
the treatment effectiveness. Previous mindfulness-based interventions studies and meta-analyses 
with mixed clinical and non-clinical population found contradictory results regarding treatment 
duration  (Carmody & Baer, 2009; de Vibe, Bjørndal, Tipton, Hammerstrøm, & Kowalski, 2012; 
Hofmann, Sawyer, Witt, & Oh, 2010; Klainin-Yobas, Cho, & Creedy, 2012; Sedlmeier et al., 
2012), and when a significant moderation was found, it was very weak (e.g., β = .01; Khoury et 
al., 2013).  
From a clinical side, Gaudiano et al. (2013) recommended tailoring therapy to patient 
severity so as not to overwhelm the individual with treatment goals and strategies. This is 
particularly true when a patient show cognitive challenges. In such a case, an individual modality 
can be more suited as it is easier to tailor the intervention to the patient’s needs. However, results 
did not show significant differences between individual and group modalities. Future studies 
should further investigate potential difference among treatment modalities.  
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Among the limitations of this meta-analysis is the small number of included studies, 
which led to insufficient power and might have led to non-significant results in some 
subanalyses; the high heterogeneity among some study groups further reduced the scope of the 
obtained results. Furthermore, the assessed outcomes varied widely from study to study. Due to 
the limited number of available studies, we also inevitably included studies with different levels 
of quality, which we quantified and included in the analyses. To address our own expectancy 
bias, we implemented liberal selection criteria and included a large variety of studies.  
Beside these limitations, results support the feasibility and effectiveness of mindfulness 
interventions for individuals with psychotic disorders specifically in treating negative symptoms, 
therefore mindfulness interventions can be a useful adjunct to pharmacotherapy. Furthermore, 
the findings suggest that mindfulness is a potentially active component in the treatment 
effectiveness. However, more research is warranted to confirm the obtained results and to 
investigate long-term effectiveness of mindfulness interventions. In addition, it is recommended 
that future studies include at least a validated measure of the strategy or strategies implemented 
in the intervention protocol (i.e., measure of mindfulness, acceptance, and/or compassion), and at 
least one validate measure of distress as it is a central target in the mindfulness interventions for 
psychosis. It will be important to clarify the similarities and differences between traditional CBT 
versus mindfulness interventions for psychosis. For example, it is unclear whether they differ in 
terms of their outcomes, mechanisms of action, both, or neither. Also, future studies should 
further investigate potential moderators (e.g., severity, duration of illness, and insight into 
illness) and mediators (e.g., acceptance, mindfulness, compassion) of outcomes within each 
clinical trial. Furthermore, future studies of mindfulness interventions should better account for 
nonspecific effects (e.g., support), as these are known to be effective for psychosis (Penn et al., 
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2004). Beyond the scope of this meta-analysis and its implications, better consensus regarding 
conceptualizations and operational definitions of mindfulness are needed to enhance the 
assessment of the efficacy of mindfulness interventions. 
5. Role of funding source 
No official funding was provided to conduct the current meta-analysis. Materials (e.g., 
software) were provided by the Laboratory for Education on Schizophrenia and Psychoses 
Oriented to Intervention and Recovery of Dr. Tania Lecomte.  
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Table 1.  
 
Description and Effect Size Analyses of the Efficacy of the selected Studies  
 
Study 
Type 
Participants 
(N) 
M. 
Age 
% 
Male 
Treatment 
Group (n) 
Comp. 
Group (n) 
Rnd 
Ass 
% 
Att 
Tx 
hrs 
Clinical 
Measures 
(Mind. 
Measures)      
Pre-
Post g 
(gm) 
Fup 
wks  
PreFu
p 
g(gm) 
Cntrl 
g 
post 
(gm) 
Cntrl 
g 
fup  
Sc 
Bach & 
Hayes, 
2002; 
Bach et 
al., 2012 
inpatients 
with 
positive 
psychotic 
Sx (80) 
39.3 63.75 ACT + 
TAU (35) 
TAU (35) yes 10.0 3 HR - 17 - 0.54 0.48 7 
Chadwick 
et al., 
2005 
outpatients 
with 
distressing 
psychosis 
(10) 
33.1 60 Mindfulness 
+ Socratic 
Discussion 
(10) 
N/A N/A 26.7 7.5 CORE 
(MQ) 
0.47 - - - - 3 
Gaudiano 
& 
Herbert, 
2006 
inpatients 
with 
psychotic 
Sx (40) 
40.0 64 ACT + 
ETAU (19) 
ETAU 
(21) 
yes 5.0 3 BPRS; CGI; 
SRPS; SDS; 
Rhosp; HR 
0.95 17 - 0.32 - 8 
Chadwick 
et al., 
2009 
outpatients 
with 
distressing 
voices (21) 
41.6 - Mindfulness 
+ 
metacogniti
-ve insight 
(11) 
Waitlist 
(11) 
yes 22.7 10 CORE; 
PSYRAT; 
BAVQ-r 
(SMQ; 
SMVQ) 
.49 
(.37) 
- - 0.37 
(.64) 
- 6 
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Table 1. (continued). 
Study 
Type 
Participants 
(N) 
M. 
Age 
% 
Male 
Treatment 
Group (n) 
Comp. 
Group (n) 
Rnd. 
Ass. 
% 
Att 
Tx 
hrs 
Clinical 
Measures 
(Mindf. 
Measures)      
Pre-
Post g 
(gm) 
Fup 
wks  
Pre-
Fup 
g(gm) 
Cntrl 
g 
post 
(gm) 
Cntrl 
g 
fup  
Sc 
Laithwaite 
et al., 
2009 
RAP 
inpatients in 
High 
Security 
Settings 
(19) 
36.9 100 CMT (18) N/A N/A 5.26 20 BDI–II; 
RSE; SIP–
AD; 
PANSS; 
SCS; OAS 
(SeSC) 
0.19 
(0.21) 
6 0.30 
(0.27) 
- - 5 
Dannahy 
et al., 
2011 
Outpatients 
with 
distressing 
voices (62) 
41.1 35.48 PBCT (62) N/A N/A 19 18 CORE-OM; 
V. control / 
distress; 
VAY 
0.44 4 0.47 - - 3 
Johnson et 
al., 2011 
SZ 
spectrum 
(18) 
29.4 83 LKM (18) N/A N/A 11.1 7 mDES; 
DRM; 
CAINS 
beta; TEPS; 
SPWB; 
THS;  
SWLS 
0.5 13 0.46 - - 3 
White et 
al., 2011 
Psychotic 
disorder 
(27) 
34 77.78 ACT1 + 
TAU (14) 
TAU (13) yes 11.1 10 HADS; 
PANSS 
(AAQ-II; 
KIMS) 
0.76 
(0.96) 
- - 0.55 
(0.76) 
- 9 
Langer et 
al., 2012 
SZ 
spectrum 
(23) 
34.7 58.74 MBCT (7) Waitlist 
(11) 
yes 21.7 8 CGI-SCH 
(AAQ-II; 
SMQ) 
1.01 
(0.39) 
- - 0.55 
(0.55) 
0.41 7 
 
  
 170 
Table 1. (continued). 
Study 
Type 
Participants 
(N) 
M. 
Age 
% 
Male 
Treatment 
Group (n) 
Comp. 
Group (n) 
Rnd. 
Ass. 
% 
Att 
Tx 
hrs 
Clinical 
Measures 
(Mindf. 
Measures)      
Pre-
Post g 
(gm) 
Fup 
wks  
Pre-
Fup 
g(gm) 
Cntrl 
g 
post 
(gm) 
Cntrl 
g 
fup  
Sc 
Shawyer 
et al., 
2012 
SZ 
spectrum 
with CHs 
(44) 
39.8 55.81 ABCBT(12) Befrien-
ding (14); 
Wailist 
(17) 
yes 9.1 12 PANSS; 
mGAF; 
PSYRATS; 
QoL; 
BAVQ-r; 
IS; VAAS; 
RSQ 
0.31 26 0.35 0.09 0.06 9 
Van der 
Valk et 
al., 2013 
Early 
Psychosis 
outpatients 
(17) 
31.8 70.58 Mindfulness
(16) 
N/A N/A 18.8 8 SCL-90; 
(SMQ) 
0.28 
(0.36) 
- - - - 3 
Gaudiano 
et al., 
2013 
MDD with 
psychotic 
features 
(25) 
49.6 14 ADAPT 
(11) 
N/A N/A 21.4 24 BPRS; PDI-
21; LSHS-
R; 
WHODAS-
II; BADS; 
VLQ 
(AAQ-II; 
CAMS-R) 
0.91 
(1.37) 
 
40 1.11 
(1.73) 
  5 
Chien & 
Lee, 2013 
Patients 
with SZ 
(96) 
25.8 55 Mindfulness 
Based 
PsyEd. (48) 
Usual care 
(48) 
yes 6 12 ITAQ; 
BPRS; 
SSQ-6; 
SLOF; 
Rhosp 
0.45 78 0.92 0.57 1.11 5 
Note. M. = Mean; Comp. = Comparison; Rnd. Ass, = Random Assignment; Att = Attrition; Tx = Treatment; hrs = hours; Mindf. = Mindfulness; Fup 
= Follow-up; wks = weeks;  Cntrl = Control; gm = Hedge’s g of Mindfulness, Compassion and Acceptance outcomes; Sc = Quality Score; Scor = 
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Score; Sx = Symptoms; ACT= Acceptance and Commitment Therapy; TAU = Treatment As Usual; HR = Hospitalization Rate; CORE = Clinical 
Outcomes in Routine Evaluation; MQ = Mindfulness Questionnaire; ETAU = Enhanced Treatment As Usual; BPRS = Brief Psychiatric Rating 
Scale; CGI = Clinical Global Impressions Scale; SRPS = Self-ratings of psychotic symptoms; SDS = Sheehan Disability Scale; Rhosp = 
Rehospitalization data; PSYRATS; Psychiatric Symptom Rating Scale; BAVQ-r; Beliefs about Voices Questionnaire revised; SMQ = Southampton 
Mindfulness Questionnaire; SMVQ = Southampton Mindfulness Voices Questionnaire; RAP = Recovery After Psychosis; CMT = Compassionate 
Mind Training; BDI–II = Beck Depression Inventory – II; RSE = Rosenberg Self-Esteem measure; SIP–AD = Self-Image Profile for Adults; PANSS 
= Positive and Negative Syndrome Scale; SCS = Social Comparison Scale; OAS = External Shame (the Other as Shamer Scale); SeSC = Self 
Compassion Scale; PBCT = Person-Based Cognitive Therapy; CORE-OM = Clinical Outcomes in Routine Evaluation – Outcome Measure; V. = 
Voice; VAY = Voice And You; SZ = Schizophrenia; LKM = Loving-Kindness Meditation; mDES = Modified Differential Emotions Scale; DRM = 
Day Reconstruction Method; CAINS beta = beta version of the Clinical Assessment Interview for Negative Symptoms; TEPS = Temporal 
Experience of Pleasure Scale; SPWB = Scales of Psychological Well Being; THS = Trait Hope Scale; SWLS  = Satisfaction with Life Scale; 
1Acceptance and Commitment Therapy with strong mindfulness component; HADS = Hospital Anxiety and Depression Scale; AAQ-II = Acceptance 
and Action Questionnaire-II; KIMS = Kentucky Inventory of Mindfulness Skills; CGI-SCH = Clinical Global Impression-Schizophrenia Scale; 
ABCBT = Acceptance-based cognitive behavior Therapy; CHs = Command Hallucinations; mGAF = Modified Global Assessment of Functioning 
scale; QoL = Quality of Life Enjoyment and Satisfaction Questionnaire;  IS = Insight Scale; VAAS = Voices Acceptance and Action Scale; RSQ = 
Recovery Style Questionnaire; SCL-90; ADAPT = Acceptance Based Depression and Psychosis Therapy; PDI-21 = Peters Delusions Inventory–21 
Items; LSHS-R = Launay–Slade Hallucinations Scale–Revised; WHODAS-II = World Health Organization Disability Assessment Scale–II; BADS = 
Behavioral Activation in Depression Scale; VLQ = Valued Living Questionnaire; CAMS-R = Cognitive and Affective Mindfulness Scale–Revised; 
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PsyEd. = Psychoeducation; ITAQ = Insight and Treatment Attitudes Questionnaire SSQ-6; Six-item Social Support Questionnaire; SLOF = Specific 
Level of Functioning scale.
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Table 2.  
 
Effect sizes and other statistics for different groups of studies at different time points 
 
Study 
design 
Time 
point 
Division 
criteria Studies group Ns g 95% CI p I
2(%)  
Q 
Within-
group 
(pre-post 
analyses) 
End of 
Tx 
- 
all 12 .52 [.40, .64] < .0001 75.50 
44.81 
Tx 
protocol 
acceptance-
based studies1 5 .63 [.40, 0.86] < .0001 88.55 
34.94 
mindfulness-
based studies2 5 .43 [.32, .54] < .0001 6.79 
4.29 
compassion-
based studies3 2 .36 [.07, .66] < .05 61.83 
2.62 
outcome 
mindfulness 5 .96 [.43, 1.49] < .0001 75.75 
16.50 
thought 
disorder 1 .85 [.39, 1.30]  < .001 0 
0 
negative 
symptoms 4 .75 [.34, 1.16] < .001 73.34 
11.25 
functioning 4 .51 [.08, .93] <.05 81.61 
16.31 
positive 
symptoms 7 .32 [.18, .45] < .0081 2.08 
.89 
affective 
symptoms4 6 .43 [.21, .65] < .0001 69.39 
16.34 
quality of life 
measures 3 .49 [.20, .78] < .005 38.15 
3.23 
acceptance 
measures 3 .63 [-.05, 1.3] .07, ns 81.84 
11.01 
  compassion 
measures 1 .21 [-.38, .80] .48, ns 0 
0 
Fwp - 
all 6 .62 [.36, .87] < .0001 92.70 
68.50 
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Table 2 (continued). 
Study 
design 
Time 
point 
Division 
criteria Studies group Ns g 95% CI p I
2(%)  
Q 
Between-
group 
End of 
Tx 
- 
all 7 .41 [.23, .58] < .0001 44.54 
10.82 
control 
group 
type 
TAU 3 .46 [.26, .65] < .0001 0 
1.1 
waitlist 
controls 2 .43 [-.09, .95] .11, ns 0 
.11 
treatment 
control group5 2 .33 [-.14, .81] .17, ns 88.99 
9.08 
Tx 
protocol 
acceptance-
based studies 4 .35 [.12, .58] < .005 54.89 
6.65 
 mindfulness-
based studies 3 .55 [.36, .75] < .0001 0 
0.36 
outcome 
mindfulness 3 .99 [.48, 1.50] < .0001 0 
.97 
negative 
symptoms 3 .56 [.15, .96] < .01 0 
1.36 
Re-
hospitalization 2 .60 [.35, .86] < .0001 0 
.44 
functioning 3 .13 [-.18, .44] .40, ns 0 
1.86 
positive 
symptoms 4 .19 [-.18, .55] .31, ns 0 
.94 
affective 
symptoms4 2 .20 [-.51, .91] .59, ns 75.90 
4.15 
quality of life 
measures 1 .20 [-.43, .84] .53, ns 0 
0 
acceptance 
measures 2 .27 [-.31, .84] .36, ns 0 
.10 
Fwp - 
all 3 .55 [-.06, 1.16] .08, ns 95.02 
40.17 
 175 
Note. Ns= Number of studies; Tx = Treatment; 1acceptance-based studies (i.e., using ACT or 
ABCT protocols); 2mindfulness-based studies (i.e., Mindfulness-Based Cognitive Therapy or 
mindfulness with cognitive/behavioral strategies); 3compassion-based studies (i.e., 
Compassionate Mind Training); 4affective symptoms (i.e., depression, distress, anxiety and 
emotional dysregulation); 5comparison with an active treatment; Fwp = Follow-up; TAU = 
Treatment As Usual; 5treatment control group (i.e., befriending, psychoeducation). 
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Figure 1. Flow diagram of the study selection process in PubMed.
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Figure 2. Funnel plot of precision by Hedge’s g for pre-post data. Note that in the absence of a publication bias, the studies should be 
distributed symmetrically with larger studies appearing towards the top of the graph and clustered around the mean effect size and 
smaller studies towards the bottom. 
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Figure 3. Relationship between third-wave strategies outcomes effect sizes and clinical outcomes effect sizes at the end of treatment.
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Abstract 
Aim: Emerging evidence supports the priority of integrating emotion regulation 
strategies in cognitive behaviour therapy for early psychosis, which is a period of intense 
distress. Therefore, we developed a new treatment for emotional regulation combining third 
wave strategies, namely, compassion, acceptance, and mindfulness (CAM) for individuals with 
early psychosis. The purpose of this study was to examine the acceptability, feasibility, and 
potential clinical utility of CAM. Method: A nonrandomized, noncontrolled prospective follow-
up study was conducted. Outpatients from the First Psychotic Episode Clinic in Montreal were 
offered CAM, which consisted of eight-week 60 to 75 minutes weekly group sessions. Measures 
of adherence to medication, symptoms, emotional regulation, distress, insight, social functioning, 
and mindfulness were administered at baseline, post-treatment, and at 3-month follow-up. A 
short feedback interview was also conducted after the treatment. Results: Of the 17 individuals 
who started CAM, 12 (70.6 %) completed the therapy. Average class attendance was 77 %. Post-
treatment feedback indicated that participants found the intervention acceptable, and helpful. 
Quantitative results suggest the intervention was feasible and associated with a large increase in 
emotional self-regulation, a decrease in psychological symptoms, especially anxiety, depression, 
and somatic concerns, and improvements in self-care. Conclusion: Overall results support the 
acceptability, feasibility and potential clinical utility of the new developed treatment. A 
significant increase in emotional self-regulation and a decrease in affective symptoms were 
found. No significant changes were observed on measures of mindfulness, insight, distress, and 
social functioning. Controlled research is warranted to validate the effectiveness of the new 
treatment. 
Key words: early psychosis, compassion, acceptance, mindfulness, schizophrenia 
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1. Introduction 
Psychosocial treatments for psychosis and schizophrenia have evolved over the past 20 
years to target cognitive biases associated with psychotic disorders. For many individuals, 
psychotic symptoms can be modified through specific cognitive and behaviour strategies. Recent 
research is suggesting that individuals with schizophrenia present high levels of emotional 
deregulation on the experiential, processing and expressive levels that could exacerbate their 
distress and their social impairments (Trémeau, 2006). Emotional distress seems to be at its 
highest level at the onset of the illness and at the first psychotic episode due to the adaptation to 
the illness and to social stigma (Birchwood et al., 2007; Crisp, Gelder, Rix, Meltzer, & 
Rowlands, 2000; Reed, 2008). 
In a previous paper, we discussed the role of emotional experience in the aetiology and 
the development of the illness and we argued for the priority of integrating emotion regulation 
strategies in cognitive behaviour therapy for psychosis (CBTp)(Khoury & Lecomte, 2012). More 
specifically, emotional regulation strategies can help individuals experiencing psychotic 
symptoms for the first time to better manage their reactions following a psychotic episode. 
Among the emotional regulation strategies for individuals with psychosis are: reappraisal, 
exposure, detachment, metacognition, acceptance, compassion, and mindfulness. Some of these 
strategies namely, exposure, reappraisal and metacognition have been used in CBTp, and have 
been demonstrated to be effective and valuable treatment strategies for positive and negative 
symptoms, as well as for anxiety and depression (A.T. Beck, Rector, Stolar, & Grant, 2009; Tai 
& Turkington, 2009; Wykes, Steel, Everitt, & Tarrier, 2008). More recently applied strategies 
such as acceptance, detachment, compassion and mindfulness, often identified as part of what is 
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known as the third wave of cognitive behaviour therapies, are now being considered as useful 
adjuncts to CBTp (Tai & Turkington, 2009). 
In a recent meta-analysis including 14 trials and enrolling a total of 468 participants, we 
investigated the feasibility and effectiveness of third-wave cognitive-behavioural interventions 
for individuals with psychosis (Khoury, Lecomte, Gaudiano, & Paquin, 2013). Results suggest 
that the effects on combined clinical outcomes were between small and moderate, were 
maintained at follow-up, and were higher for negative symptoms compared with positive ones. 
Third wave strategies such as compassion, acceptance, and mindfulness, were strong moderators 
of the treatment’s effectiveness. In addition, the practice of meditation did not present adverse 
effects on psychotic symptoms, and was well accepted and tolerated by participants. In fact, 
participants showed higher levels of mindfulness following the treatment and at follow-up. In 
addition, two recent systematic reviews found that meditation and mindfulness techniques are 
useful adjuncts to usual care for psychotic disorders in reducing distress, hospitalization rates, 
and increasing feelings of self-efficacy (Davis & Kurzban, 2012; Helgason & Sarris, 2013). 
To date, few studies have tested these treatment strategies in early psychosis, which is a 
period of intense distress, stigma, and social isolation (Brunet, Birchwood, Upthegrove, Michail, 
& Ross, 2012; Crisp et al., 2000; Lolich & Leiderman, 2008; Reed, 2008). Learning emotion 
regulation strategies might prove useful in diminishing distress associated with psychotic 
experience. As such, we developed an 8-sessions group-based treatment for individuals with 
early psychosis using third wave strategies, namely compassion, acceptance, and mindfulness 
(we called it CAM). 
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The purpose of this pilot study was to determine the treatment’s acceptability for 
participants, its feasibility and potential clinical utility for individuals with early psychosis. We 
hypothesized that CAM would be 1) feasible and favourably received; and associated with 
improvements in 2) emotional self-regulation; 3) symptoms, particularly affective ones; 4) 
insight, 5) distress; and 6) maintained at 3-month follow-up. 
2. Method 
2.1. Participants 
Twenty seven individuals from the first psychotic episode clinic at the Louis-H 
Lafontaine Hospital in Montreal (Canada) were approached to participate in this study. Inclusion 
criteria consisted of: a first psychotic episode, currently followed by the first episode clinic, 
fluent in French, no known organic disorder or mental retardation, and capacity to offer informed 
consent.  
Among the approached participants, 17 agreed to participate and provided data at pre-
treatment, among them 12 only completed the treatment (i.e. attended four sessions or more) and 
provided data after the treatment, and 10 provided data at follow-up (i.e., three months later). 
Average therapy attendance among the participants was 6.17 sessions (SD = 1.34) out of 8. 
Among the non-completers, three attended one session and two attended two sessions. Among 
the reasons of quitting the group, one refused to sign the consent form, one was too ill and 
realized he couldn’t follow the sessions, one was asked by his case manager to leave the group as 
he was disturbing other participants (had a comorbid diagnosis of attention deficit/hyperactivity 
disorder), one started working full-time and could no longer attend the group, and one did not 
provide any reason for quitting. Only one of the non-completers accepted to provide data at post-
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treatment, however the data was discarded as the participant was overly confused and psychotic 
at the time of the assessment. Demographics of the participants are presented in Table 1. 
2.2. Instruments 
All of the measures were taken at baseline, post-treatment and three-month follow-up, 
except for the social demographic measure taken only at baseline, and the brief feed-back 
interview conducted at the end of treatment.  
2.2.1. Social Demographic Questionnaire. This questionnaire is based on the Canadian 
version of the PSR Toolkit (Arns, 1998) and includes information regarding the age, number of 
hospitalizations, occupation, schooling level, and the age at the first psychiatric consultation. 
Further questions regarding diagnosis, alcohol and drug consumption, medication and previous 
treatments were added.  
2.2.2. Medication Adherence Questionnaire. Medication adherence was assessed with 
a combination of the MAS/MCS (Willey et al., 2000), which asks the participants if they have 
been taking their medication as directed, and if not what are their intentions regarding taking 
their medication. Three questions also pertain to the frequency of forgetting, missing or 
modifying the dose intentionally.  
2.2.3. Brief Psychiatric Rating Scale-Expanded. The BPRS is a semi-structured 
interview assessing the presence and the severity of psychiatric symptoms on a 7-point Likert 
scale. The expanded version includes 24 items (Lukoff, Nuechterlein, & Ventura, 1986), and can 
be divided among the following factors: positive symptoms, negative symptoms, anxiety-
depression, and manic-excitement (Ventura, Nuechterlein, Subotnik, Gutkind, & Gilbert, 2000). 
A total score of the 24 items can also be calculated. 
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2.2.4. Social functioning Scale (Birchwood, Smith, Cochrane, & Wetton, 1990). The 
SFS is widely used to assess many dimensions of social functioning, namely social 
engagement/withdrawal, interpersonal behaviours, pro-social activities, recreation and hobbies, 
skills of independent living (independence/competence), and employment/occupation.  
2.2.5. Emotional self-regulation. In evaluating the emotional self-regulation of 
participants, we used the Cognitive Emotion Regulation Questionnaire (CERQ) (N. Garnefski & 
Vivian Kraaij, 2007). This measure is a self-report questionnaire consisting of nine distinct 
subscales (with four items in each subscale) covering cognitive and emotional dimensions (focus 
on thought/rumination, catastrophizing, self-blame, blaming others, positive refocusing, refocus 
on planning, positive reappraisal, putting into perspective). In addition, the scale incorporates an 
acceptance dimension, and it has been used with clinical populations (Garnefski & Kraaij, 2006; 
N. Garnefski & V. Kraaij, 2007), but not yet with psychotic-related disorders.  
2.2.6. Psychological Distress. The Psychological Distress Manifestation Measure Scale 
(Poulin, Lemoine, Poirier, & Lambert, 2005) is a short self-report questionnaire with 23 
manifestations grouped in 4 factorial dimensions: self-depreciation (7 items), irritability (5 
items), anxiety/depression (5 items), and social disengagement (6 items).  
2.2.7. Freiburg Mindfulness Inventory (FMI) – short version. To measure the level of 
mindfulness, we used the Freiburg Mindfulness Inventory – short version (Buchheld, Grossman, 
& Walach, 2001). The short version (14 items) is a self-report questionnaire that was developed 
and validated by Walach and collegues (2006). The items can be grouped in four factors: 
attention to the present moment; non-judgmental, non-evaluative attitude toward self and others; 
openness to one’s own negative and positive sensations, perceptions, mood states, emotions and 
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thoughts; and process-oriented, insightful understanding of experience at a more general level 
than immediate experience. The FMI-short version showed good reliability, and construct 
validity. 
2.2.8. Cognitive Insight. In evaluating the participants’ ability to understand their 
symptoms and their behaviours, we used the Beck Cognitive Insight Scale (BCIS) (Aaron T. 
Beck, Baruch, Balter, Steer, & Warman, 2004). The BCIS comprises 15-items where 
respondents are asked to rate how much they agree with each statement by using a 4-point scale 
that ranges from 0 (do not agree at all) to 3 (agree completely). This self-report instrument 
contains two scales. The first scale measures objectivity, reflection, and openness to feedback, 
whereas the second addresses decision-making such as: jumping to conclusions, certainty about 
being right, and resistance to correction. The BCIS shows good psychometric properties.  
2.2.9. Feedback Interview. In the feedback interview, participants were asked open-
ended questions regarding what they mostly liked in the therapy, what they mostly disliked, what 
skills they learned, what skills they aim to implement in their lives, in which areas of their lives 
they perceive amelioration, if any, and whether they recommend this therapy to a friend and 
why. 
2.3. Procedure 
  The study was approved by the Hospital’s and University’s research and ethics boards. 
Interested participants were contacted by a research assistant, who explained to them the consent 
form. The understanding of the consent form was assessed via a short questionnaire consisting of 
10 true/false items about different aspects of the project. A well-informed consent was 
determined by getting the right answers for the 10 items after no more than three trials. After 
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signing the consent form, each participant was interviewed separately by a trained research 
assistant for the BPRS. Participants then completed the remaining questionnaires with the help of 
a research assistant. Three groups were conducted over the course of twelve months. 
2.3.1. Treatment protocol (CAM). The treatment included eight sessions, each of 60 to 
75 minutes. Two therapists conducted the sessions. One of the therapists (i.e., first author) had 
mindfulness experience and both therapists had clinical training with the target population, and 
were supervised by an experienced clinician in the field (i.e., second author). Participants had 
access to their usual treatment at the clinic, which included, medication, regular follow-ups with 
the psychiatrist (biweekly), and case management by a social worker, occupational therapist or 
psychiatric nurse (weekly). No other psychological treatment (individual or group) was offered 
to the participants of this study during the treatment or follow-up periods. Other groups (e.g., 
cognitive behaviour therapy and cognitive remediation) are also available at the clinic. CAM was 
based on the integration of strategies for emotion regulation in early psychosis. Mindfulness was 
introduced gradually and practiced using concrete exercises at the beginning (e.g., mindful 
eating, and breathing). Later on, mindfulness meditation practice was introduced but exercises 
lasted less than 15 minutes in order to decrease the risk of experiencing intense psychotic 
symptoms while meditating. We provided meditation mats for the mindfulness exercises. 
Acceptance, detachment, and compassion skills were taught through concrete strategies, such as 
acceptance of thoughts and emotions, defusion from own thoughts, and building compassion 
towards self and others. We chose to not use abstract or theoretical material (e.g., metaphors) 
given the cognitive difficulties of many individuals with psychotic disorders. The treatment also 
included exercises on individual values, and personal objectives. Other strategies of emotion 
regulation were also discussed (e.g., narrative writing and social support). A treatment manual 
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was developed and each participant was provided a copy. The manual included materials for 
each session and practice exercises. A summary for each session is presented in Table 2. 
2.4. Statistical analyses 
Considering the modest sample size, the preliminary nature of this study, and the 
importance of balancing Type I and Type II error, unadjusted p-values are reported. Also, 
approaching significance results (p < 0.10) are noted accordingly. Independent-samples t-tests 
and Wilcoxon-Mann-Whitney tests were conducted to examine potential pre-treatment 
differences between completers and non-completers of treatment. Preliminary analyses also 
investigated differences in medication adherence at different time points. Differences between 
the three therapy groups were explored using oneway ANOVA. Primary analyses using paired t-
tests aimed to explore the differences in clinical measures between baseline (pre-treatment) and 
both post-treatment and 3-month follow-up. Effect sizes were also reported accordingly. 
Qualitative data from the treatment feedback interview was reviewed for themes related to 
perceived benefits and challenges of CAM. 
3. Results 
3.1. Completers versus non-completers 
Preliminary analyses were conducted to examine the comparability between completers 
and non-completers of the treatment. No significant differences were found between the two 
groups on sociodemographic data or on any other baseline measure, except for social 
functioning. Indeed, non-completers had lower social functioning namely on the interpersonal 
behaviours subscale of the SFS (t(15) = -2.14, p < .05). Social demographic data for completers 
are presented in Table 1. 
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3.2. Medication Adherence 
Most participants (11/12) reported taking their medication as prescribed at baseline, and 
one participant reported planning to take the medication as directed. No significant differences 
were observed between baseline and post-treatment (t(11) = 1.00, p = .34, ns), nor at the three-
month follow-up. Given these results, medication adherence data were excluded from the main 
analyses. 
3.3. Differences between therapy groups 
One-Way ANOVA tests were conducted at three time points (pre, post, and follow-up) to 
investigate the differences between the three CAM groups. No significant differences on clinical 
measures were found between the three groups at any of the three time points.  
3.4. Potential intervention effects 
Table 3 provides means and standard deviations for all the measures as well as within-
group effect sizes for differences between baseline/post-treatment and baseline/3-month follow-
up assessments. Analyses revealed large improvements (d = 1.00) in regulating negative 
emotions (i.e., self-blaming, rumination, and catastrophizing) among participants at three-month 
follow-up. Participants also showed a moderate improvement (d = 0.61) in total regulation of 
emotions (i.e., positive and negative) at three-month follow-up, although results only approached 
significance (p = 0.06). For the BPRS total score, results showed a small effect (d = 0.25) at 
follow up, not statistically significant (p = 0.11). Positive symptoms showed a small 
improvement at post treatment (d = 0.36), and depression-anxiety subscale showed a moderate to 
large improvement at follow-up (d = 0.68), but results were a trend toward significance in both 
cases. The symptoms that mostly improved were: anxiety (d = 0.92), depression (d = 0.91), self-
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neglect (d = 0.71), and somatic concerns (d = 0.50). The values of effect sizes were calculated at 
3-month follow-up, and results were statistically significant for anxiety, self-neglect, and somatic 
concerns (p < 0.05), and approached significance for depression (p = 0.065). No significant 
improvements were found for social functioning, insight, and distress measures. 
 Regarding who improved or not, six participants (50 %) showed improvements on overall 
symptoms from baseline to post-treatment and follow-up, while two showed deteriorations and 
four did not show any change. Participants who did not improve (n = 6) had significantly lower 
symptoms at baseline (t(10) = -5.01, p < .005), specifically lower positive psychotic symptoms 
(t(10) = -2.70, p < .05), a higher level of mindfulness (t(10) = 2.84, p < .05), and better social 
functioning (t(10) = 3.00, p < .05) compared with those who improved (n = 6). The two groups 
did not differ on measures of insight, emotional regulation, distress, and sociodemographic 
measures. 
In regards to mindfulness, eight participants (67 %) showed improvements from baseline 
to post-treatment and follow-up, while three showed a slight decline and one did not show any 
change. Even though the results are not statistically significant, the effect size at follow-up for 
mindfulness was moderate (d = 0.40). 
3.5. Qualitative results 
The attendance rate was 77 % for the treatment completers. The majority of participants 
(n = 8) reported that the treatment was a positive experience, describing it as “nice, wonderful, 
interesting and nourishing”, while one participant considered the experience as negative and 
“not enough nourishing”, and three were ambivalent, describing their experience as “ok, normal, 
ordinary, or convenient”. Regarding the components of the treatment, mindfulness was the most 
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retained (n = 8), liked (n = 4), and practiced (n = 8), followed by interactions with the other 
group members and/or the therapists (n = 5), while compassion and acceptance were less 
reported by participants. The most common complaint was the lack of attendance among other 
participants. Nine of the twelve participants reported changes in their daily lives following the 
treatment and nine reported that they would recommend the therapy to a friend.  
4. Discussion 
 Overall results support the feasibility of the new developed treatment, supporting our first 
hypothesis. The majority of the participants found the treatment positive and helpful. The aim of 
the treatment is to help individuals in early psychosis to regulate negative emotions associated 
with the illness and accompanying stigma. The treatment focused on mindfulness, acceptance 
and compassion as strategies to regulate negative emotions. Qualitative results indicate that the 
majority of participants were able to learn and integrate these strategies, especially mindfulness. 
We used a group format as it is recommended for individuals with early psychosis to increase 
peer-to-peer interactions, feelings of normalcy, and modelling (Saksa, Cohen, Srihari, & Woods, 
2009). Most of the participants expressed an interest in the group format and some of them 
complained about the lack of attendance of some participants. 
As expected, participants reported large improvements in regulating negative emotions 
(specifically self-blaming, rumination, and catastrophizing), and moderate to large improvements 
on affective symptoms (specifically depression, anxiety, and somatic concerns). Results showed 
also a large improvement on self-care, which could be related to an increase in self-awareness. 
These results support our second and third hypotheses, and are consistent with the theoretical 
background of this study regarding the role of emotional self- regulation in treating psychosis. 
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Results from previous studies that integrated third wave interventions for psychosis suggested 
small to moderate effects on psychotic symptoms (Khoury et al., 2013), a finding that was not 
supported in our study. Plausible reasons for the absence of such effects are the small number of 
participants and the low baseline levels of positive symptoms (M = 9.92, SD = 5.32) and 
negative symptoms (M = 6.83, SD = 2.08) among participants. 
Most of the results were stronger at 3-month follow-up than immediately following the 8-week 
CAM sessions, suggesting that the treatment might be more beneficial in the long run, as 
suggested by many CBT studies (Wykes et al., 2008). More longitudinal results will be needed to 
reach conclusive results.  
 Participants did not show statistically significant improvements on the mindfulness 
measure, although an improvement at follow-up was observed and mindfulness was mentioned 
qualitatively by most. Long-term improvements on mindfulness were also observed elsewhere 
(Khoury et al., 2013). An explanation of the absence of measured improvements in mindfulness 
could be linked to the scale itself, as the FMI is designed to detect improvements among skilled 
meditators whereas the participants here had no previous experience in meditation. In addition, 
many of the strategies taught in the treatment pertained to general aspects of mindfulness (e.g., 
eating mindfully, loving-kindness/compassionate meditation) rather than direct mindfulness 
meditation practice. Furthermore, we did not measure the daily mindfulness practice of 
participants. In fact, some anecdotally mentioned weekly meditation practice whereas others 
appeared to have more difficulties grasping the idea of mindfulness, qualifying the group 
exercises as learning to ‘eat more slowly’ or ‘relaxation’. It is recommended that future studies 
measure the daily mindfulness practice of participants and perhaps use a more comprehensive 
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measure of mindfulness (e.g., Mindfulness and Awareness Scale (Brown & Ryan, 2003) or Five-
Facet Mindfulness Questionnaire (Baer et al., 2008)). 
Regarding the lack of improvements in social functioning, insight, and distress, the former two 
were not directly addressed in the brief CAM treatment, whereas the latter might need further 
investigation, perhaps considering using another measure of distress.  
 The current study has several limitations. First, the uncontrolled study design precludes 
any causal inferences about the efficacy of the tested treatment (i.e., perhaps everyone in the first 
episode program improved similarly, or the improvements here were linked to other mechanisms 
than the treatment, such as social interaction within a group setting or the regular follow-up at 
the clinic). The study did not include measures of compassion or acceptance, or concrete 
behavioural measures of mindfulness practice which are essential components of the treatment. 
Finally, we did not record the reasons for irregular attendance among some participants.  
In conclusion, the CAM group protocol for emotional regulation appears acceptable, 
feasible, and shows promise in terms of potential clinical treatment for early psychosis. Further 
studies are warranted in order to determine its efficacy in improving acceptance, compassion, 
and mindfulness practice, and in diminishing distress and symptoms.  
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Table 1.  
 
Social demographic data of participants completing the CAM intervention (N=12) 
 
Measure  
Age, years [Mean (SD)] 29.08 (8.13) 
Sex (male/female) 8 / 4  
Years of education [Mean (SD)] 10.83 (1.47) 
DSM IV Diagnosis, n  
    Paranoid schizophrenia 6 
    Schizophrenia, not otherwise specified 2 
    Psychosis, not otherwise specified 4 
Age of first visit to a psychiatrist [Mean (SD)] 21.88 (6.00) 
Age of first hospitalization [Mean (SD)] 21.92 (5.92) 
Number of psychiatric hospitalizations [Mean (SD)] 3.00 (2.98) 
Marital status, n  
    Single, never married 10 
    Married/remarried 1 
    Divorced 1 
Country of birth, n  
    Canada 11 
    Haiti 1 
Race, n  
    Occidental 7 
    First nation/Inuit 1 
    Asian 1 
    African/Caribbean 2 
    Others 1 
Work status (employed/unemployed) 3 / 9 
Did jail time (yes/no) 4 /8 
Had therapy in the last 6 months (yes/no) 5 / 7 
Alcohol/Drug use, n   
    Alcohol only 1 
    Drugs only 1 
    Both 1 
    None 9 
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Table 2.  
Highlights of the protocol sessions  
 
   
Session 1 
 
Presenting to the group 
Explaining the module 
Introduction to mindfulness 
Mindfulness Exercise: eating an apple mindfully 
  Session 2 Values: define your own values, differences between values and goals 
Group discussion about values 
Mindfulness exercise: calming and self-soothing breathing  
Session 3 What prevents me from advancing in the direction of my own values? 
Group discussion 
Mindfulness Exercise: Imagine yourself in a peaceful and safe place 
Session 4 Acceptance: what is it? Difference between acceptance and resignation 
Detachment: being an external observer 
What you do when faced with threatening feelings or thoughts 
Group Discussion 
Mindfulness Exercise: Exposure via imagery to a difficult memory or thought while 
practicing calming and self-soothing breathing (from session 2) 
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Table 2 (continued). 
 
Session 5 Compassion: what is it? 
The role of compassion in the acceptance of threatening thoughts and emotions 
Group discussion about how to generate compassion towards oneself 
Mindfulness Exercise: compassion towards oneself using Loving-Kindness Meditation 
Session 6 The role of compassion towards others in one’s own well-being 
Group discussion about how to generate compassion towards others  
Mindfulness Exercise: compassion towards others using Loving-Kindness Meditation 
Session 7 Other ways to increase wellness: narrative writing and social support 
Group discussion about ways to feel good in short term versus long term 
Mindfulness Exercise: half-smile 
Session 8 Revision of the Module 
The role of positive emotions such as hope and optimism in well-being 
Feedback from participants 
Mindfulness Exercise: Vipassana Meditation  
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Table 3.  
 
Means, Standard Deviations and Effect Sizes (Cohen’s d) for all measures at Pre, Post and 3-month Follow-up 
 
Outcome T0 (baseline) T1 (post-therapy) 
Effect size 
(d)  
T2 (3-months 
 follow-up) 
Effect size 
(d)  
Measure Mean (SD) Mean (SD) Pre-Post p-value Mean (SD) Pre-Follow-up p-value 
Symptoms        
BPRS total 41.83 (13.59) 37.83 (6.86) 0.279 0.156 38.70 (9.75) 0.246 0.109 
Positive 9.92 (5.32) 7.08 (3.60) 0.361 0.087∆ 8.40 (3.97) 0.203 0.343 
Negative 6.83 (2.08) 6.00 (2.04) 0.404 0.166 6.70 (2.79) 0.200 0.575 
Depression-anxiety 10.50 (5.20) 9.00 (3.84) 0.318 0.250 8.10 (2.81) 0.676 0.082∆ 
Manic-excitement 7.92 (2.87) 9.25 (5.03) -0.198 0.382 7.70 (2.36) 0.136 0.522 
Mindfulness        
FMI total 38.25 (7.36) 38.92 (7.54) 0.089 0.507 41.30 (9.20) 0.403 0.186 
Emotional regulation        
CERQ total 114.42 (17.14) 115.75 (20.24) 0.070 0.775 125.60 (19.29) 0.611 0.060∆ 
Positive 61.25 (12.76) 62.17 (13.60) 0.070 0.777 63.70 (14.12) 0.182 0.540 
Negative 53.17 (9.21) 53.58 (11.84) 0.038 0.877 61.90 (8.08) 1.003 0.007** 
Insight        
BCIS total 39.00 (8.19) 36.92 (4.98) -0.269 0.230 36.40 (6.43) -0.341 0.239 
Psychological distress        
PDMMS total 54.00 (20.81) 54.17 (16.71) -0.008 0.958 51.80 (17.50) 0.114 0.905 
Social functioning        
SFS total 122.17 (18.21) 124.83 (18.60) 0.144 0.548 121.30 (23.66) -0.040 0.985 
∆ p < .10 (approaching significance). * p < .05. ** p < .01. 
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General Discussion 
In this thesis, the point was made for the pertinence of using emotion regulation 
strategies, such as acceptance, compassion and mindfulness, in treating individuals with 
psychotic disorders. In fact, many researchers and clinicians support such argument. For 
example, Greenberg and Pascual Leone (2006) consider emotion regulation as central to 
recovery, pointing out that it must be the first goal of an effective treatment. More treatments are 
integrating emotion regulation strategies as part of their protocols (e.g., Acceptance and 
Commitment Therapy, Mindfulness-Based Cognitive Therapy, Dialectical Behavior Therapy, 
Compassion Focused Therapy, and Emotion Focused Therapy). Some of the protocols have been 
briefly described elsewhere (Benoit & Khoury, 2012). Among the emotion regulation strategies, 
mindfulness in particular is now considered a central mechanism (Khoury & Lecomte, 2012; 
Khoury, Lecomte, & Lalonde, 2012). 
In fact, an increasing number of studies during the last decade are using mindfulness 
either as a central part of their protocols (e.g., Mindfulness-Based Stress Reduction, 
Mindfulness-Based Cognitive Therapy, and Mindfulness-Based Relapse Prevention) or as an 
additional component (e.g., Dialectical Behavior Therapy, Acceptance and Commitment 
Therapy, and Person-Based Cognitive Therapy). Protocols with a mindfulness component are 
growing fast in numbers and are now implemented for almost every psychological disorder 
(including all DSM axis-I and many axis-II disorders), physical or medical conditions, and 
among non-clinical populations. As reflected in the meta-analyses presented in this thesis, one of 
the problems in this growing body of literature is the large difference among the mindfulness 
protocols regarding the ways mindfulness is implemented and/or practiced, outcomes are 
measured, and treatment is offered to participants. Some of the protocols are individually-based 
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while others are group-based, some of them are conducted or supervised by qualified 
mindfulness teachers and qualified clinicians while others lack these qualifications. One of the 
most common shortcomings in these interventions is that over half of them did not measure 
mindfulness among participants, whereas it was assumed that mindfulness was a central 
component in the treatment. Other differences among the mindfulness treatments are the number 
of sessions, total duration of treatment and the home practice recommended by therapists.  
To assess the effectiveness of mindfulness based interventions and to delineate the factors 
contributing to their effectiveness, we conducted a comprehensive meta-analysis including all 
treatments where mindfulness meditation is a central component. The results showed that 
mindfulness is moderately to highly effective in treating all sorts of psychological disorders and 
physical/medical conditions. The effects were also maintained at an average of six months 
following the end of the treatment (last session). Findings suggested higher effects on 
psychological disorders than on physical/medical conditions. In addition, mindfulness based 
interventions were shown to be more effective than psychoeducation, supportive therapy, and 
relaxation, even though the effect sizes were moderate to small. In comparison with traditional 
Cognitive Behavioral Therapies, mindfulness based interventions were shown to be equally 
effective, even though the results are not statistically significant. Perhaps one of the most 
significant findings is that mindfulness strongly moderated the effectiveness of the treatments, 
most likely via regulating negative emotions associated with the psychological disorder or 
medical illness. For example, even when physical symptoms (e.g., pain) did not decrease, the 
associated distress and affective symptoms (e.g., anxiety, depression, and emotional stress) 
showed significant statistical and clinical improvements. Another significant outcome is the role 
of mindfulness training and experience of therapist(s) in ameliorating the effect size of the 
  206
treatments. These results suggest that future treatments should require that therapists have 
previous experience or follow a formal curriculum in mindfulness. In addition, therapists can 
have indirect influence on participants, for example a mindful, compassionate and accepting 
therapist can have positive influence on the mindfulness, compassion and acceptance of the 
participants as well as on their clinical outcomes (Grepmair et al., 2007). Indirect effects are part 
of what is called the “common factors” in psychotherapy. In a recent article, Wampold referred 
to those factors as “humanism” and argued that they are central to any treatment’s effectiveness 
(Wampold, 2012). In summary, the findings of this meta-analysis encourage conducting more 
rigorous mindfulness based studies to establish their effectiveness in comparison with, or in 
addition to other equivalent treatments (e.g., CBT) and to delineate their mechanisms of action. 
The next question was the degree to which results regarding the effectiveness of the 
mindfulness based therapy could also be found in individuals with psychotic disorders. A further 
question is the potential role of mindfulness and other emotion regulation strategies in the 
effectiveness of interventions in psychosis/schizophrenia. We already argued in our first article 
and book chapter (i.e. introduction) for the importance of these strategies in addressing the 
distress associated with the illness and in increasing the levels of well-being and functioning 
among individuals with psychosis or schizophrenia. Therefore, we conducted our second meta-
analysis, which included all existing interventions using any of the third wave emotion regulation 
strategies (i.e., mindfulness, acceptance, and compassion) for psychosis/schizophrenia. Even 
though the effects were small for positive symptoms, there were larger for negative and affective 
symptoms, indicating a significant reduction in distress, depression and anxiety associated with 
experiencing intense psychotic symptoms, and an increase in functioning and quality of life. 
Benefits were also maintained at follow-up, suggesting long-term effects of these interventions. 
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Another important finding was that mindfulness was a strong moderator of treatment efficacy 
and acceptance/compassion were complementary strategies increasing its effectiveness, 
suggesting again emotion regulation as the mechanism of action in these interventions. In fact, 
the results suggest that these interventions are beneficial in helping individuals regulate their 
negative emotions via teaching them to better adapt to their symptoms, and as result decrease 
their distress and increase their levels of functioning and their global well-being.  
Studies targeting psychotic disorders and integrating emotional regulation strategies 
showed large heterogeneity and differences in the obtained effect sizes. These variances are due 
to differences in the design (e.g., pre-post versus controlled), the protocols (e.g., ACT, MBCT, 
and PBCT), the target population (e.g., inpatients versus outpatients), and symptoms targeted 
(e.g., positive, negative, affective, functioning, or rehospitalization/relapse). Psychotic disorders 
are also somewhat heterogeneous and can involve a large spectrum of symptoms. Beside these 
differences, findings encourage the implementation of interventions using emotion regulation 
strategies as adjunct to pharmacotherapy in treating individuals with psychotic disorders. 
Findings from both meta-analyses suggest a central role for emotion regulation strategies 
in the effectiveness of the investigated interventions. In addition, results showed low attrition 
rates among participants (16.29 % in the first meta-analysis and 12.14 % in the second), values 
that are lower than the ones usually obtained in similar interventions (e.g., CBT) suggesting high 
commitment among participants to these interventions. A plausible reason behind the low 
attrition rates is the focus of these interventions on reducing distress rather than symptoms, an 
objective that is likely to increase the collaboration among participants. 
The next objective in this thesis was to develop a new treatment for early psychosis using 
our findings from existing research. On the basis of the results from both meta-analyses, we 
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came to the conclusion that mindfulness should be a central component of a new treatment and 
that acceptance and compassion can be complementary to mindfulness in increasing the 
treatment’s efficacy. Therefore we thought to design a treatment that combines mindfulness, 
acceptance and compassion. A challenge we faced when designing the treatment was to adapt it 
for individuals with early psychosis. As we know, early psychosis is a period of intense distress 
associated with dysfunction , stigma, and social isolation (Brunet, Birchwood, Upthegrove, 
Michail, & Ross, 2012; Crisp, Gelder, Rix, Meltzer, & Rowlands, 2000; Lolich & Leiderman, 
2008; Reed, 2008) and the diagnosis itself of schizophrenia can be further stigmatizing (Tranulis, 
Lecomte, El Khoury, Lavarenne, & Brodeur-Côté, 2013). In addition, many individuals suffer 
cognitive difficulties before and following a psychotic episode, rendering it challenging for them 
to assimilate some of the intervention’s material. Therefore, we used strategies involving senses 
and bodily sensations beside thoughts and emotions in teaching mindfulness. For example, we 
started by a simple exercise focusing of eating mindfully an apple and we moved slowly towards 
bodily sensations during sitting meditation and to contemplating thoughts and emotions later in 
the treatment module. In teaching acceptance, we also focused on discussing specific life events 
pertaining to the participants and how to accept them as a way to feel better and to move in the 
direction of values and life goals. We avoided metaphors and abstract or theoretical material as 
they are hard to understand and participants might not relate to them. In teaching compassion, we 
used material from Compassionate Mind Training (Gilbert, 2009) as it was already implemented 
and validated with individuals with different psychotic disorders. We concentrated on practices 
that can help participants to self-sooth. We also integrated elements from Loving-Kindness 
meditation (Salzberg, 1995) as it has both self-soothing and mindfulness elements. The module 
was designed in such way that each session has a specific theme, a mindfulness practice related 
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to the discussed theme at the end of the session, and homework to practice the taught element. 
The treatment was also designed in a group format to increase feelings of normalcy and 
modeling among participants. 
Finally, to validate the effectiveness of the new developed treatment, we conducted a 
non-controlled pilot study. Twelve individuals completed the treatment. Qualitative results 
suggest the feasibility, and acceptability of the new treatment. Most of the participants reported 
integrating these strategies in their daily life. Quantitative results showed large improvements in 
regulating negative emotions (e.g., self-blaming, rumination, and catastrophizing), and on self-
care, moderate to large improvements on affective symptoms (specifically depression, anxiety, 
and somatic concerns). Improvements were higher at three-month follow-up suggesting a 
potential increasing long-term effect of the new treatment. 
The attrition rate obtained in this pilot study (30%) was higher than the ones found in 
other studies with similar populations and using similar strategies, but similar to others using a 
group format. Reasons behind such high attrition rate are perhaps the inclusion of individuals 
with comorbid disorders (e.g., social anxiety, attention deficit hyperactivity disorder, and 
borderline personality disorder) and having heterogeneous groups in ages (e.g., young males in 
their twenties with middle-aged women). These factors among others rendered some groups less 
cohesive and perhaps influenced the sense of belonging to the group, leading as consequence to 
higher attrition rates.  
This thesis helped in answering many questions regarding the role and utility of emotion 
regulation strategies in psychotherapy specifically in treating a psychotic population; however, 
other questions remain unanswered. Perhaps a central one is regarding how to match an 
intervention for emotion regulation with a specific target population. Interventions can vary in 
  210
the strategies they use, the delivering format, the duration of sessions and homework practice. 
Individuals with psychosis vary also in their diagnosis, stage of illness, symptoms, and specific 
needs. Future research must aim at delineating the factors that can render an intervention more 
effective for a specific target population. 
It is noteworthy that mindfulness was implemented according to the common Western 
protocols emphasizing on non-judgmental observation, awareness, and acceptance of internal 
and external phenomena. However, this implementation of mindfulness is rather narrow and 
excludes important components of mindfulness according to Buddhist traditions. In fact, the 
earliest teachings of Buddha involves the combination of (1) concentration associated with calm 
abiding (Samatha) practice to acquire direct experience, and (2) discriminative analysis 
associated with insight (Vipassana) practice to acquire insight and wisdom. Unfortunately, 
Western mindfulness failed to implement the first component of mindfulness and partially 
implemented the second one. For example, Buddhist teachings emphasize the overly changing 
and impermanent aspect of all phenomena (internal and external) including one self’s ego. 
Moreover, Buddhist teachings point out that attachment to the ego is a permanent source of 
suffering. Unfortunately, these important principles are largely missed in the Western teachings 
of mindfulness. Perhaps a further integration of Buddhist teachings in contemporary 
mindfulness-based therapy could be beneficial. In fact, some new protocols based on Buddhist 
teachings are currently under development and validation (e.g., Rapgay & Bystrisky, 2009; 
Rapgay, Bystrisky, Dafter, & Spearman, 2011). These attempts, even though somewhat partial 
and preliminary are rather encouraging.  
Beside third wave strategies, many other interventions also aim at regulating emotions in 
severe mental illness including psychotic disorders (for e.g., mentalization; Bateman & Fonagy, 
  211
2004; metacognitive training; Hutton, Morrison, Wardle, & Wells, 2013; Kumar et al., 2013; 
narrative training; Lysaker et al., 2011; Lysaker, Glynn, Wilkniss, & Silverstein, 2010). These 
interventions utilize different strategies in regulating emotions. For example, metacognitive 
training aims at regulating emotions via targeting the associated attribution biases (Hutton et al., 
2013; Kumar et al., 2013; Naughton et al., 2012). Narrative treatment aims at normalizing the 
experience of the person and to increase self-compassion, helping as result in regulating negative 
emotions and in reducing distress (e.g., Lysaker et al., 2011; Lysaker et al., 2010; Pérez-Álvarez, 
García-Montes, Vallina-Fernández, Perona-Garcelán, & Cuevas-Yust, 2011). Mentalization 
focuses on regulating emotions via increasing the ability to recognize one’s own and others’ 
mental states (such as thoughts, beliefs, and intentions) as explanations of behaviours (Fonagy & 
Bateman, 2006).  
Another important factor in the selection of a treatment by most institutions and service 
providers is cost-effectiveness. Many studies have compared cost-effectiveness of different types 
of psychotropic medications. Few studies have explored the cost-effectiveness of psychosocial 
treatments for psychosis or schizophrenia and overall results are inconclusive with some 
suggesting reductions in cost when including a psychosocial treatment (e.g., Karow et al., 2012; 
Kuipers et al., 1998; Startup, Jackson, Evans, & Bendix, 2005), while others reported 
insignificant cost reductions (e.g., van der Gaag, Stant, Wolters, Buskens, & Wiersma, 2011), 
even if clinical improvements were documented. Findings are more conclusive for early 
interventions in psychosis, suggesting both clinical and cost effectiveness (e.g., Cocchi, Mapelli, 
Meneghelli, & Preti, 2011). However, no study compared the cost-effectiveness among different 
psychosocial treatments. On the basis of treatment duration and the available data, one can 
conclude that short-term cognitive behavioral therapies (e.g., traditional CBT or third wave 
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interventions) might be among the most cost effective psychosocial interventions in addition to 
family interventions, which are also shown to be effective (e.g., Devaramane, Pai, & Vella, 
2011; Heekerens, 2008; Pharoah, Mari, Rathbone, & Wong, 2010). In addition, technology and 
specifically the Internet present an additional support for delivering cognitive behavioral and 
mindfulness-based interventions at a low cost, and results support their effectiveness for a wide 
range of disorders (e.g., Andersson et al., 2012; Hedman et al., 2013; Ljótsson et al., 2010). For 
example, a randomized web-based mindfulness training for 50 individuals with psychotic 
disorders or suicidal thoughts showed a significant decrease in stress, distress and improvement 
in regulating negative emotions (Glück & Maercker, 2011). These results suggest the potential of 
designing and delivering short-term, clinically effective and highly cost-effective treatments for 
severe mental illnesses including schizophrenia. Álvarez-Jiménez and colleagues (2012) argued 
that internet-based technologies have the potential to transform psychosis treatments by 
enhancing their accessibility, fostering engagement with mental health services, and maintaining 
treatment benefits over the long term. However, it is noteworthy that internet-based applications 
should be only used as adjuncts to a treatment as therapeutic relationship as been shown to be 
central in a treatment’s efficacy (e.g., Horvath & Bedi, 2002; Horvath, Del Re, Flückiger, & 
Symonds, 2011; Horvath & Symonds, 1991; Martin, Garske, & Davis, 2000). 
Whether the intervention is cognitive-behavioral, metacognitive, mindfulness-based, 
third-wave based, or mentalization-based, and despite the method of delivering the intervention, 
emotion regulation remains a central component for its effectiveness. In fact, emotion regulation 
appears central in most psychosocial interventions and for all psychological disorders. 
Individuals with psychosis or schizophrenia, showing large dysregulations in experiencing, 
expressing and processing their own emotions and understanding and relating to the emotions of 
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others are certainly an ideal target for emotion regulation strategies. More rigourous studies 
exploring the most clinically and cost effective strategies in delivering emotion regulation based 
treatments for individuals with psychotic disorders are warranted. 
In summary, emotion regulation appears to be a central component in treating different 
psychological disorders and/or physical or medical conditions including psychotic spectrum 
disorders. Mindfulness meditation seems to be effective in regulating emotions, and mindfulness 
based therapy is effective in treating a wide range of disorders and conditions. Other strategies, 
namely acceptance and compassion, can be complementary to mindfulness in regulating 
emotions and are shown to be effective in treating psychotic spectrum disorders. A new 
treatment using mindfulness, acceptance, and compassion is feasible and preliminary results 
suggest that it enhances emotional regulation and decreases affective symptoms among 
individuals in early psychosis. More research is warranted to validate long-term effectiveness of 
the new developed treatment. 
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